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Thesis Summary 
 
Left Ventricular Hypertrophy (LVH) is common in Type 2 Diabetes (T2DM) 
and despite optimal treatment of blood pressure can still persist.  We know 
LVH is a cardiovascular (CV) risk factor in its own right and contributes to high 
CV event rates in patients with T2DM.  Apart from hypertension, other factors 
contribute to the development of LVH in patients with T2DM, in particular 
oxidative stress (OS) has been implicated in LVH development.  Allopurinol is 
a potent anti-oxidant, acting by blocking the enzyme Xanthine Oxidase, and 
has been previously shown to reduce vascular OS.  Therefore the main aim of 
this thesis was to investigate whether allopurinol regresses LVH in patients 
with T2DM. 
 
The trial design was a randomised, double blind, placebo controlled study in 
66 patients with T2DM with echocardiographic evidence of LVH.  Allopurinol 
600mg/day or placebo was given for nine months over the study period.  The 
primary outcome was reduction in left ventricular mass (LVM) as calculated by 
cardiac magnetic resonance imaging (CMR) at baseline and at nine months 
follow-up.  The secondary end-points were change in flow mediated dilatation 
(FMD) and augmentation index (AIx). 
 
Allopurinol significantly reduced absolute LVM (-2.65 ± 5.91g and placebo 
group +1.21 ± 5.10g (p=0.012)) and LVM indexed to body surface area (-1.32 
± 2.84g/m2 and placebo group +0.65 ± 3.07g/m2 (p=0.017)). When analysis 
was made of high and low baseline LVM then the effects of allopurinol were 
 13 
 
exaggerated in the high LVM mass group.  No significant change was seen in 
either FMD or AIx. 
 
This thesis shows that allopurinol regresses LVM in patients with T2DM and 
LVH and controlled blood pressure.  Regressing LVH has been shown 
previously to improve CV mortality and morbidity.  Therefore allopurinol may 
become a useful therapy to reduce CV events in T2DM patients with LVH. 
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CHAPTER ONE 
INTRODUCTION 
 
1. The Culprit of Left Ventricular Hypertrophy in Diabetes 
 
a. The Increasing Problem of Type 2 Diabetes 
 
i. Definition and Diagnosis of Diabetes Mellitus 
 
The World Health Organisation (WHO) in 1999 defined diabetes as (1): ‘The 
term diabetes mellitus describes a metabolic disorder of multiple aetiology 
characterised by chronic hyperglycaemia with disturbances of carbohydrate, 
fat and protein metabolism resulting from defects of insulin secretion, insulin 
action, or both’.  The WHO consensus on the levels of blood glucose to 
diagnose diabetes are summarised in table 1.1.1. 
 
Table 1.1.1. Diagnostic values for diagnosing diabetes (1). 
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It is recommended the term ‘insulin dependent diabetes mellitus’ and ‘non 
insulin dependent diabetes mellitus’ are ‘phased out’ and the terms Type 1 
Diabetes (T1DM) and Type 2 Diabetes (T2DM) should be used instead (1).  
The definition of type T1DM describes insulin deficiency due to loss of beta-
islet cells from the pancreas, including autoimmunity and idiopathic causes.  It 
does not include cases where the cause of beta islet cell destruction is 
attributable to a specific disease process or underlying disease process e.g. 
cystic fibrosis and fibrocalculous pancreatopathy (1).  An important feature of 
T1DM is that they are prone to ketoacidosis.  T2DM encompasses defects in 
insulin secretion and insulin resistance.  It is the most common form of 
diabetes and it comprises almost 90% of all cases (1). 
 
 ii. The Incidence and Burden of Diabetes Mellitus 
 
In 2006 Diabetes UK produced the report ‘Diabetes: State of the Nations’ 
where diabetes is described as ‘one of the greatest health challenges facing 
the UK today’ (2).  The prevalence of diabetes has increased over the last 
nine years and it is estimated over two million people in the UK are living with 
diabetes, and it could be that up to half have not had their condition 
diagnosed (2).  In 2006 the estimated prevalence of diabetes in Scotland was 
3.4%, published in ‘Diabetes: State of the Nations’ (2).  Gonzalez et al (2009) 
published data on the increase in incidence of T1DM and T2DM in the UK 
general population from 1996 to 2005 (3).  Their data was sourced from the 
Health Improvement Network database, using data on 49,999 prevalent cases 
and 42,642 incident cases (T1DM n=1,256 and T2DM n=41,386) of diabetes 
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in UK patients aged 10 to 79 years old.  Prevalence increased from 2.8% in 
1996 to 4.3% in 2005 while the incidence rose from 2.71 per 1,000 person 
years in 1996 to 4.42 per 1,000 person years in 2005.  Possible mechanisms 
for this increase include an ageing population and rising obesity levels, as the 
proportion of individuals newly diagnosed with T2DM who were obese 
increased from 46% to 56% between 1996 and 2006 (3).  Geiss et al (2006) 
looked at the factors associated with the incidence of Diabetes in the United 
States using the National Health Interview Survey data from 1997 to 2003 (4).  
This study also showed an increasing incidence, again of note here was its 
correlation with obesity.  Their multivariate adjusted incidence increased with 
age and BMI, implying obesity is a major factor in the increasing incidence of 
T2DM (4).  Table 1.1.2 is taken from the report ‘Diabetes: State of the Nations 
2006’ and shows the estimated prevalence of diabetes in the whole of the UK 
in 2005 and 2006 (2). 
Nation Prevalence Number of people 
UK 3.5% 2,238,000 
England 3.6% 1,891,000 
Northern Ireland 3.1% 55,000 
Scotland 3.4% 170,00 
Wales 4.1% 127,000 
Table 1.1.2. Prevalence of diabetes in the UK 2005/06 (2) 
 
Diabetes is a huge burden on the NHS, accounting for about £1 billion in 
annual expenditure (about 5% of total expenditure) (2).  Diabetes is the 
leading cause of blindness in the working age population (2, 5).  One 
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thousand patients with diabetes start dialysis due to renal failure in the UK 
every year and about 20-25% patients starting renal replacement 
programmes are patients with diabetes (2, 5).  In patients with T2DM the 
average life expectancy is reduced by eight to ten years and about 70% of 
deaths are attributable to atherosclerotic disease (5).  
 
b. Diabetes and Cardiovascular Disease  
 
It is well known that patients with T2DM are at an increased risk of 
cardiovascular (CV) disease which accounts for 70% of total mortality (6).  In 
patients with T2DM insulin resistance results in impaired glucose metabolism 
along with increased likelihood of hypertension, central obesity, endothelial 
dysfunction, abnormal lipid profiles and prothrombotic factors (7, 8).  
Unfortunately not only is the incidence of these CV risk factors increased in 
patients with T2DM but T2DM is itself a major CV risk factor (9).  There is a 
two to four fold risk of developing coronary heart disease (CHD), stroke and 
peripheral vascular disease (PVD) in T2DM than in patients without diabetes 
(6, 7).  Patients with diabetes are more likely to develop multi-vessel coronary 
artery disease (CAD) which is itself at increased risk of plaque ulceration and 
thrombosis (10).   Similar differences have been described in peripheral blood 
vessels (10).  The mortality after cardiac events (including sudden death) is 
also significantly increased compared to the non-diabetic population (7, 11).  
Further more, despite death from CV disease falling over the last 35 years, 
there has not been a decline in CV deaths in T2DM (7).  Atherosclerosis and 
its complications in T2DM are now well accepted as important target areas for 
 18 
 
treatment and funding and there are national targets and guidelines to help 
address this problem.  Increased CAD is not the only myocardial problem in 
diabetes e.g. left ventricular hypertrophy (LVH) is also common in those with 
diabetes and would appear to be at least as adverse as CAD.  This is 
discussed in more detail in Section 2. 
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2. Left Ventricular Hypertrophy in Patients with Diabetes  
  
a. Definitions of Left Ventricular Hypertrophy 
  
LVH is a condition whereby the cardiac myocyte responds to biomechanical 
stress from either extrinsic or intrinsic sources.  The precise mechanisms 
whereby LVH arises are discussed later.  At a cellular level, the 
cardiomyocyte increases in size and has enhanced protein synthesis (12).  
There are three main ways to detect LVH clinically: electrocardiogram (ECG), 
echocardiogram (echo) and cardiac magnetic resonance imaging (CMR) 
scanning. 
 
 i. Electrocardiographic Criteria for Left Ventricular Hypertrophy  
 
ECG criteria for LVH include the Sokolow Lyon or Cornell voltage criteria.  
The Sokolow Lyon criteria are defined as the sum of the S wave in V1 and the 
R wave from the highest of either V5 or V6.  LVH is diagnosed if the sum is 
greater than 35mm.  The Cornell voltage criterion is defined as the sum of the 
S wave in V3 and the R wave in aVL.  Values of greater than 20mm in women 
and 28mm in men are defined as representing LVH on an ECG.  It is now well 
accepted the Sokolow Lyon and Cornell voltage criteria perform poorly at 
detecting LVH in comparison with echo (13, 14).  When the ECG criteria that 
was used in the LIFE study where applied to a population of patients with 
diabetes, it was found many patients with echo LVH would be missed (15).  
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ii. Echocardiographic Criteria for Left Ventricular Hypertrophy 
 
Echocardiographic measurements of LVH are generally defined using the 
American Society of Echocardiography (ASE) recommendations (16).  It is 
recommended that M mode measurements are taken at end diastole at the 
onset of the QRS complex.  Left ventricular mass (LVM) is indexed to body 
surface area (BSA) and LVH defined as greater than 95g/m2 in women and 
115g/m2.  LVM can also be indexed to height to avoid underestimating the 
prevalence of LVH in obese patients.  The ASE recommends cut offs as 
44g/m2.7 for women and 48g/m2.7 for men when LVM is index to height.  Both 
these methods of assessing LVH have been prognostically validated (16). 
 
iii. Cardiac MRI Criteria for Left Ventricular Hypertrophy 
 
CMR scanning of the heart is an accurate measurement of LVM and is highly 
reproducible (17-19).  There is a poor correlation between echo calculated 
LVM and CMR calculated LVM.  In general echo M mode LVM calculations 
show overestimation and large measurement variability when compared with 
CMR measurements (20).  Simpson et al (2009) found that mean LVM was 
higher in their echo derived data than the mean CMR derived LVM index 
(LVMI) in their study of 51 subjects (21). This is a common finding that has 
been previously reported and is due to the ways by which LVM is estimated 
(22). The echo method makes large geometric assumptions because it is 
based on two-dimensional data, whereas the CMR method makes fewer 
geometric assumptions because it is calculated from three-dimensional data.  
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There are limitations however when using CMR to measure LVM.  There is 
inter-observer variability when deciding which basal and apical slices to 
include and each slice has a large cross sectional area which can have large 
affects on mass and volume measurements (23).  There are also difficulties 
encountered when defining the most basal slice adjacent to the mitral valve 
plane due to partial volume effects (23).  The values that are considered as a 
normal range for LVM using CMR are therefore lower than for echo.   
 
The normal ranges for LVM derived from CMR vary depending on whether 
fast gradient echo imaging techniques (FLASH) or steady state free 
precession (SSFP) techniques are used.  The traditional FLASH images are 
accurate for assessment of assessment of LV volumes, mass and function 
(24).  The SSFP images are quicker but have greater contrast at the 
epicardial border with less blood flow dependence and greater fat to 
myocardial contrast at the epicardial border (24).  Therefore there are 
differences in CMR derived LVM when using different imaging techniques.  
Malayeri et al (2008) analysed the results from 50 individuals using the two 
techniques, FLASH and SSFP (24).  They found LVM was significantly lower 
using the SSFP technique, with a mean difference of 4.8g at end systole and 
6.0g at end diastole. 
 
Average LVM values using SSFP techniques:  Clay et al (2005) studied 40 
normal subjects, comprising 20 males and 20 females aged between 19 to 54 
(23).  They used 1.5 Tesla (T) MRI machine and also used SSFP sequences.  
Alfakih et al (2003) analysed their cohort of 60 normal subjects with SSFP 
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sequences as well as FLASH sequences (25).  Table 1.2.1 shows the normal 
values derived from these two studies using SSFP techniques. 
 
 Men   Women   
Parameter Mean +/- SD Normal 
range 
Mean +/- SD Normal 
range 
LVM (g) 
(Clay et al) 
136.2 ± 20.5 95-177 69.2 ± 15.5 65-127 
LVM (g) 
(Alfakih et al) 
128.8 ± 23.2 85-181 88.1 ± 11.7 66-114 
LVMI (g/m2) 
(Clay et al) 
68.0 ± 8.8 50-86 53.7 ± 8.9 36-72 
LVMI (g/m2) 
(Alfakih et al) 
62.4 ± 7.6 46-83 48.8 ± 5.4 37-67 
LVM indexed to 
height (g/m) 
(Clay et al) 
76.0 ± 10.4 55-89 54.9 ± 15.0 25-85 
LVM indexed to 
height (g/m) 
(Alfakih et al) 
73.5 ± 11.9 51-100 54.2 ± 6.8 41-69 
Table 1.2.1. The normal values for LVM and LVM indexed to body surface 
area and height using SSFP MRI (23, 25). 
 
Average LVM values using FLASH imaging techniques:  Natori et al (2006) 
performed CMR on 400 men and 400 women of different races at random 
(26).  They excluded patients with traditional CV risk factors.  The female 
group comprised of 170 white, 80 African-American, 83 Hispanic and 67 
Asian-American volunteers. The male group included 68 white, 98 African-
American, 78 Hispanic and 56 Asian-American volunteers.  The MRI machine 
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was a 1.5T and the imaging technique was FLASH.  In comparison with Natori 
et al (2006), Alfakih et al (2003) studied 60 normal subjects, 30 male and 30 
female aged 20-65 and produced normal values for FLASH techniques (25). 
Table 1.2.2 shows the normal values for LVM and LVM indexed to body 
surface area and height for both studies. 
 
 Men  Women  
Parameter Mean +/- SD  Normal 
range 
Mean +/- SD Normal 
range 
LV mass (g) 
(Natori et al) 
163.8 ± 35.8  113.6 ± 24.2  
LV mass (g) 
(Alfakih et al) 
154.2 ± 26.7 108-211 103.4 ± 13.5 82-132 
LV mass 
indexed to body 
surface area 
(g/m2) 
85.1 ± 15.2  66.9 ± 10.9  
LV mass 
indexed to body 
surface area 
(g/m2) 
(Alfakih et al) 
75.1 ± 8.8 60-96 57.3 ± 5.6 4 -77 
LV mass 
indexed to 
height (g/m) 
(Natori et al) 
94 ± 19  71 ± 14  
LV mass 
indexed to 
height (g/m) 
(Alfakih et al) 
87.9 ± 13.4 65-115 63.6 ± 7.8 50-80 
LV mass 
indexed to body 
mass index 
(g/kg/m2)  
(Natori et al) 
6.32 ± 1.21  4.39 ± 0.82  
Table 1.2.2. The normal values for LVM and LVM indexed to body surface 
area, height and body mass index using FLASH MRI (25, 26). 
 
Cain et al (2009) more recently looked at 96 healthy volunteers aged 11-81 
years with 50 of the subjects being male (27).  They used a 1.5T machine and 
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FLASH MRI and found that LVM varied over a broad age range as LVM rises 
in adolescence and peaks in middle age.  Table 1.2.3 shows a summary of 
the predicted lower, mean and upper limits for normal LV parameters in males 
and females of different ages. 
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Table 1.2.3. Summary of the predicted lower, mean and upper limits for 
normal LV parameters in males and females of different ages (27). 
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Recently, newer 3T MRI machines are being phased in and the above data 
was all derived on 1.5T machines.  Both sequences have been shown to have 
no difference in the quantification of LVM and volumes when using either 1.5T 
or the higher field strength 3T MRI machines and therefore normal LVM 
ranges should be transferable to both types of MRI machines (28). 
 
b.     Prevalence of Left Ventricular Hypertrophy 
 
LVH is common in a number of conditions namely CAD, PVD, hypertension 
and obesity.  The Framingham heart study found that prevalence of LVH 
increases with age as 33% of men and 49% of women aged 70 or older had 
LVH in their cohort (29). Framingham also found that a significant association 
between blood pressure (BP) and LVH was present even at levels of systolic 
pressure below 140 mm Hg (age adjusted). There is a nine fold (women) to 
tenfold (men) increase in age adjusted LVH prevalence from the leanest to 
the most obese group. In Framingham’s multivariate analysis, age, BP, 
obesity, valve disease, and myocardial infarction were all independently 
associated with LVH in both sexes.  Ang et al (2007) found the prevalence of 
LVH in CAD was as high as 73%, and interestingly 62% of these patients had 
non-hypertensive 24hour BP recordings (30).  Up to half of patients with newly 
diagnosed PVD have LVH (31).   
 
It is becoming increasingly recognised that diabetes is an independent 
predictor of LVH.  Dawson et al (2005) performed an echo on 500 patients 
with T2DM to look for abnormalities of LV function (32).  Standard echo M 
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mode measurements were taken of the LV and indexed to body surface area 
and height.  LVH was highly prevalent, of the 371 patients in whom LVM could 
be successfully measured, 264 (71%) had LVH when LVM was indexed to 
height and 159 (43%) when LV mass was indexed to body surface area.  
When this data was published these measurements were applied to the old 
higher ASE guidelines for defining echo LVH as LVMI greater than 110 g/m2 
in women and greater than 134 g/m2 in men and LVMI to height as greater 
than 47g/m2.7 in women and greater than 50 g/m2.7 in men.  When the new 
ASE definitions of LVH (LVMI greater than 95 g/m2 in women and greater 
than 115 g/m2 in men and LVMI to height as greater than 45g/m2.7 in women 
and greater than 49 g/m2.7 in men) were applied to their data they found the 
prevalence of LVH was even higher and is summarised in table 1.2.4. 
 
 Mild LVH (%) Moderate 
LVH (%) 
Severe LVH 
(%) 
Overall 
prevalence 
(%) 
Indexed to 
BSA: 
 
Women 
 
Men 
 
 
 
 
18 
 
18 
 
 
 
21 
 
15 
 
 
 
26 
 
30 
 
 
 
65 
 
63 
Indexed to 
height: 
 
Women 
 
Men 
 
 
 
 
19 
 
15 
 
 
 
19 
 
16 
 
 
 
45 
 
41 
 
 
 
85 
 
72 
Table 1.2.4. Prevalence of LVH as defined by the new ASE guidelines (32). 
 
Nakamura et al (1994) showed in a smaller number of patients, again using 
echo M mode, that LVMI in hypertensive patients with glucose intolerance 
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was significantly higher than that in hypertensive patients without glucose 
intolerance.  The mean LVM in the glucose intolerance and hypertension 
group was 115.6 +/- 28.2 g/m2 whereas the mean LVM in the hypertensive 
only group was 102.1 +/- 22.1 g/m2 (P <0.05) (33).  Framingham data showed 
that after accounting for confounding factors, in women with diabetes there is 
an independent association of higher LVM and wall thickness (34).  A survey 
performed on patients attending our local diabetes clinic found LVH was 
present in 32% (57 of 173) of patients with T2DM, independent of BP or the 
use of angiotensin-converting enzyme (ACE) inhibitors (35). 
 
Barrios et al (2009) used ECG criteria to look at the prevalence of LVH in 
diabetic patients (36).  LVH was more common again than in the patients 
without diabetes population at baseline.  37.5% of diabetic and 26.4% of non-
diabetic patients fulfilled criteria of ECG LVH by the Cornell criteria (p=0.02), 
25.7% and 23.2%, respectively, by Sokolow Lyon criteria (p=0.18), 11.8% and 
13.7% by Cornell voltage index (p=0.16), and 14.3% and 11.6% by Sokolow 
Lyon voltage index (p=0.10).  The differences in prevalence are different if 
echo or ECG criteria are used as it is well accepted the classic Sokolow Lyon 
and Cornell voltage criteria underestimate LVH when compared with echo, as 
discussed in the previous chapter (13, 14). 
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c.    Increased Cardiovascular Risk Associated with Left Ventricular 
Hypertrophy 
 
The presence of LVH on ECG or echo is well known to confer a higher risk of 
CV events and mortality from many studies over the last 20 to 30 years (37, 
38).  Levy et al (1990) studied 3,220 patients in the Framingham Heart Study 
to look at the relationship of echo LVH to the incidence of CV events (37).  
The patients included were over 40 years old and did not have apparent CV 
disease. They found that LVH predicts a higher incidence of clinical events 
attributable to CV disease, including death, and this was evident even after 
correcting for traditional risk factors.  In men, the risk factor-adjusted relative 
risk of CV disease was 1.49 for each increment of 50g/m2 in LVM corrected 
for height (95% CI, 1.20 to 1.85); in women, it was 1.57 (95% CI, 1.20 to 
2.04). 
 
Liao et al (1995) directly compared the survival of echo LVH with CAD.  They 
included 1,089 black patients and followed them up for a mean of five years.   
Interestingly they found that LVH was associated with higher risk ratio than 
CAD (relative risk for LVH 2.4 (95% CI 1.7 to 3.2) and relative risk for multi-
vessel CAD 1.6 (95% CI, 1.1 to 2.2)) (39).  It is debatable whether this extra 
risk extends to Caucasian populations, as it is well known black patients have 
higher CV deaths and heart failure (40-43).  Surprisingly this type of study has 
not been replicated on a wider scale in other race groups. 
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Vakili et al (2000) analysed the results of 45,545 patients published in 20 
studies between 1960 and 2000 to review the association between LVH and 
CV events (38).  The studies included in this large meta-analysis diagnosed 
LVH either on ECG, echo or on both.  When ECG criteria for LVH was 
studied, LVH was associated with 1.6 to 4.0 fold higher risk of future CV 
events and included 14, 450 patients (38). The studies included varied on the 
criteria used to diagnose LVH on ECG.  Therefore some patients may have 
met the criteria for one study but not the other.  Studies using echo LVH 
included less patients, (n=3, 651) and had an adjusted relative risk (RR) of CV 
events of 1.5 to 3.5, see Figure 1.2.1 (38).  Overall the events defining CV 
end points varied amongst the different studies and this should be borne in 
mind when reviewing the data, but regardless of this or the LVH definitions 
used, a strong trend was shown between LVH and adverse events in this 
meta-analysis (38). 
 
 
Figure 1.2.1 Summary of mean risk ratio for available studies of baseline LVH 
for CV events (38). 
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It is not clear whether men or women have worse outcome if they have LVH, 
and this is reflected in a number of studies.  Levy et al (1990) used echo to 
diagnose LVH and found that the risk ratio for CV events was 2.0 (95% CI, 
1.44 to 2.81) for women and 1.6 (95% CI, 1.14 to 1.94) for men.  Dunn et 
al (1990) found the opposite.  They studied 3,780 patients, using ECG to 
diagnose LVH, who attended Glasgow BP Clinic between 1968 and 1983.  
All-cause age-adjusted mortality (deaths per 1000 patient-years) was 
41.4 for men and 22.1 for women (44). 
 
d.  Left Ventricular Hypertrophy and its Association with Increased 
Cardiovascular Risk 
 
i. Myocardial Ischaemia and Left Ventricular Hypertrophy 
 
In patients with LVH and normal coronary arteries, coronary flow reserve is 
reduced, which can lead to exertional myocardial ischaemia due to an inability 
to meet the metabolic needs of the thickened myocardium.  Andren et al 
(1999) performed exercise tests on elderly male patients with either LVH and 
hypertension, or LVH and normal BP and compared these with healthy 
controls (n=58).  None of the recruited patients had known CAD (45).  The 
hypertensive subjects with LVH showed more pronounced ST depression on 
exercise testing when compared with the healthy group without LVH.  In both 
of the LVH groups, more than 20% of the subjects had ST-segment 
depression greater than or equal to one millimetre (usually considered to be a 
significant change), compared with only 5% of the healthy group without LVH. 
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There are differing theories as to why coronary flow reserve is reduced in 
LVH.  One possible mechanism is the result of increases in extra vascular 
compressive forces caused by LVH.  This may result in wall stress leading to 
interstitial fibrosis and changes in the of coronary arteries (and small micro-
arteries) leading to reduced myocardial blood flow (46).  This hypothesis fits in 
with the observation that the degree of LVH correlates in a linear fashion with 
the amount of reduction in coronary flow reserve.  Opherk et al (1984) first 
showed this by measuring coronary blood flow using the argon method in 12 
control subjects and in 16 patients with hypertension and LVH at rest and 
after intravenous administration of dipyridamole. In the patients with 
hypertension and LVH, coronary blood flow response to dipyridamole was 
markedly reduced and during coronary vasodilatation there was a linear 
correlation between coronary resistance (46).  Hamasaki et al (2000) 
confirmed similar findings, using a different technique of intravascular 
ultrasound, in the left anterior descending coronary artery (47).  They studied 
111 patients with normal coronary arteries divided into three groups: normal 
BP, hypertension and LVH, or hypertension and no LVH.  The response to 
both acetylcholine and adenosine was significantly impaired in patients with 
LVH. 
 
In contrast to the above studies, other researchers have found that impaired 
coronary flow reserve in hypertensive patients is not always related the 
degree of LVH.   Gimelli et al (1998) has proposed the possible reason for 
these alternative findings is that endothelial dysfunction is caused by vascular 
remodelling such as media thickening, peri-vascular fibrosis or functional 
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vascular alterations independent of the degree of LVH (48).  This may result 
in changes in the ability of the coronary arteries to vasodilate.  This was first 
shown by Vogt et al (1992), they studied over 200 hypertensive patients with 
no CAD.  They found that LVM and coronary vascular resistance were not 
directly related (49).  Gimelli et al (1998) studied 50 untreated hypertensive 
patients and 13 normotensive patients and measured coronary reserve and 
resistance before and after dipyridamole (48).  They found that LVM was not 
correlated with global myocardial blood flow.  Patients with LVH did have a 
heterogeneous flow pattern with regional defects and normal blood flow in 
non-affected areas of the myocardium. 
 
With regard to coronary flow reserve in patients with diabetes, a Japanese 
group looked at 92 subjects consisting of 70 diabetic patients without overt 
cardiac disease and 22 normal controls to assess myocardial blood flow 
reserve during exercise using myocardial contrast echocardiography (50).  
Myocardial blood flow reserve was significantly reduced in patients with 
diabetes compared with controls.  They showed that diabetic patients have 
exercise induced delayed onset of LV relaxation in association with impaired 
coronary microcirculatory function in the absence of co-existent heart disease. 
 
In summary it may be both mechanisms for myocardial ischaemia co-exist to 
different degrees in patients with LVH and hypertension.  Because there is 
also evidence that there are changes in coronary microvasculature specifically 
in diabetic patients, the combination of hypertension, diabetes and LVH will 
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have a significant impact on coronary artery flow reserve and hence 
ischaemia. 
 
ii. Arrhythmias and Left Ventricular Hypertrophy 
 
For a long time it has been accepted that LVH is associated with ventricular 
ectopy, ventricular arrhythmias and cardiac sudden death.  Messerli et al 
(1984) looked at a small number of patients with LVH and found they had 
more premature ventricular ectopics (51).  McLenachan et al (1987) also 
showed that not only are ventricular ectopics common in patients with LVH, 
but so were episodes of non-sustained ventricular tachycardia (VT) (52).  16% 
of their patients with LVH had non-sustained VT of five beats or more. Siegel 
et al (1990) found the odds ratio (OR) for having episodes of VT in LVH was 
2.3 (confidence interval of 0.7 – 7.1) in their cohort of patients (53).  These 
studies suggest non-sustained VT is highly prevalent in patients with LVH but 
none of these studies actively excluded CAD and it is known there is also a 
strong association with CAD.  Ghali et al (1991) was the first to show the 
association of LVH and ventricular arrhythmias in patients with normal 
coronary arteries proven by coronary angiography (54).  In their cohort, they 
showed the frequency and complexity of ventricular arrhythmias was 
significantly related to the presence of LVH. They found for every one 
millimetre increase in the thickness of inter-ventricular septum or posterior 
wall there was an associated two to threefold increase, respectively, in the 
occurrence and complexity of ventricular arrhythmias (54).  The association 
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between LVH and ventricular arrhythmias has also been confirmed by 
electrophysiological testing (55). 
 
The reasons why patients with LVH may be prone to ventricular arrhythmias 
are due to changes in the myocardium in LVH.  Cosin Aguilar et al (1993) 
explains that LVH leads to electrical changes, growth of the collagen matrix 
and ischaemia that contribute to arrhythmias (56).  These myocardial changes 
increase re-entry electrical mechanisms, long QTc and prolonged action 
potentials further contributing to the risk of ventricular arrhythmias (47).  
 
iii. Left Atrial Size and Left Ventricular Hypertrophy 
 
Another mechanism whereby LVH increases CV risk is its association with left 
atrial (LA) dilatation.  LVH leads to reduced compliance of the LV and leading 
to the LA needing to provide higher filling pressures leading to diastolic heart 
failure and eventually to LA dilatation (57, 58).  LA dilatation is related to LV 
mass and it does not matter if the LVH is eccentric or concentric (59).  Other 
features strongly associated with increased LA size in LVH include high BMI, 
high systolic BP and the presence of mitral regurgitation and atrial fibrillation 
(AF) (60).  Stritzke et al (2009) studied the association of obesity and 
hypertension to LA volume (61).  Patients were followed up prospectively over 
10 years.  After adjustment for age and sex, the OR between obesity and LA 
enlargement was 2.7 while hypertension was less at 1.1.  It would therefore 
seem obesity is a greater determinant of LA enlargement than hypertension. 
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LA size is important because it is considered a CV risk factor in its own right.  
The LIFE trial looked at LA diameter by annual echo correlated with CV 
events in 881 hypertensive patients (41% women) with ECG LVH during a 
mean follow up period of 4.8 years (62).  They found that baseline LA 
diameter predicted the incidence of CV events (defined as death, myocardial 
infarction or stroke) with a hazard ratio of 1.98 (95% confidence interval [CI] 
1.02 - 3.83) adjusted for significant effects of Framingham risk score and 
history of AF.  Framingham also showed a correlation between LA size, death 
and stroke (63).  All subjects 50 years of age and older from the Framingham 
Heart Study were studied with an 8 year of follow up. After multivariable 
adjustment, for every 10-millimetre increase in LA size, the relative risk of 
stroke was 2.4 in men (95% confidence interval 1.6 - 3.7) and 1.4 in women 
(95% confidence interval 0.9 - 2.1); the relative risk of death was 1.3 in men 
(95% confidence interval 1.0 - 1.5) and 1.4 in women (95% confidence 
interval 1.1 to 1.7).  LA size has also been associated with sudden cardiac 
death in patients with heart failure (64). 
 
LA dilatation (which we now know is related to LVH) and diabetes are risk 
factors for development of AF, therefore special consideration to AF in 
diabetes is given below. 
 
iv. Atrial Fibrillation in Diabetes 
 
Why is AF important in diabetes and LVH? It is becoming increasingly 
recognised that in addition to traditional risk factors for AF, such as 
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hypertension, ischaemic (IHD) and heart failure, diabetes is also a risk factor 
for AF.  The exact pathophysiology for this observation is unclear but is 
possibly related to the dilated LA found in patients with LVH and also the 
direct glucose affects on the myocardium causing electrical instability.  
Obesity and hypertension are also strongly associated with LA dilatation, 
which in turn is a strong risk factor for AF, as discussed previously.  Therefore 
co-morbid vascular disease associated with diabetes is one possible reason 
for the association of diabetes with AF.   Rutter et al (2003) investigated the 
impact of insulin resistance on heart structure and function in a community 
based sample of Framingham study patients (65).  They found that the more 
severe glucose intolerance, the higher the LA size in both men and women.  
Lind et al (1996) also found a correlation between diabetes and LA size (66). 
 
AF in diabetes is important because diabetes may mask the cardiac 
symptoms associated with the onset of AF and this masking of symptoms is a 
potential mechanism for the increased risk of stroke in patients with diabetes, 
i.e. if AF is under diagnosed then anti-coagulation will not be considered. The 
development of AF in a diabetic patient has also been shown to increase the 
risk of stroke in diabetic patients (67).  Stroke risk is most commonly 
measured by the well-validated ‘CHADS2’ score (68, 69).  One large study, 
Wilhelmsen et al (2001), did not find a correlation between AF and diabetes 
(70), but subsequent larger studies have shown significant correlations and 
these are summarised in table 2.5. 
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Author Total 
number 
of 
patients 
Prevalence of 
AF in diabetics 
Prevalence 
of AF in non 
diabetics 
Odds ratio 95% 
Confidence 
interval 
Hazard 
ratio 
95% 
Confidence 
interval 
p value 
Movahed et al 
(2005) 
845748     2.13 2.10 - 2.16     <0.05 
Ostgren et al 
(2004) 
1739 4 2 2 0.9 - 4.7     <0.05 
Nichols et al 
(2009) 
17372 3.6 2.5     1.26 1.08 -1.46 <0.05 
Benjamin et al 
(1994) 
4731     1.4 (men) 1.6 
(women) 
      <0.05 
Aksnes et al 
(2008) 
15245         1.49 1.14 - 1.94 <0.05 
Psaty et al (1997) 5201     1.08 1.03 - 1.13     <0.05 
Table 1.2.5 Comparison of the association of AF with Diabetes from the major 
published studies expressed as odds and hazard ratios. 
 
In an analysis of all 84,5748 in-patient records from all the Veterans Health 
Administrations hospitals in America (71), Movahed et al (2005) reported a 
significant correlation between diabetes and AF.  AF occurred in 14.9% of 
diabetic patients compared with 10.3% in the control group of patients with 
hypertension but no diabetes.  Atrial flutter occurred in 4% of diabetic patients 
compared with 2.5% in the control group.  When congestive heart failure, 
CAD and LVH were accounted for, diabetes still remained a strong 
independent risk factor for AF and atrial flutter, with odds ratios of 2.13 and 
2.20 respectively.   This study is by far the largest study looking at the 
correlation between diabetes and AF.  There are a number of drawbacks in 
that this study was retrospective and was conducted in hospitalised patients 
only. 
 
The two other larger studies, Nichols et al (2009) and Aksnes et al (2008) 
reported similar findings from large diabetes registries (72, 73).  Nichols et al 
(2009) found after adjustment for other risk factors, diabetes was associated 
with a 26% increased risk of AF among women, but intriguingly diabetes was 
not a predictor among men.  The Framingham Heart Study, Östgren et al 
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(2004) and Psaty et al (1997) looked at smaller numbers of patients but found 
similar significant correlations (74-76).  Aksnes et al (2008) studied large 
numbers of patients in the VALUE trial to see who developed AF (73).  Of the 
patients who developed AF during the follow up period, diabetic patients had 
a significantly higher chance of developing AF that was also more persistent. 
 
v. Summary 
 
The development of LVH in a diabetic patient is an ominous sign.  This is due 
to not only the already increased CV risk that comes with being diabetic but 
also because LVH has been shown to be a serious risk factor in its own right 
in a number of ways.  LVH, hypertension and diabetes affects coronary flow 
reserve inducing ischaemia.  LVH induces arrhythmias such as VT and AF 
that are associated with considerable morbidity and mortality.  LVH impedes 
ventricular filling and leads to diastolic heart failure that may even later 
transform into systolic heart failure.  Finally, LVH increases LA size, which is a 
CV risk factor in its own right.  Therefore the combination of these factors in a 
diabetic patient with LVH means it should be an important target for future 
therapies. 
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3. The Development of Left Ventricular Hypertrophy  
 
Hypertension is the most commonly thought of and studied cause of LVH due 
to its haemodynamic effects on the LV.  However BP trials have suggested 
that different agents regress LVH more than others independent of BP, i.e. 
ACE inhibitors and Angiotensin Receptor Blockers (ARBs) regress LVH more 
than agents such as beta-blockers, and the degree of LVH varies even for 
similar levels of hypertension (77-79).  These trials are discussed in detail in 
chapter 4: ‘Treating Left Ventricular Hypertrophy’.  It seems there must be 
more to LVH than BP and the view that BP is the only pathogenic mechanism 
in the development of LVH is now considered too simplistic. Here, pathogenic 
theories for the development of LVH are discussed individually. 
 
a. Blood Pressure and Obesity 
 
The main theory for the development of LVH is based around changes in the 
myocardium in response to haemodynamic burden, most commonly due to 
increase after-load as a result of hypertension.  Increase in haemodynamic 
over load can be either due to increased pressure (e.g. hypertension, aortic 
stenosis) or volume overloads (e.g. aortic regurgitation, mitral regurgitation or 
anaemia).  The response of the heart to haemodynamic pressure increases 
causes the heart to compensate in three ways: shifting of the Frank-Starling 
curve to the right leading to increased cardiac output, increase in cardiac 
muscle mass to adjust to increased after-load and neuro-hormonal 
mechanisms to increase contractility (80).  It is the increase in muscle mass 
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as a result of myocardial hypertrophy (not hyperplasia) that is the key long-
term compensatory mechanism in response to a haemodynamic burden.  
Pressure overload tends to lead to concentric hypertrophy and volume 
overload tends to lead to eccentric hypertrophy. 
 
Thus hypertension is a key cause for the development of LVH in the general 
population and there is a correlation between the degree of hypertension and 
the development of LVH (29, 81, 82).  In particular, ambulatory BP (ABPM) 
monitoring is superior to office BP monitoring of hypertension.  Verdecchia et 
al (1990) showed in 165 untreated hypertensive patients compared with 92 
healthy patients that 24 hour ABPM was better at predicting LVH than office 
BP readings (83).  There was a stronger correlation between ABPM than 
office BP in terms of predicting LVH.  They also correlated ABPM to office BP 
and when ABPM was higher than predicted, this group had the highest 
prevalence of LVH (6-10% and 35-39% respectively) (84, 85). 
 
We already know LVH is common in people with diabetes.  Hypertension and 
obesity are more common in patients with T2DM; in fact T2DM patients are up 
to twice as likely to develop hypertension as without diabetes.  Obesity is 
independently associated with LVH, and the combination of hypertension and 
obesity is additive (17 fold increase in risk of developing LVH) (82, 86, 87).  
LVH may be more common in diabetes because of the close relationship 
between insulin resistance, obesity and hypertension (88-90).  However, 
patients of normal weight and BP are at risk of LVH.  Dawson et al (2005) 
found that LVH occurred independently of BP in a cohort of 500 diabetic 
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patients (32).  There were more patients in the LVH group who had a history 
of hypertension (8% with no LVH and 13% with LVH) and this was significant 
for only one LVM parameter.  Framingham found that 28% of females in their 
cohort aged over 60 years with BP below 139mmHg had LVH on echo (87). 
 
There must be other factors contributing to the development of LVH that are 
not mediated just by obesity and/or BP, and it seems LVH is mediated by the 
interaction of other variables such as genes, oxidative stress (OS), endothelial 
function, renin angiotensin system (RAS) and direct effects of insulin and 
glucose on the myocardium. Of course, these factors also interplay with 
hypertension and obesity, and are discussed in turn below. 
 
b. Oxidative stress in Diabetes 
 
 i. The Concept of Oxidative Stress 
 
Reactive oxygen species (ROS) is a collective term for the by products of the 
metabolism of oxygen in a normal cell that can be also abnormally increased 
in particular diseases and stress states such as atherosclerosis, neuro-
degeneration, renal disease and cancer.  ROS include super oxide anions 
(O2-) and hydrogen peroxide (H2O2) that undergo further reactions to produce 
more ROS.  In particular, O2- interacts with nitric oxide (NO) to produce 
peroxynitrite (ONOO-) and H2O2 is converted to hydroxyl radicals (OH-) via 
Fenton chemistry, as shown in Figure 1.3.1 (91, 92). 
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Figure 1.3.1.  The principle reactions involved in the generation and 
degradation of hydrogen peroxide (92). 
 
O2- is formed by mitochondrial respiration or by various enzymes including 
NAD(P)H oxidase, NO synthase and xanthine oxidase (XO) (91).  XO is the 
enzyme blocked by allopurinol, which is discussed in detail later.  In normal 
cells, these ROS are maintained at low levels by two principle enzymes, 
superoxide dismutase (SOD) and catalase, that mop-up and scavenge ROS 
and degrade them to inactive molecules (92).  SOD is found in three various 
forms, mnSOD, CuSOD and ZnSOD.  In the human heart, it is estimated that 
mnSOD makes up 90% of the activity in myocytes, wheras CuSOD and 
ZnSOD is extracellular (91).  In fact, homozygous mutant mice for the mnSOD 
gene die rapidly of cardiomyopathy (93).  MnSOD is also implicated in 
myocardial adaptation after induced myocardial infarction in rats (94).  The 
redox state of a cell describes the balance between generation and removal 
of ROS.  ROS cause damage to cell signalling, proteins, DNA and RNA due 
to their unpaired valence shell electrons that can lead to a cycle of imbalance 
of the redox state which is known as OS (95).  The regulation and chemistry 
involved in ROS is summarised in figure 1.3.2. 
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Figure 1.3.2.  The basic pathway for the generation of ROS (95). 
 
The two main sources of ROS in LVH and heart failure that have been 
implicated to date are XO and NADPH (92).  Firstly, XO produces O2- as a by-
product of purine metabolism, (discussed in detail in ‘section 5: Xanthine 
Oxidoreductase and Allopurinol’) and XO related OS is found in pressure 
overload of the heart and heart failure, see Figure 1.3.3 (95).  This has also 
been clearly demonstrated in several in vitro studies, including one in which 
XO was the source of the OS and caused the hypertrophic phenotype (96-98). 
 
Figure 1.3.3. Role of XO in pressure overload and heart failure (95). 
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Secondly, NADPH oxidase catalyses the electron transfers from NADPH to 
oxygen, thereby producing O2- and NADPH oxidase activity that has been 
found to be increased in heart failure and LVH in experimental models (91, 
93) (99-101). 
 
 ii. Oxidative Stress Causing Left Ventricular Hypertrophy  
 
ROS are involved in the development and perpetuation of myocyte 
hypertrophy in two ways.  Markers of increased OS, namely isoprostane-2, 
have been found systemically and in pericardial fluid in patients with heart 
failure (92, 98).  In frank heart failure, ROS are thought to cause free radical 
oxidation and damage such as cell damage, apoptosis and necrosis (92).  
However, ROS can cause more subtle damage, as is the case in myocyte 
hypertrophy, where these ROS are thought to activate a variety of 
hypertrophy signalling kinases and transcription factors leading to the 
development and perpetuation of myocyte hypertrophy (95, 102).  ROS also 
appear to mediate the hypertrophic response to other known hypertrophic 
stimuli in redox sensitive pathways, such as mechanical strain, angiotensin, 
tumour necrosis factor-α (TNF-α) and α-adrenergic, see Figure 1.3.4 (91, 95).  
A self perpetuating cycle appears to occur in that pressure overload produces 
OS which further exacerbates the hypertrophic response to the pressure 
overload (95). 
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Figure 1.3.4. ROS mediated myocyte hypertrophy (91).    
 
The main pathophysiological effects of OS in LVH and heart failure are 
summarised by Sneddon et al 2006, Figure 1.3.5.  In summary, ROS cause 
damage in three principles ways.  Oxidative damage causes myocyte 
dysfunction and cell death, inactivation of NO leads to endothelial dysfunction 
and deficiencies of redox signalling leads to hypertrophy and fibrosis. 
 
Figure 1.3.5.  Pathophysiological effects of oxidative stress in LVH and heart 
failure (92). 
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 iii. Diabetes as a Source of Oxidative Stress 
 
Patients with diabetes are known to have increased OS.  In T2DM there is 
principally increased mitochondrial ROS (especially O2-) production from free 
fatty acids in vessels and endocardium (103).  Giacco et al (2010) have 
described a hyperglycaemic memory, whereby ROS generated due to 
hyperglycaemia in diabetes drive persistence pro-inflammatory genes that 
remain after glycaemia is normalised (103).  These increased ROS may in 
part lead to the micro- and macro-vascular complications in diabetes, 
including LVH and heart failure. 
 
The two main enzymes that are targets for treatments in reducing OS in heart 
failure and LVH are NADPH oxidase and XO.  ACE inhibitors and ARBs 
inhibit ACE NADPH oxidase and are in widespread use (92).  Inhibition of XO 
is the subject of this thesis and is discussed in detail. 
 
c. Endothelial function 
 
i. Principles of Endothelial Function 
 
Until the 1980’s the endothelium was thought of as an inert barrier in the 
blood vessel.  In 1980, the landmark paper by Furchgott et al (1980), showed 
that the endothelium dilates in response to acetylcholine (104).  Soon after, it 
was discovered NO also plays a vital role in the function of the endothelium 
(105). 
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Blood vessels are made up of three distinct layers, or tunicas, namely the 
intima, media and adventitia (106).  The tunica intima is made up of a single 
layer endothelial cells which are flat epithelial cells, which have many 
functions that will be discussed in turn, and are attached to underlying 
connective tissue (106).  The endothelium lines the intimal surface of the 
entire vascular tree, and is in fact the largest endocrine organ in the body.  
The endothelium has five main roles: it acts as a barrier between blood and 
tissues, it regulates haemostasis, regulates blood flow, regulates diapedesis 
(leucocyte extravasation) and is involved in cell signalling.  This discussion 
will focus on the vasodilatory properties of the endothelium, as the other 
functions are out of the scope of this thesis. 
 
Vasodilators 
NO: NO was initially identified as Endothelial Derived Relaxing Factor (EDRF) 
in 1980, however EDRF was later found to be NO.  NO is a potent vasodilator 
and its synthesis and actions are through the second messenger cyclic GMP 
that is calcium dependent.  NO only acts locally as it has a half life of only a 
few seconds (107).  NO is a free radical that reacts with other ROS, in 
particular superoxide to produce either the highly toxic peroxynitrite or the 
non-toxic nitrate (these reactions are described in more detail in the chapter 
on OS).  NO is synthesised from the amino acid L-arginine in a variety of cells 
namely endothelial cells, platelets, neutrophils, monocytes, mast cells and 
adrenal cells (108).  NO also plays a role in platelet aggregation, smooth 
muscle proliferation and endothelial cell inflammatory response.  The precise 
mechanisms for the release of NO are still unknown, however shear stress is 
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probably the physiological stimulus for the continual release of NO, as NO 
activity is highest in arteries where shear stress is the highest (107).  
Synthesis of NO is also stimulated by acetylcholine, bradykinin and substance 
P and the release of NO accounts for the vasodilatory actions of these 
mediators, and hence are known as endothelium dependent vasodilators 
(107).  Calcium stimulates nitric oxide synthase (NOS) to produce NO.  NOS 
is found in three different forms: neuronal, macrophage and endothelial.  
Figure 1.3.6 shows the NO signalling pathway (109). 
 
 
Figure 1.3.6. The nitric oxide signalling pathway (109). 
 
NO is the dominant factor in vasodilatation, however there are other factors as 
discussed below.  Removal of the endothelium usually leads to 
vasoconstriction and this effect is mimicked by NOS inhibitors (107). 
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Prostanoids: Prostacyclin and prostaglandin E2 and D2 are vasodilators 
(107).  Blocking prostanoid synthesis with aspirin or non-steroidal anti-
inflammatory drugs does not affect vascular tone, except in the kidneys (107). 
 
Endothelial derived hyperpolarising factor (EDHF): EDHF was discovered by 
observations that vasodilatation was preserved in the presence of NOS and 
cyclo-oxygenase inhibitors (107). The role of EDHF is still largely unknown in 
human vasculature (107).  It may be that EDHF plays and important role in 
small arteries.  
 
Vasoconstrictors 
The predominant influence on arteries is dilation, however, there are some 
important vasoconstrictor factors synthesised by the endothelium.  These 
include endothelin, angiotensin II, various prostanoids and O2-.  Endothelin 
has a long duration of action and it is thought to provide background 
counteracting vasoconstrictor influence (110).  The tissue RAS may contribute 
to vascular tone, as ACE is found in the endothelium.  Endothelial derived 
angiotensin II can diffuse through the wall and stimulate neurones to produce 
noradrenaline, a possible link between the endothelium and nervous system 
(111). O2- probably influences vascular tone secondary to its inhibitory effects 
on NO mediated vasoconstriction, although it does have direct constrictor 
actions in some vessels (107). 
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ii. Endothelial Dysfunction in Diabetes 
 
Endothelial dysfunction is the term used to describe the response of the 
endothelium to injury that leads to activation of signalling pathways and a 
cascade of inflammatory pathways (112).  Deanfield et al (2007) argue that it 
should actually be called endothelial activation, as there is a switch from a 
quiescent phenotype towards a host defence response at the level of the 
endothelium (112).  The understanding of endothelial dysfunction is tied in 
with knowledge of OS, as discussed previously.  In principle, OS describes a 
state whereby there is reduced formation or accelerated degradation of NO, 
and this degradation of NO by ROS is key to the mechanisms underlying 
endothelial dysfunction (109). 
 
eNOS uncoupling is a term that describes the fact that eNOS can switch to 
generate ROS under certain circumstances (113).  The ROS that eNOS can 
switch to produce are O2- if the co-factor BH4 is oxidised or H202 if there is a 
deficiency of the substrate L-arginine (113).  The normal function of eNOS 
requires, amongst other things, the essential cofactor (6R)-5,6,7,8-tetrahydro-
L-biopterin (BH4) that is highly sensitive to oxidation by peroxynitrite.  We 
have already discussed that O2- reacts with vascular NO to form the highly 
reactive peroxynitrite, and the cofactor BH4 is highly sensitive to oxidation by 
peroxynitrite.  It is the diminished levels of BH4 that promote O2- production by 
eNOS.  
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In OS the usual NO mediated activation of cellular process changes because 
H202 that is produced by ROS and the uncoupling of eNOS can diffuse 
through cells in a similar fashion to NO (114). H202 reacts with cysteine 
groups in proteins to alter function that have differing results to NO, such as 
phosphorylation of transcription factors, nuclear chromatin remodelling, 
induction of transcription genes and protease activation (114).   
 
It is thought that prolonged production of ROS may exceed the normal 
enzymic counterbalances and lead to abnormal endothelial activation (112).  
Obesity and T2DM in particular lead to increased glucose and free fatty acids 
and therefore there is more substrate available to the mitochondrion during 
oxidative phosphorylation leading to an imbalance and disruption of the redox 
state (112, 115).  Importantly XO is an important source of ROS (112).  
Furthermore, CV risk factors such as hypertension, hypercholesterolemia, 
diabetes or chronic smoking stimulate the production of ROS in the vascular 
wall (113).  NADPH oxidases represent major sources of this ROS and have 
been found to be ‘up regulated’ and activated in animal models of 
hypertension, diabetes, sedentary lifestyle and in patients with CV risk factors 
(113).  The interaction of ROS with NO leads to a vicious cycle of endothelial 
activation and inflammation.  
 
iii. Augmentation Index 
 
The peripheral pulse and BP is the standard method of clinical assessment; 
however this does not necessarily reflect central aortic pressure.  Central 
 53 
 
aortic pressure is thought by some to be a better predictor of outcomes than 
simple peripheral BP (116).  Applanation tonometry at the radial artery is an 
accurate, simple and reproducible method of measuring central pulse 
pressure, in particular an estimation of the ascending pressure wave can be 
made (116). 
 
The central pressure waveform is a result of the summation of the forward 
transmission of the cardiac pressure (i.e. LV systolic pressure) impulse as it 
spreads through the vasculature and the backward reflection generated by the 
peripheral vascular system (117).  Essentially, these points of reflection within 
the peripheral vascular system occur at the interface between large arteries 
and resistance vessels (peripheral arteries and arterioles) (116).  Wave 
reflection results in augmentation of the aortic pressure wave, and is 
dependent on three factors: ventricular ejection contraction and length of 
contraction, amplitude of the reflected wave (reflecting the elasticity of the 
entire vascular tree) and velocity of the pulse wave from the peripheral tree 
(116, 117).  A number of physical and physiological parameters affect the 
wave form, including systolic BP, heart rate and smaller stature (116).  
Augmentation index (AIx) is a measure of the effect of the wave reflection on 
the aortic pressure and it is calculated as the ratio of the increment in 
pressure due to early wave reflection, and thus gives an index of aortic 
stiffness, Figure 1.3.7. 
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Figure 1.3.7. Central pulse pressure waveform or augmentation index. AIx is 
the additional pressure added to the forward wave by the reflected wave. AIx 
is the ratio between augmentation pressure and central pulse pressure. The 
dicrotic notch represents closure of the aortic valve and is used to calculate 
ejection duration. Time to wave reflection is calculated at the point of rise in 
the initial ejection wave to the onset of the reflected wave. The reflected wave 
in this central pressure waveform results in augmentation of systolic flow 
(116). 
 
Figure 1.3.8 shows that a pressure wave returning due to an increased pulse 
wave velocity will augment systole that can lead to increased cardiac loading 
and potentially lead to LVH (116).  Endothelial dysfunction leads to increased 
peripheral vascular resistance and hence increased AIx.  Patients with 
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diabetes also exhibit higher central augmentation pressures (118). This is 
another reason why LVH may be more prominent in diabetes.   
 
 
Figure 1.3.8.  Effects of changes in LV workload on AIx.  Reflection of the 
pulse wave during the systolic period leads to an increase in LV workload 
(black upward arrows) and a decrease in the diastolic pressure (black 
downward arrows). Reflection of the pulse wave during the diastolic period 
leads to a decrease in LV workload and an increase in diastolic pressure 
(116). 
 
Various studies have correlated AIx with hypertension (119), diabetes (118), 
LVH (120), atherosclerosis (118) and diastolic dysfunction (121).  AIx also 
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correlated better with worse CV outcomes than simple office BP in follow up 
studies (116).  Therefore it has been suggested in the future it could be used 
as an additive to standard office BP to guide BP and other secondary 
prevention treatments, although it is not currently widely used in the United 
Kingdom. 
 
iv. Pulse Wave Velocity 
 
Pulse wave velocity (PWV) is part of apllanation tonometry that relates to 
arterial vessel stiffness.  It can be measured between the carotid arterial and 
radial or femoral artery.  If the artery becomes stiffer in conditions such as 
atherosclerosis then the PWV will increase.  Lehmann et al (1998) showed 
that PWV increases proportionally with increases in the number of risk factors 
patients have (122).  PWV is also increased in advancing age and diabetes 
(123).  Aortic stiffness has been correlated with worse CV outcomes in 
hypertensive patients (124). 
 
v. Flow Mediated Dilatation and Prognostic Value of Endothelial 
Dysfunction 
 
Measurement of endothelial function relies mainly on measuring ‘endothelial 
dependent vasomotor tone’ in response to pharmacological or physiological 
stresses.  This tests the endothelial release of NO and other endothelial 
derived factors that cause dilatation of the artery.  This can be then contrasted 
with ‘endothelial independent’ dilatation, such as caused by nitrates that are 
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usually given orally.  Initial studies of endothelial function involved 
acetylcholine as the stimuli which was used because acetylcholine normally 
causes NO release (and other vasodilators) (112).  Following on from this, 
studies tested endothelial function with other pharmacological endothelial 
agonists such as substance P and adenosine.  Physiological responses to 
cold water testing and flow mediated dilatation (FMD) are other ways of 
unmasking physiological responses in the artery (125). 
 
The main technique in the past was to measure venous occlusion 
plethysmography of the forearm, but this technique requires cannulation of the 
artery, making it invasive for the patient (126).  Therefore an ultrasound 
technique of the brachial artery was developed in the 1990’s to measure FMD 
in response to sheer arterial stress caused by occlusion of the artery (127).  
The original FMD studies showed that atherosclerotic arteries do not dilate in 
the same way as healthy arteries (125).  FMD measures reactive hyperaemia 
caused by occlusion of the brachial artery that leads to local release of NO, 
and dilatation of the brachial artery.  Again, this can be compared with 
sublingual administration of nitrates that cause ‘endothelial independent’ 
dilatation.  There is a wide range of normal values ranging from 5% to 21%, 
and this may be due to individual methodology used (128).  FMD has a 
number of advantages; it is cheap, non-invasive and well tolerated.  It is also 
reproducible in the hands of trained operators (129).  In contrast to this, it 
should be noted that Hardie et al (1997) found poor FMD reproducibility in 
healthy subjects (130), highlighting operators needing to be well trained and 
have experience in the technique which can be technically challenging at 
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times.  Also, environmental factors influence the test, such as temperature, 
eating and caffeine, so adherence to a strict protocol of fasting before the test 
is important (128). 
 
FMD is now established as a prognostic marker for CV disease, however not 
all studies have shown it to be independent of traditional risk factor 
assessment.  Shimbo et al (2006) was the first to show in a prognostic study 
the association between FMD and and CV outcomes in a patient group of 
multiple ethnicities (131).  They included 842 patients without stroke or 
myocardial infarction and followed patients up at 36 months.  Lower FMD 
levels predicted CV events (myocardial infarction, stroke and vascular death), 
HR 1.12 for every 1% decrease in FMD (95% CI, 1.01-1.25; p=0.03). The risk 
of events in patients with FMD in the lower two tertiles (FMD <7.5%) was 
significantly higher than those in the highest tertile, HR=3.28 (95% CI 1.07-
10.06; p=0.04) for lowest versus highest tertile, and HR=3.05, (95% CI 1.03-
9.66; p=0.04) for middle versus highest tertile.  In their multivariate analysis 
including CV risk factors, the increase in risk associated with FMD was no 
longer statistically significant; therefore their findings are not independent of 
traditional CV risk factors.  This was confirmed by Yeboah et al (2008) who 
found FMD in older patients added little to prognostic risk factor scoring, 
although it did predict future events (132). 
 
Shechter et al (2007) and Rossi et al (2008) have been able to show a benefit 
over and above CV risk factors in predicting CV outcome with FMD.  Shechter 
et al (2007) performed FMD prospectively on 110 patients, 46 had CV disease 
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and 64 where healthy controls (133).  They found FMD was significantly lower 
in CV disease patients (9.5 +/- 8.0% vs. 13.5 +/- 8.0%, P = 0.012) compared 
to healthy controls (13.4 +/- 8.0% vs. 16.7 +/- 11.0%, P = 0.084; respectively). 
In addition, an inverse correlation between FMD and the number of traditional 
CV risk factors was found among all study patients.  Mean follow-up was 15 
months, and the composite CV endpoints (all-cause mortality, myocardial 
infarction, hospitalisation for heart failure or angina, stroke, coronary artery 
bypass grafting and percutaneous coronary interventions) were significantly 
more common in subjects with FMD less than 6% compared to subjects with 
FMD greater than 6% (33.3% vs. 12.1%, P < 0.03, respectively).  Finally, 
Rossi et al (2008), studied a different cohort of patients and in much larger 
numbers (134).  In total 2,264 post menopausal women were recruited for 
FMD with a mean follow up of 45 months.  Risk adjusted RR values were 1.0, 
1.33 (95% confidence interval [CI] 1.09 to 4.09), and 4.42 (95% CI 2.97 to 
8.01) for women in the higher, intermediate, and lower tertile of FMD, 
respectively (p < 0.0001 for trend).  The event rate for women in the lower 
tertile (FMD 4.5%) was greater than the combined event rate noted in the 
other two tertiles (women in the lower tertile accounted for 51 events [56.6% 
of total events]).  When added to age and other conventional CV risk factors 
(smoking habits, presence of hypercholesterolemia, history of diabetes, 
hypertension), FMD contributed significantly to the model predicting CV 
events. 
 
One pilot study has also shown that improving endothelial function may 
improve CV outcomes, but this was a small study on 68 patients with CAD 
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(135).  In general terms, drugs used to treat CV risk factors i.e. lipid lowering 
strategies and ACE inhibitors do improve endothelial function (112).  
Allopurinol also improves endothelial function in various studies, and this is 
discussed later.  In summary endothelial function does seem to predict future 
CV events, but it is not a mainstream test and it’s value over and above 
traditional risk factor evaluation is still under research.  There are also 
limitations to the test as discussed. 
  
d. Direct Affects of Glucose and Insulin on the Development of Left 
Ventricular Hypertrophy 
 
Two studies have correlated increased plasma insulin levels with increased 
LVM.  Verdecchia et al (1999) studied 101 non-diabetic patients with 
hypertension to determine the effects of insulin and insulin like growth factor 
(IGF-1) on LVM (136).  IGF-1 and post load insulin accounted for over 40% of 
variability of LVM, after multivariate analysis, insulin and IGF-1 where 
powerful, independent predictors of LVM.   A year later, Hirayama et al (2000) 
showed similar findings in 42 T2DM patients with raised LVM and plasma 
insulin levels (137).  These patients also had normal office BP. 
 
Rutter et al (2003) investigated the impact of insulin resistance on heart 
structure and function in a community based sample of Framingham study 
patients (65).  Interestingly, hyperglycaemia correlated more closely with LVM 
in women than men and in their regression analysis they felt these changes 
could be accounted for by obesity.  Importantly, they found that the more 
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severe glucose intolerance, the higher the LA size in both men and women.  
Lind et al (1996) also found a correlation between diabetes and LA size (66).  
Overall it appears that insulin resistance probably acts on the myocardium to 
cause LVH.  This study confirms findings from other previous studies, which 
have all shown a correlation between LVM and insulin resistance (136, 138-
141). 
 
The potential mechanisms by which hyperinsulinaemia and insulin resistance 
are associated with LVH has been reviewed by Young et al (2002) (142).  It 
has been known for some time that insulin exerts a growth stimulating effect 
on myocytes and also stimulated collagen synthesis in vascular smooth 
muscle (143, 144).  Furthermore, insulin may lead to increased activity of the 
sympathetic nervous system, that may also proliferate myocardial cells (145).  
An overview of these potential mechanisms are elegantly summarised in 
Figure 1.3.9, by Rutter et al (2003) (65). 
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Figure 1.3.9. Potential mechanisms by which insulin resistance are associated 
with left ventricular hypertrophy(65). 
 
Glucotoxicity has been implicated in the generation of ROS and insulin 
resistance and may thereby also affect cardiac gene expression (142).  Fatty 
acids appear to do the same (142).  Following on from this, glucose and fatty 
acids seem to be central to altered metabolic adaptation in response to 
pressure overload as well as the fact that glucose leads to transcriptional 
alterations of a number of genes (142).  The end result of these transcriptional 
alterations is induction of foetal genes and substrate switching, enabling the 
heart to maintain cardiac output.  It should be noted that in hearts without 
pressure overload there is also switching to foetal gene expression, possibly 
in a response to glucose (142).  The concept of metabolic maladaptation, as 
discussed by Young et al (2002) encompasses three main concepts, as 
summarised in Figure 1.3.10.  These are lipotoxicity, glucotoxicity and 
glucolipotoxicity (142).  Lipotoxicity is the theory whereby a hyperlipid 
environment results in accumulation of lipids within the heart.  This excess 
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accumulation of lipids can cause ROS, and apoptosis resulting in contractile 
dysfunction (142). Glucotoxicity is similar to lipotoxicity in that chronic 
hyperglycaemia leads to ROS formation.  It also appears that hypertrophied 
and diabetic hearts there is insulin resistance as a result of chronic 
hyperglycaemia (142).  Finally, glucolipotoxicity is the combination of these 
two processes, possibly accelerated by the suggestion that hyperglycaemia 
down regulates the expression of fatty acid metabolising genes, therefore 
accelerating the deposition of lipids and accelerating cardiac dysfunction 
(142). 
 
 
Figure 1.3.10.  Summary of the possible mechanisms for metabolic adaptation 
and maladaptation of the heart (142). 
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e. Other Causes of Left Ventricular Hypertrophy 
 
 ii.  Genetic Factors 
 
Hypertension and LVH have a degree of genetic co-segregation (146).  
Various studies have found a link between a genetic predisposition and LVH, 
however cause and effect of LVH determinants with relation to genes can be 
difficult to establish, and are often described as ‘complex traits’.  It has been 
estimated that about 30% of LVH has a genetic component (147).  
Shigematsu Y et al 2005 found a genetic predisposition to LVH and insulin 
resistant that was independent of other traditional risk factors of LVH in a 
small cohort of 72 patients (148).  Hong et al (2012) performed a genome-
wide association study (GWAS) of ECG-LVH, in which the community-based 
Korea Association REsource (KARE) study (8432 controls and 398 cases) 
was analysed (149).  There was consistent association with the 19q13.1 
region that contains the RYR1 gene.  Mutations in RYR1, which encodes a 
major calcium channel in the skeletal muscle, have been reported to correlate 
with CV diseases.  Otherwise currently specific genes known to cause LVH 
directly are unknown. 
 
 ii. Renin Angiotensin System 
 
The RAS seems to be important in the development of LVH, in particular 
angiotensin II.  In rat models, angiotensin II causes myocyte hypertrophy 
(150).  Angiotensin II is weakly correlated to LV mass, but when urinary 
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sodium excretion is also factored in, there is a strong correlation (151).  
Sodium excretion is an interesting addition to this study as it suggests that it is 
uncontrolled regulation of the RAS in humans may lead to changes in LVM, 
not only through hypertrophic effects of angiotensin II, but also through 
increased BP.  It has also been shown that the angiotensin II receptor may be 
‘hyper-responsive’ in some patients which also correlates with increased LVM 
(152).  Uncontrolled RAS implies high RAS activation than would be expected 
for an individual’s sodium status. 
 
f. Brain Natriuretic Peptide in Left Ventricular Hypertrophy 
 
Brain Natriuretic Peptide (BNP) is a neurohormone secreted by cardiac 
ventricles in response to stretch of cardiac myocytes.  It was originally isolated 
from pigs’ brains, hence the name (153).  In general, any stress on the heart 
causing pressure or volume overload of the heart results in BNP release that 
is detectable in the blood.  BNP acts in the kidney to cause excretion of 
sodium, blood vessels to cause smooth muscle relaxation and vasodilatation 
(154).  BNP correlates with increasing LVM, and this has been shown in 
numerous patient groups including the elderly, hypertensive patients and the 
general population (155-158). 
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4. Treating Left Ventricular Hypertrophy 
 
a. Benefits and Established ways of Regressing Left Ventricular 
Hypertrophy 
 
Regressing LVH improves prognosis in patients with hypertension as detected 
by echo and the early studies did not focus on any particular agent to reduce 
BP and LVM.  Verdecchia et al (1998) followed up 430 patients with essential 
hypertension, 26% of patients had echo LVH with an LVMI of 125g/m2 or 
greater (159).  Patients were treated with a combination of lifestyle and 
various anti-hypertensives to ensure BP was below 140/90.  For patients who 
had a decrease in LVM from baseline there were fewer CV events compared 
with patients who had an increase in baseline LVM (1.78 vs. 3.03 per 100 
person-years).  In the small subset of patients with echo LVH, CV events were 
lower if there was a decrease in LVM (1.58 vs. 6.27 per 100 person-years).  
Importantly, this improved prognosis was independent of baseline LVM and 
BP and also the degree of BP reduction.  Another small study by Koren et al 
(2002) found similar findings in 172 patients with essential hypertension (160).  
In this trial anti-hypertensives were prescribed at the discretion of the 
physician.  Fewer of the 91 patients with unchanged or decreased LVM 
experienced CV events than the 81 patients whose LVM increased during 
follow-up (8.8% vs. 19.8%).  Absence or presence of LVH on the follow-up 
echo was the strongest predictor subsequent CV events.  Verdecchia et al 
(2003) confirmed these initial findings with a meta-analysis of four trials (161).  
They found that regressing LVH with antihypertensives is associated with a 
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significant reduction in CV events (OR 0.41, 95% CI 0.21 – 0.78).  More 
recently Pierdomenico et al (2008) confirmed these early studies that 
regressing LVH over a two year period with any anti-hypertensive to lower BP 
reduces CV risk (RR 0.36, 95% CI 0.19 – 0.68) (162).  This was the case 
regardless of ECG findings of LVH. 
 
Klingbeil et al (2003) performed a meta analysis of 80 double blind 
randomised clinical trials to study the effect of different anti-hypertensives on 
LVM (79).  In total, 3,767 patients were included in the active arm and 346 in 
the placebo arm.  The results showed that after adjustment for treatment 
duration and change in diastolic BP, there was a significant difference (P = 
0.004) among medication classes.  LVMI decreased by 13% with ARB’s (95% 
CI, 8% - 18%), by 11% with calcium antagonists (95% CI, 9% - 13%), by 10% 
with ACE inhibitors (95% CI, 8% - 12%), by 8% with diuretics (95% CI, 5% - 
10%), and by 6% with beta-blockers (95% CI, 3% - 8%).  In pair wise 
comparisons, ARB’s, calcium antagonists, and ACE inhibitors were more 
effective at reducing LVM than were beta-blockers.  
 
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 
and the Heart Outcomes Prevention Evaluation (HOPE) study have 
specifically looked at reducing BP with ARBs and ACE inhibitors in much 
larger numbers of patients, in contrast to the studies discussed above, that 
both included a variety of anti-hypertensives to reduce blood BP.  Many sub-
group analyses have been published in relation to these two trials therefore 
they will be dealt with separately. 
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i. Losartan Intervention For Endpoint Reduction in Hypertension 
(LIFE) Study 
 
The LIFE trial was designed in the 1990’s to answer the question as to which 
anti-hypertensive, in this case the ARB losartan, is most effective at reducing 
morbidity and mortality in hypertensive patients and signs of ECG LVH (163).  
Losartan based therapy was compared with atenolol based therapy in patients 
with hypertension and evidence of LVH from ECG criteria.  The LIFE trial was 
a double masked, randomised parallel group study of 9,193 patients aged 55-
80.  1,195 patients (13%) of patients recruited had diabetes and 86% were 
white.  Mean follow up was 4.8 years.  The fall in BP was similar in both the 
losartan and atenolol arms, but despite this the primary composite endpoint 
occurred for losartan was 23.8 per 1,000 patient-years and atenolol was 27.9 
per 1,000 patient-years (RR 0.87, 95% CI 0.77 - 0.98).  Losartan was better 
than atenolol in terms of CV mortality (RR was 0.89, 95% CI 0.73-1.07) with 
232 and 309, fatal or non-fatal strokes (RR 0.75, 95% CI 0.63-0.89) and 
myocardial infarctions (RR 1.07, 95% CI 0.88-1.31).  There were also 
improved ECG criteria for LVH in the losartan arm.  Because of the similar 
falls in BP with both atenolol and losartan this raises the question of what 
losartan does differently to atenolol.  It has been suggested that losartan may 
regress LVH more aggressively, because angiotensin II may have detrimental 
effects itself or because losartan has specific effects that are still unknown.  
Interestingly and never fully accounted for, the incidence for new-onset 
diabetes was less frequent with losartan by 25% (163).  Okin et al (2003) 
specifically analysed the ECG’s of all the patients in LIFE and found that 
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losartan resulted in greater LVH regression than atenolol (164).  Importantly, 
this finding holds true for echo LVH as well (165). 
 
In a sub group analysis of LIFE, Deveraux et al (2002) performed serial echos 
on 754 patients with ECG LVH to assess LVH regression (77).  They found 
that LVM decreased after sustained BP reduction of at least two years.  There 
was a small, and not significant, fall in BP after one year.  This suggests that 
at least two years treatment is needed to see the full benefits of anti-
hypertensive treatment and also that the benefits are seen after sustained BP 
control. 
 
The onset of diabetes in was studied in more depth at a later date by Okin et 
al (2007) (166).  A sub-set of 7,998 LIFE patients without diabetes were 
followed up with serial ECGs to see who developed diabetes.  Resolution or 
absence of ECG LVH criteria was associated with a lower incidence of 
diabetes, even after adjusting for losartan and other risk factors for diabetes.  
Analysis of 1,195 patients in the LIFE trial with diabetes confirmed the original 
findings of the trial that losartan is more effective than atenolol at reducing CV 
morbidity and mortality in patients with diabetes, ECG LVH and hypertension 
(167).  Further analysis of LIFE has shown that in patients with diabetes and 
established ECG LVH that reduction in BP does not regress LVH to the same 
extent as in a non-diabetic (168).  This may explain in part why despite BP 
treatment, patients with diabetes still fair worse in terms of CV morbidity and 
mortality. 
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Over the last decade, sub group analyses of LIFE have shown that losartan 
has beneficial effects over atenolol in a number of outcomes.  Losartan has 
beneficial effects on CV risk, hospitalisation for heart failure, sudden cardiac 
death, new onset AF, stroke and major CV events (162, 169-172). 
 
Finally an interesting sub-study from 2004 looked at the effects of uric acid in 
the LIFE study (173).  The increase in uric over 4.8 years in the LIFE 
study was attenuated by losartan compared with atenolol treatment, 
appearing to explain 29% of the treatment effect on the primary 
composite end point. The association between uric acid and events was 
stronger in women than in men (173). 
 
 ii. The Heart Outcomes Prevention Evaluation (HOPE) Study 
 
The HOPE study does look specifically at LVH, but included high risk patients 
(n=9,297) without heart failure (174).  The cohort included 9,297 patients in 
total and of these 8,162 had CV disease, 4,355 had hypertension and 3,777 
had diabetes.  Ramipril (10mg) was compared with placebo and the primary 
outcome was the composite endpoint of myocardial infarction, stroke or death 
from CV causes. The primary endpoint was reached in 14% of the ramipril 
group and 17.8% in the placebo group, relative risk reduction 0.78 (95% CI 
0.70 – 0.86, p <0.001).  Significantly fewer patients in the ramipril group had a 
cardiac arrest, worsening angina, heart failure or a new diagnosis of diabetes.  
These differences were seen after correcting for diabetes, age, and most 
importantly hypertension. 
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The Effects of Ramipril on Cardiovascular and Micro-vascular Outcomes in 
People with Diabetes Mellitus (MICRO HOPE) study should be mentioned 
here because it specifically looked at the sub-group of patients with diabetes 
recruited in HOPE (n=3,577) (78).  Ramipril reduced the risk of the combined 
primary outcome of myocardial infarction, stroke or CV death in diabetic 
patients by 25%.  After adjustment for BP changes, the results remained 
significant.   
 
In summary although ECG is not the most reliable way to look for LVH, if a 
patient is hypertensive and have ECG and/or echo LVH then the blockade of 
the RAS should be considered along with tight BP control.  The benefits 
extend to people with diabetes and blockade of the RAS also has beneficial 
effects on the development of new onset diabetes. 
 
iii. Regressing Left Ventricular Hypertrophy in the Context of 
Normal Blood Pressure 
 
The data on regressing LVH in the context of normal BP is limited. The HOPE 
trial is of particular relevance because of later sub-group analyses of patients 
(n= 8,281) who had two comparable ECG’s over the study period and a small 
group who had echo (175, 176).  Because some patients included did not 
have clinical hypertension this gives us unique information about the effects of 
ramipril in patients with ECG LVH and normal BP.  In total, 676 patients had 
baseline LVH on ECG.  In the group of patients who had regression or 
prevention of LVH, in the ramipril arm 12.3% reached the primary end point of 
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CV death, myocardial infarction or stroke, compared with 15.8% in the 
placebo arm.  There was also a reduction in heart failure.  These changes 
were independent of BP.  Lonn et al (2004) echoed 506 patients with normal 
BP (baseline average BP 131/76) to quantify LVM (176).  After four years of 
treatment, LVM increased in the placebo group by 3.98 ± 2.08g/m2 and by  
4.16 ± 1.86g/m2 in the ramipril 2.5mg group.  In the group of patients who 
received 10mg ramipril it decreased by 2.02 ± 2.25g/m2.  This sub-study is 
interesting because it suggests that ramipril reduces LVM by other means 
than just BP, possibly due to angiotensin II effects, which were discussed in 
detail previously. 
 
A small study by Nielsen et al (1998) studied the effect of ramipril compared 
to placebo in 38 patients with normal BP and T2DM with no microalbinuria 
(177).  BP was almost identical at baseline (132/76 ± 3/1 vs. 133/74 ± 
5/2mmHg) and remained stable during follow-up (134/76 ± 3/1 vs. 136/74 ± 
6/2mmHg) in the ramipril and placebo groups respectively.  LVM was 
comparable at baseline and decreased significantly more in the ramipril group 
(17.6 ± 3.0) as compared with the placebo group (5.7 ± 4.6 g/m2).  
 
iv. Non-Pharmacological Ways of Regressing Left Ventricular 
Hypertrophy 
 
Weight loss and dietary sodium restriction have been shown to be effective in 
regressing LVH in a small number of studies.  MacMahon et al (1986) studied 
41 men with hypertension and obesity and found that weight loss on average 
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of 8.3kg over a 21-week period resulted in reduced LV dimension when 
compared to placebo.  This was independent of BP. 
 
The Treatment of Mild Hypertension Study (TOMHS) included 844 patients in 
a double-blind, placebo-controlled clinical trial mildly hypertensive patients 
randomised to nutritional-hygienic intervention plus placebo or nutritional-
hygienic intervention plus one of five classes of antihypertensive agents 
including a diuretic (chlorthalidone), beta-blocker (acebutolol), alpha-
antagonist (doxazosin), calcium antagonist (amlodipine), or an ACE inhibitor 
(enalapril) (178).  Serial echos were performed over four years. Changes in 
blood pressure averaged 16/12mmHg in the active treatment groups and 9/9 
mmHg in the nutritional-hygienic intervention only group.  All groups showed 
significant decreases in LVM from baseline that appeared at three months 
and continued for 48 months. Changes in weight, urinary sodium excretion, 
and systolic BP were moderately correlated with changes in LVM. 
 
Jula et al (1994) also studied the effects on LVH of a non-pharmacological 
treatment program based mainly on sodium restriction and weight loss (179).   
The study was small (n=76) and the patients were un-treated hypertensives 
who were followed up with serial echo for one year. The daily sodium 
excretion, BP and weight decreased significantly in the treatment group.  After 
one year of sodium restriction, LVM decreased by 5.4% and LVMI decreased 
by 4.7% whereas no changes occurred in these parameters in the control 
group. 
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b. Potential Ways of Regressing Left Ventricular Hypertrophy 
 
The strategies described above are only partly effective.  Mancia et al (2002) 
studied 2,051 people involved in the Pressioni Arteriose Monitoate E Loro 
Associazioni (PAMELA) study population (180).  They found that LVH persists 
in about 20% of hypertensives who attain target BP, therefore LVH in patients 
with controlled BP is common and it would seem blockade of the RAS and 
anti-hypertensives do not hold all the answers in terms of reducing the risk 
from LVH.  Furthermore, LVH carries the same risk in normotensive 
individuals as in those with high BP.  Brown et al (2000) showed that during 
16.8 years follow up of hypertensive patients, after adjustment, normotensives 
with LVH had survival similar to hypertensive adults with LVH.  They also had 
lower survival than normotensive and hypertensive adults with no LVH (181).  
Since LVH regression is effective regardless of BP we thought it valuable to 
study the XO inhibitor allopurinol as a potential way of decreasing LVM in 
diabetic patients with LVH and normal BP. 
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5. Xanthine Oxidase and Allopurinol 
 
a. History of the Xanthine Oxidase Inhibitor Allopurinol 
 
Allopurinol is a XO inhibitor approved for use in Britain by the Food and Drug 
Administration in 1966.  Allopurinol is the mainstay of treatment for gout and is 
also indicated for uric acid and calcium oxalate stones and prophylaxis of 
hyperuricaemia associated with chemotherapy agents (182). 
 
Allopurinol was originally synthesised as an attempt to increase the efficacy of 
new antineoplastic agents in the mid-1950s, such as 6-mercaptopurine (6-
MP) (183).  6-MP was being investigated at the Sloan-Kettering Institute by 
the eventual Nobel Prize winners Gertrude Elion and George Hitchings for its 
anti-cancer properties.  6-MP was showing promise as a drug that could be 
used in the fight against leukaemia as it was displaying very high activity 
against leukaemia in children (184).  The enzyme XO was being studied as 
part of these experiments, as inhibiting XO was thought to potentiate the anti 
tumour properties of 6-MP.  Elion and Hitchings where experimenting with a 
number of drugs to inhibit XO to potentiate 6-MP and one of these was 
allopurinol.  It was during these experiments that the potential XO inhibitor 
properties of allopurinol were discovered, as it was already known that XO 
was involved in the formation of uric acid from xanthine.  Subsequent tests 
showed effective reduction of urinary and serum uric acid with allopurinol 
(183, 184).  Figure 1.5.1 shows that XO mediates the conversion of 
hypothanxine to xanthine and xanthine to uric acid (183). 
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Figure 1.5.1 Purine degradation pathway (184). 
 
In 1988 the discovery of 6-MP and allopurinol led Gertrude Elion and George 
Hitchings to be awarded the Nobel Prize in Physiology and Medicine (184, 
185).  Interestingly this Nobel Prize was shared with the former Chancellor of 
Dundee University Sir James Black who developed the first clinically useful 
beta blocker, propranolol, in 1964.  The discovery of allopurinol was 
presented in 1988 Nobel Lecture the ‘Purine Path to Chemotherapy’ (185).  
Since its discovery, allopurinol has been the mainstay of the treatment of gout 
for nearly fifty years.  In recent times, exciting new discoveries have found 
new uses for allopurinol in patients with CV disease, which is discussed later 
in this thesis (186). 
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b. Xanthine Oxidase 
 
i. Structure 
 
Before we consider the biochemistry of allopurinol it is important to 
understand the role of XO and xanthine dehydrogenase (XDH) in the Purine 
degradation pathway, Figure 1.5.1.  XO and XDH are inconvertible forms of 
the same enzyme known as Xanthine Oxidoreductase (XOR) (187).  XOR 
was first identified 100 years ago in milk and belongs to the family of enzymes 
called molybdoenzymes which also includes aldehyde oxidase and sulphite 
oxidase (188).  In man the enzyme is found in the dehydrogenase form and 
has been most extensively studied in bovine milk.  Both enzymes are 
structurally similar; they have identical x-ray absorption spectra because they 
have the same ligand environment and co-ordinating geometry around a 
molybdenum centre (184).  These two forms of XOR can be inter-converted 
irreversibly by sulphide reagents or reversibly from XDH to XO by proteolysis 
(187).  Harrison et al (2002) describes the XOR structure as consisting of a 
homodimer of approximately 300kDa.  Each subunit is identical and contains 
four redox centres, a molybdenum co-factor (Mo-co), one FAD and two Fe2S2 
sites, see Figure 1.5.2.  The Mo-co comprises an organic pterin derivative 
called molybdopterin, containing a cyclised dithiolene side chain with one Mo 
atom (187).  Each of the subunits acts independently as a catalyst.   
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Figure 1.5.2. A:  Molybdopterin and B:  Molybdenum co-factor (Mo-co) (187). 
 
The crystal structure of the XDH dimer divided into the three major domains 
and two connecting loops is shown in Figure 1.5.3.  The hydroxylation of 
xanthine takes place at the molybdopterin centre and the other electrons 
introduced are rapidly transferred to the other linearly aligned redox centres 
(184). 
 
Figure 1.5.3. Crystal structure of xanthine dehydrogenase (184). 
 
 
 
 
 79 
 
ii. Actions 
 
Both XO and XDH catalyse the final stages of purine metabolism, namely 
hypoxanthine to xanthine and xanthine to uric acid (188).  During this process 
XOR produces the ROS 02- and H202, by reduction of molecular oxygen when 
hypoxanthine is catalysed to xanthine.  XOR also catalyses the 
hydroxygenation of N-heterocyclic and aldehyde substrates through the Mo 
site.  At the Mo site NADH donates its electrons to FAD which then in turn 
forms either NADH from NAD+ or the ROS 02- and H202 from oxygen (187).  
XO only reduces oxygen whereas XDH can reduce both oxygen and NAD+ 
(188).  This is shown schematically in figure 1.5.4. 
 
 
Figure 1.5.4. Formation of reactive oxygen species and NADH from the XOR 
catalysed oxidation of xanthine and hypoxanthine (187). 
 
The mechanism of how XOR reacts with xanthine to oxidise oxygen is 
complex and some aspects are uncertain (184, 187-189).  Xia et al (1999) 
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investigated the mechanism of how XOR reacts with xanthine.  They found 
that the reductive half reduction occurs at Mo-co where XOR accepts two 
electrons from xanthine, reducing Mo (VI) to Mo (IV), as shown in Figure 1.5.5 
(189).  Hille R et al (1981) showed that a fully reduced XOR transfers 
electrons to generate H202.  XOR then transfers its remaining electrons in 
separate steps with each electron independently reducing oxygen to produce 
02-, as shown in Figure 1.5.5 (190). 
 
 
Figure 1.5.5. Mechanism of XOR reaction with xanthine (188). 
 
XOR has also been shown to catalyse the reduction of nitrates to nitrites and 
nitrites to NO (187).  Under anaerobic conditions and in the presence of nitrite 
and xanthine or NADH, NO is generated at the Mo site.  In the presence of 
molecular oxygen this is reduced at the FAD to give 02- which reacts rapidly 
with NO to give peroxynitrite (187), shown in Figure 1.5.6.  The formation of 
ROS, NO and peroxynitrite are important in endothelial function and the 
pathophysiology of XOR and are discussed below. 
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Figure 1.5.6 XOR catalysed production of peroxynitrite (187). 
 
iii.  Distribution 
 
XOR has been found in all species studied to date, but there is variation in the 
distribution amongst these species.  XOR is studied using 
immunocytochemistry which can recognise inactive and active forms, 
therefore studies looking at distribution have been inconsistent (191).  In man 
XOR activity is found in the highest levels in the liver and intestine, with 
activity present in most other tissues studied including the lung, kidney, heart, 
brain and plasma (191, 192).  The presence of XOR in cardiac tissue has 
been studied by Muxfeldt et al (1987) (193) and Bruder et al (1983) (194).  
Plasma XOR, or circulating XOR, has been reported in varying quantities 
around human bodies and has also been found to be higher in certain disease 
states including liver damage (195, 196).  Most notably higher levels of 
circulating XOR have been found in rheumatoid arthritis, mixed connective 
tissue disease, scleroderma and atherosclerosis (187, 197).  XOR has also 
been shown to circulate around the body in higher levels in liver ischaemia 
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and reperfusion, haemorrhagic shock, during thoracic surgery, liver 
transplantation and hind limb ischaemia and reperfusion (184).  There is 
evidence that circulating XOR triggers endothelial dysfunction at remote sites, 
such as lung tissue, mediating tissue damage in these conditions.  Circulating 
XOR binds to endothelial cells via glycosaminoglycans where it acquires 
higher oxidant producing capacity and increased stability (198).  It may be that 
this circulating XOR is more important in the pathophysiology of endothelial 
dysfunction than XOR produced from endothelial cells (199, 200). 
 
The gene encoding human XOR is located on the short arm of chromosome 2 
and comprises 36 exons (188).  A number of physiological conditions have 
been shown to affect transcription of the XOR gene and are summarised in 
Table 1.5.1. 
 
Positive regulators Negative regulators  
Hypoxia Hyperoxia 
Lipopolysaccharide  
Interferon γ  
Interleukin – 1  
Interleukin – 6  
Tumour necrosis factor α  
Dexamethasone  
Cortisol  
Prolactin  
Table 1.5.1. Regulation of XOR gene expression (188). 
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 iv. Possible Pathophysiological Roles of XOR 
 
ROS generated by XOR have been studied as causal mechanisms of tissue 
damage.  ROS cause injury via the production of superoxide and hydrogen 
peroxide that undergo further reactions to form highly active hydroxyl free 
radicals (Haber-Weiss Reaction) and peroxynitrite, described above.  These 
free radicals cause lipid peroxidation and DNA and amino acid oxidation.  This 
results in disruption of the membrane architecture and lysosomal enzyme 
release, genetic mutations and enzyme dysfunction (188).  These pathological 
process have led XOR to be implicated in myocarditis, hypertension and heart 
failure at the level of the endothelium (188). 
 
The ROS produced by XOR may be important in the pathophysiology of heart 
failure through the process of mechanoenergetic uncoupling.  
Mechanoenergetic uncoupling in heart failure describes worsening LV 
function in the setting of unchanged oxygen demand by the myocardium i.e. 
the heart requires extra oxygen to maintain the same mechanical function.  
This leads to a fall in the mechanical contractibility of the myocardium (201).  
At the level of the myofilament ROS may decrease the responsiveness to 
calcium activation and may also increase oxygen consumption by the whole 
heart.  It is postulated these two mechanisms worsen mechanoenergetic 
uncoupling in heart failure (201). 
 
The concept of ischaemia reperfusion injury (IR) was first introduced by 
Granger et al (1981) (202).  Granger et al (1981) investigated the idea that 
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XOR generated ROS cause ischaemic bowel injury due to ATP catalysation 
during ischaemia.  When the tissue is reperfused there is generation of 02- 
and H202 when the readmitted oxygen, hypoxanthine and XO combine (202), 
shown in Figure 1.5.7.  
 
 
Figure 1.5.7. Mechanism of ROS during ischaemia reperfusion injury (187). 
 
These oxygen derived ROS may also play an important role in the pathology 
of myocardial dysfunction after ischaemic events (203).  The idea that IR 
plays a role in tissue damage led to research into the role of allopurinol in 
attenuating endothelial damage in a number of tissues.  As mentioned before 
there are low levels of XOR activity in rabbit, pig and human hearts so the role 
of XOR mediated injury in IR is open to debate (191, 192).  It is possible the 
circulating XOR that binds to endothelial tissue is released by XOR rich 
tissues such as the liver that provides the XOR in IR.  The concept of 
circulating XOR is discussed above.  The idea of XOR interacting with 
neutrophils that are known to invade post ischaemic tissue has also been 
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researched at a micro vascular level (204).  Granger et al (1981) studied 
whether XOR derived oxidants play a role in leukocyte microvascular 
interactions initiated by IR in cat intestine.  Their findings showed there was 
some evidence XOR derived ROS initiate leukocyte reperfusion in IR intestine 
(204). 
 
These IR interactions and the involvement of neutrophils are important in 
understanding the possible therapeutic benefits of allopurinol not just in IR but 
in other vascular pathologies.   
 
c. Biochemistry of Allopurinol 
 
Allopurinol is a weak acid that is rapidly converted to oxypurinol by the 
enzyme aldehyde oxoreductase.  The chemical structure of allopurinol is 1,5-
dihydro-4H-pyrazole [3,4-d] pyrimidin-4-one, as shown in Figure 1.5.8. 
Allopurinol is an analogue of hypoxanthine and oxypurinol is an analogue of 
xanthine.  Oxypurinol is a non-competitive inhibitor of XO.   Oxypurinol has a 
longer half life and persists for longer in tissues than allopurinol, hence it is 
the formation of oxypurinol that is responsible for the most of the 
pharmacological activity of allopurinol (205). 
 
 
Figure 1.5.8. Chemical structures of allopurinol and oxypurinol (184). 
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d. Clinical Pharmacokinetics of Allopurinol 
 
In animals allopurinol is found in highest concentrations in vascular tissue, 
blood, liver, intestine and the heart.   Allopurinol binds negligibly to plasma 
proteins (206).  Allopurinol is well absorbed from the gastrointestinal tract after 
an oral dose but it is poorly absorbed from the rectum (207),(206).  Breithaupt 
et al (1982) used a high pressure liquid chromatographic method to measure 
allopurinol and oxypurinol absorption orally and intravenously.  They 
measured allopurinol in the plasma and urine of six healthy volunteers after 
single doses of oral and intravenous allopurinol (208).  The total recovery from 
urine was 77% (allopurinol 8%, oxypurinol 69%) after 300mg oral allopurinol.  
88% was recovered from the urine when 300mg allopurinol was given 
intravenously.  They found only 10% of allopurinol is not absorbed when given 
via the oral route compared to intravenously (208). 
 
 The mean half life of allopurinol has been measured at between one to two 
hours, compared to the half life of oxypurinol of 16 to 23 hours in various 
different studies (205) (207).  The maximum concentration of allopurinol has 
been shown to be achieved after about one hour and 60% to 70% of 
allopurinol is rapidly converted to oxypurinol by XO (183, 206).  In summary 
the pharmacological activity of allopurinol is due largely to oxypurinol, as a 
large proportion of allopurinol is converted to oxypurinol that has a much 
longer half life (205). 
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The pharmacokinetic parameters of allopurinol, with normal renal function, 
after oral dosage from Day et al (2007) are as follows (205): 
 Bioavailability of 79 +/- 20% 
 Elimination half life 1.2 +/-0.3 hours 
 Apparent oral clearance of 15.8 +/- 5.2mL/min/kg 
Apparent volume of distribution after oral administration of 1.31 +/- 0.41 
L/kg 
 
Day et al (2007) showed that 90mg of oxypurinol is formed from every 100mg 
of allopurinol.  Based on their calculations the pharmacokinetic parameters of 
oxypurinol, with normal renal function, after oral dosage from Day et al (2007) 
are as follows (205): 
 Elimination half life 23.3 +/- 6 hours 
 Apparent oral clearance of 0.31 +/- 0.07mL/min/kg 
Apparent volume of distribution after oral administration of 0.59 +/- 0.16 
L/kg 
 
Oxypurinol is primarily excreted by the kidneys, whereas allopurinol is 
eliminated by metabolism (209).  After glomerular filtration, oxypurinol is 
absorbed in the renal tubules, which is the main reason why oxypurinol has a 
longer half life than allopurinol (210).  Renal tubular absorption of oxypurinol is 
affected by changes in urine pH, glomerular filtration and uric acid 
concentrations (183).  It follows that allopurinol elimination is not reduced with 
age because it is eliminated by metabolism, whereas oxypurinol elimination is 
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reduced in the elderly because of age dependent decline on renal function 
(209). 
 
e. Dose response studies of allopurinol 
 
Graham et al (1996) studied the dose response of allopurinol and how it 
relates to the steady state oxypurinol concentration.  They found that the 
oxypurinol concentration in steady state increased over the dosage range of 
allopurinol from 50mg to 600mg in a linear fashion.  This linear increase in 
oxypurinol concentration did not occur between 600mg and 900mg of 
allopurinol.  This is possibly due to saturation of XO or the saturation of the 
renal tubular absorption of oxypurinol (183).  The dose response studies 
performed by Graham et al (1996) are summarised in Table 1.5.2. 
 
Allopurinol dose per day 
(mg) 
Steady state oxypurinol concentration 
(mg/L) 
50 1.77  +/- 1.59 
100 2.67 +/- 1.59 
300 5.59 +/- 1.5 
600 9.56 +/- 1.92 
900 12.21 +/- 2.13 
Table 1.5.2. Oxypurinol dose response table (183). 
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f. Clinical Pharmacodynamics of Allopurinol 
 
Allopurinol is generally safe with known side effects, and as mentioned 
previously, has been used for over 40 years.  Caution should be used in 
hepatic and renal impairment.  Pregnancy and breast feeding is a contra-
indication for use.  Rashes and gastrointestinal disorders are the commonest 
side effects.  Hypersensitivity reactions occur rarely and include exfoliation, 
fever, lymphadenopathy, arthralgia, and eosinophilia resembling Stevens-
Johnson or Lyell’s syndrome.  The BNF lists malaise, headache, vertigo, 
drowsiness, visual and taste disturbances, hypertension, alopecia, 
hepatotoxicity, paraesthesia and neuropathy, gynaecomastia, blood disorders 
(including leucopenia, thrombocytopenia, haemolytic anaemia and aplastic 
anaemia) as being very rare (182). 
 
Allopurinol enhances the effects and increases the toxicity of azathioprine and 
mercaptopurine.  Allopurinol may enhance the anticoagulant effects of 
warfarin (182).  Allopurinol increases the plasma concentration of didanosine, 
ciclosporin and theophylline (182). 
 
g. Allopurinol as an ‘Antioxidant’ 
 
Various studies dating back to the 1990s have shown that high uric acid levels 
are associated with a worse prognosis in patients with CV disease (211).  
Allopurinol has been shown in various clinical trials to be potentially beneficial 
in reducing OS and improving endothelial function in a number of conditions in 
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patients with CV disease, including diabetes (212), CAD (213), chronic heart 
failure (214) and smokers (215).  However, none of these trials have shown 
reduced CV events as an endpoint because they were small trials.  As 
discussed above XO catalyses the formation of urate and also catalyses the 
formation of ROS.  It is thought these ROS species may increase CV risk, 
mechanoenergetic uncoupling and IR injury as discussed before.  It is 
important to realise that allopurinol prevents the formation of OS which is very 
different from anti-oxidant vitamins which attempt to mop up already formed 
OS. 
 
 i. Allopurinol may Improve Mechanoenergetic Uncoupling 
 
The postulated role XOR plays in mechanoenergetic uncoupling is discussed 
above and Ekelund et al (1999) therefore sought to test whether allopurinol 
improves mechanoenergetic uncoupling in dogs.  The dogs had induced heart 
failure by means of a pacemaker and allopurinol was infused intravenously.  
They showed that allopurinol improved the myocontractility and decreased 
myocardial oxygen demand possibly through its effects as an XOR inhibitor 
thereby reducing the generation of ROS (216). 
 
The potential use of allopurinol in dilated cardiomyopathy has also been 
studied on a small scale by Cappola et al (2001).  They based their study on 
the theory that ROS generated by XOR may contribute to imbalance between 
myocardial energy consumption (energetics) and LV performance 
(mechanical function) i.e. mechanoenergetic uncoupling as described before.  
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The allopurinol was given as an infusion into the left coronary artery and 
haemodynamic pressure measurements to quantify LV function were made by 
cardiac catheterisation to measure myocardial oxygen consumption, peak rate 
of rise of LV pressure, stroke work and efficiency.  The study was small only 
involving nine patients.  Inhibition of XOR by allopurinol improved myocardial 
oxygen demand 22±9% and efficiency 40±17%.  These effects seem to be 
apparent even with ACE inhibitors and beta-blockers, therefore allopurinol 
may have potential benefits in the future in the treatment of heart failure (217). 
 
 ii. Allopurinol as a Free Radical Scavenger in Animal Models 
 
Early studies in the 1980s looked at free radicals in animals.  In 1987 it was 
reported that allopurinol and oxypurinol scavenged free radicals in a pig heart, 
which do not contain XO (neither does pig blood) (218).  Therefore it would 
seem allopurinol and oxypurinol exert other non XOR mechanisms such as 
they may scavenge free radicals in the IR myocardium by themselves, 
independent of inhibiting XO (218).  Further research by Hoey et al (1988) 
also added to the idea of allopurinol and oxypurinol scavenging free radicals 
directly in animals tissues not containing XO (219).  Again, this was a study of 
IR in animal models. 
 
Malkiel et al (1993) studied the interaction of allopurinol with copper.  Copper 
can participate in single electron reactions and mediate the formation of ROS 
(220).  They found allopurinol formed a complex with copper that reduced the 
copper mediated and ascorbate driven DNA breakage.  Essentially it seems 
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allopurinol acted as a chelator with the copper ions and prevented DNA 
damage which is another possible mechanism whereby allopurinol acts as an 
anti-oxidant (220). 
 
iii. Evidence Allopurinol may be Beneficial in Ischaemia 
Reperfusion Injury 
 
Various studies have looked at outcomes in humans given allopurinol e.g. in 
post myocardial infarction and in post coronary artery bypass grafting 
patients. One of the theories behind the injury in these patients is the IR 
model discussed before.  Sisto et al (1995) randomised 81 patients to 600mg 
allopurinol and vitamin E and C treatment or placebo before they underwent 
coronary artery bypass grafting to see if there was an improvement in 
myocardial events after reperfusion in coronary artery bypass grafting.  The 
allopurinol treated patients needed less dopamine support, had fewer peri-
operative infarctions and had fewer ischaemic events on ECG monitoring 
(203).  Further studies have shown positive effects when using allopurinol to 
improve IR after coronary artery bypass surgery.  Johnson et al (1991) found 
that hospital mortality fell from 18% to 4% in their small, randomised cohort of 
169 patients in the early 1990s.  Again the need for inotropic support was 
reduced in this study (221).  Johnson et al (1991) has gone as far as to say in 
their institute in Milwaukee that allopurinol is administered to all patients 
undergoing coronary artery bypass grafting unless contraindicated.  These 
studies are small and therefore inconclusive and allopurinol is not a routine 
treatment for these patients in other centres. 
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Promising findings have been shown looking at CK-MB activity, granulocyte 
counts and malondialdehyde activity during the ischaemic period of coronary 
artery bypass grafting (222, 223).  The idea that lipid peroxidation may be 
reduced in coronary artery bypass grafting patients has been studied on a 
small scale by Belboul et al (2001) and Movahed et al (1996).  The theory is 
that lipid peroxidation is triggered by granulocyte activation via the 
complement system as a result of the by products of IR.  Belboul et al (2001) 
found allopurinol reduced malondialdehyde activity (a marker of ROS) and 
lipid peroxidation in small numbers of patients undergoing open heart surgery 
(223).  Movahed et al (1996) also found an improvement in lipid peroxidation 
products and CK-MB activity with allopurinol (222).  These small studies add 
to the idea that ROS species generated by IR may be reduced by allopurinol 
and have potentially beneficial effects, but neither of these two studies 
correlated reduced ROS activity with improved clinical outcomes. 
 
Another postulated mechanism for tissue damage in IR is the activation of 
heat shock factor 1 as it may be that heat shock factor plays a myocardial 
protective role in IR (224).  Nishizawa J et al (1999) used rat hearts to induce 
IR.  They found that ROS species generated played a role in the gene 
transcription of heat shock factor 1 and this transcription was reduced with 
allopurinol.  This provides another theoretical way that allopurinol may protect 
the heart against IR injury (224). 
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iv Allopurinol may Improve Left Ventricular Remodelling after 
Myocardial Infarction 
 
ROS generated by IR injury post myocardial infarction may play a role in 
cellular signalling pathways leading to remodelling, hypertrophy, dilatation and 
dysfunction of the LV after myocardial infarction (225, 226).  Allopurinol can 
improve LV remodelling in mice with extensive anterior myocardial infarction, 
reducing myocardial hypertrophy and interstitial fibrosis.  In mice models, 
allopurinol reduced ROS production and XO expression as measured using 
electron spin resonance spectroscopy (225).  Again using mice, a recent 
paper looked at the effects of XO inhibitors in mice with induced diabetic 
cardiomyopathy using streptozotocin.  Interestingly XO activity in the 
myocardium, liver and serum of the diabetic mice was increased.  Allopurinol 
decreased this XO activity compared with placebo over 10 weeks, which 
correlated with an improvement in systolic and diastolic function.  Therefore a 
conclusion was drawn that cardiac function in these mice improved by 
decreasing OS with XO inhibitors in diabetic mice (227). 
 
Based on these studies on animals Guan et al (2003) in Japan hypothesised 
allopurinol may have beneficial effects on free radical generation in humans 
and therefore LV function post primary coronary angioplasty (213).  They 
gave 400mg of allopurinol orally just after admission (approximately 60 
minutes before reperfusion).  It should be noted the numbers were small 
(control group 20 patients and allopurinol group 18 patients) and they used 
measurement of urinary 8-epi-prostaglandin F2α to assess free radical 
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production (213).  This study added support to the argument that allopurinol 
inhibits the generation of oxygen derived radicals in IR injury in humans.  
They also found benefits in the recovery of LV function after primary coronary 
angioplasty for myocardial infarction (213). 
 
h. Allopurinol Improves Endothelial Function in Various Cardiovascular 
Disorders 
 
In order to see if allopurinol is beneficial in heart failure, Struthers et al (2002) 
performed a retrospective cohort observational study at the University of 
Dundee on 1760 patients with chronic heart failure (228).  They found that if a 
patient receives 300mg or more of allopurinol per day, there was a 
significantly better mortality than those receiving less than 300mg over long 
periods.  This highlights the need to ensure the correct dose of allopurinol is 
used in the investigation of the potential therapeutic effects of allopurinol.  
This is discussed further in the section that concerns the ‘dose of allopurinol’ 
question. 
 
Following on from this study, George et al (2006) have shown the mechanism 
of action of allopurinol is that it improves endothelial function by profoundly 
reducing vascular OS and not by lowering uric acid (211).  The cohorts of 
patients studied were chronic heart failure patients New York Heart 
Association Class II-III.  Endothelial function was assessed by standard 
forearm venous occlusion plethysmography on a range of allopurinol 300mg 
or 600mg against placebo.  There was a marked increase in endothelial 
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function over placebo with both doses and 600mg was much better than 
300mg, discussed in further detail under the section ‘dose of allopurinol’.  In 
fact the reduction in urate on increasing allopurinol from 300mg to 600mg was 
much smaller (17%) than the added improvement in endothelial function 
(211).  The main important finding from this study was that allopurinol 
abolished the vitamin C sensitive component of vascular OS.  This implies 
that at a tissue level, allopurinol virtually eradicates OS since, after allopurinol, 
the anti-oxidant vitamin C is ineffective as there is no endogenous OS left to 
scavenge.  Furthermore probenecid, which lowers urate, had no effect on 
endothelial function, implying that the mechanism by which allopurinol 
improves endothelial function is by reducing OS and not by lowering urate.  
Doehner et al (2002) also found allopurinol improved endothelial function in 
chronic heart failure (229).  In that study allopurinol was given by intra-arterial 
infusion and orally (at 300mg once daily for one week).  Endothelial function 
was measured by an improvement in peak blood flow using venous occlusion 
plethysmography both systemically and locally.  Also of note was a decrease 
by 20% of allantoin, a marker of oxygen free radicals (229). 
 
A study of 23 patients by Butler et al (2000) looked at endothelial function in a 
cohort of T2DM with mild hypertension (212).  Diabetes is a condition 
characterised by high levels of OS, as discussed in chapter one.  The dose of 
allopurinol used was 300mg for one month in this double blind control trial.  
Bilateral venous occlusion plethysmography was used to assess endothelial 
function.  Allopurinol improved endothelial function in these patients (to near 
normal levels) but had no effect on endothelial function in matched control 
 97 
 
subjects who did not have OS (212).  To asses oxygen free radical activity, 
they used malondialdehyde levels, and this was significantly reduced in the 
allopurinol group (0.30 ± 0.04 versus 0.34 ± 0.05µmol/L for allopurinol versus 
placebo, P=0.03) (212). 
 
It is thought that there is also increased OS in obstructive sleep apnoea 
resulting in endothelial dysfunction (230).  Hence El Solh et al (2006) 
investigated the possible beneficial effects of allopurinol on endothelial 
function in this group of patients.  Twelve patients were randomised to 300mg 
of allopurinol or placebo and endothelial function was measured using FMD.  
There was a significant increase in FMD (10.4±3.2 versus 7.4±2.8% for 
placebo) indicating another potential disease where allopurinol may improve 
endothelial function (230). 
 
Guthikonda et al (2003) used allopurinol in cigarette smokers to see if it 
improved endothelial dysfunction (215).  Cigarette smoking is thought to 
cause endothelial dysfunction through increasing OS (215).  Interestingly 
600mg allopurinol was given as a single dose on the day of the study and 
endothelial function was measured assessing forearm blood flow responses 
to acetylcholine and bradykinin.  They found endothelial function was 
improved in this small number of patients and therefore that XOR may play a 
role in the endothelial dysfunction caused by cigarette smoking (215). 
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i. Allopurinol Improves Augmentation Index and Brain Natiuretic Peptide 
 
In studies published from the University of Dundee, it has often been shown 
that allopurinol reduces AIx and BNP.  In stroke patients, allopurinol reduced 
AIx from 26.08 +/- 3.31% to 20.15 +/- 2.23% compared with an increase in the 
placebo group from 23.57 +/- 3.13% to 27.64 +/- 3.44% (231).  Allopurinol 
reduced BNP significantly in 50 heart failure patients (232).  These findings 
are important, as already discussed previously, AIx reflects after load and 
BNP is raised in any condition putting pressure on the heart, suggesting 
allopurinol may therefore reduce intra-cardiac pressure, possibly by an effect 
in reducing LVM. 
 
j. Effects of Allopurinol in Ischaemic Stroke 
 
In ischaemic stroke allopurinol has shown potential in reducing complications 
as high uric acid levels have been shown to be associated with worse 
outcomes (233).  Allopurinol has beneficial effects on inflammatory markers 
after ischaemic stroke, however allopurinol has had limited effect on 
cerebrovascular activity after stroke (234, 235).  As previously discussed 
allopurinol may also have beneficial affects in stroke prevention due to in 
some part it’s affects in reducing LA size and reducing the burden of AF. 
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k.  Effects of Allopurinol on Blood Pressure 
 
Most studies to date have shown no significant effect of allopurinol on BP 
(211, 236).  There has been one study that has shown allopurinol decreases 
BP in adolescents with newly diagnosed essential hypertension (237).  The 
study design was cross-over of 30 patients over four weeks and the fall in 
systolic BP was modest (-6mmHg).  A similar finding was seen when 
allopurinol was given to 48 hyper-uricaemic patients and compared to normo-
uricaemic patients.  Allopurinol had small improvements in BP over three 
months in the hyper-uricaemic patients but there was no effect on BP in the 
normo-uricaemic patients (238).  Agarwal et al (2013) performed a systematic 
review looking at all the trials that assessed the efficacy of allopurinol on BP 
(239).  A total of 10 clinical studies with 738 participants were included in the 
analysis.  Compared with the control group, systolic BP decreased by 3.3 
mmHg (95% CI 1.4-5.3 mm Hg; P=0.001).  When the analysis was restricted 
to the higher-quality randomised controlled trials, similar changes BP was 
found with a fall in SBP by 3.3 mm Hg (95% CI, 0.8-5.8 mm Hg; P<0.001).  
There is an association between high uric acid and raised BP (240).  It may 
be that allopurinol has small effects on BP in specific sub-sets of patients with 
high uric acid. 
 
l. Allopurinol May Regress Left Ventricular Hypertrophy 
 
Cingolani et al (2006) studied oxypurinol for four weeks in patients with heart 
failure (241).  This was a short period of time, but there was a non-statistically 
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significant trend towards a reduction in LVM.  This small, short study was the 
first to suggest that XO inhibitors may regress LVH. 
 
Very recently, two studies have been published showing that allopurinol can 
regress LVH in two different cohorts, patients with renal dysfunction and 
patients with chronic stable angina (236, 242).  Kao et al (2011) studied 67 
patients with chronic kidney disease and gave 300mg once daily allopurinol 
over nine months (236).  LVM fell by 1.42 ± 4.67g/m2 in the active group and 
rose by 1.28 ± 4.45g/m2 in the placebo group.  Rekhraj et al (2013) found very 
similar results in 66 patients with chronic stable angina.  Allopurinol was given 
at a higher dose in this study, 600mg per day.  LVM fell by 2.2 ± 2.78g/m2 in 
the active group and rose by 0.53 ± 2.5g/m2 in the placebo group.  In both of 
these studies the fall in LVM is modest albeit significant, which makes it very 
possible that it could do the same in patients with diabetes. 
 
m. Dosing of Allopurinol 
 
Until recently only one study used 600mg once daily of allopurinol and this 
was by Guthikonda et al (2003) on heavy smokers (215).  At this dose, 
allopurinol rapidly reduced smoking induced endothelial dysfunction.  Most 
previous research using allopurinol had been with 300mg once daily, some of 
which have been discussed above e.g. Farquharson et al (2002) gave 300mg 
to chronic heart failure patients New York Heart Association class II – III for 
one month versus placebo.  They found that 300mg allopurinol improved 
endothelial function in this small cohort significantly using the forearm 
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plethysmography way on measuring endothelial function (214).  George et al 
(2006) then looked carefully at the dose response relationship between 
allopurinol and endothelial function.  Again this study looked at chronic heart 
failure patients New York Heart Association class II – III (30 patients).  George 
et al (2006) found increasing the dose of allopurinol from 300mg to 600mg 
improved endothelial function by 52%.  Overall allopurinol 600mg improved 
endothelial function by 143% compared to placebo.  The interesting 
conclusion is that previous studies using 300mg allopurinol had actually used 
a suboptimal dose of allopurinol.  Allopurinol was well tolerated even in this 
cohort where 600mg per day was used.   This may also help explain Struthers 
et al (2002) findings that if a patient receives 300mg or more of allopurinol per 
day there was a significantly better mortality than those receiving less than 
300mg over long periods (228).   
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6. Aims 
 
The aims of the study are based on the discussion above.  In summary, 
diabetes is still a major cause of CV morbidity and mortality despite recent 
advances in treatments.  Patients with diabetes are particularly prone to LVH, 
and LVH is an important, often forgotten, CV risk factor.  Despite aggressive 
treatments for LVH with blockade of the RAS and lowering of BP, LVH still 
remains a problem in diabetic patients.  Therefore, a treatment is needed over 
and above traditional treatments and we propose allopurinol may be of benefit 
in these patients.  There are three main reasons to suggest allopurinol may 
regress LVH in T2DM: improvement in endothelial function, reduction in AIx 
and the recent findings that allopurinol regresses LVH in kidney disease and 
chronic stable angina.  The endpoints of the study are: 
 
1. The primary endpoint is to assess if allopurinol regresses LVH in patients 
with T2DM and BP below 150/90.  LVM will be assessed by CMR. 
 
2. The secondary endpoints are to assess if allopurinol improves endothelial 
function and AIx in diabetic patients.  Endothelial function will be assessed 
using FMD and AIx with Sphygmocor technology. 
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CHAPTER TWO 
METHODS 
 
1.  Approvals and Trial Registration 
 
Ethical Approval 
The clinical trial was approved by the Tayside Research Ethics Committee A, 
reference number 09/S0501/3. 
 
Medicines and Health Regulatory Approval (MHRA) 
The clinical trial and use of allopurinol and placebo was approved by the 
MHRA, EudraCT number 2008-008485-12. 
 
Trial Registration 
This study is registered as UK Clinical Research Network Number (UKCRN) 
8766. 
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2. Study Design 
 
The study design was a single centre randomised, double blind, placebo-
controlled trial with nine months follow up. The active drug was 600mg per 
day of allopurinol.  All participants provided written informed consent to 
participate in this study. 
 
66 patients were recruited, 33 patients randomised to receive allopurinol and 
33 randomised to receive placebo.  Patients were allocated a computer 
generated treatment code (patient and investigators blinded).  Patients 
continued their other medications including anti-hypertensives and insulin. 
 
a. Study participants 
 
Patients were identified from databases of out-patients.  Patients were 
identified by the Scottish Diabetes Research Network, the Health Informatics 
Centre or the Scottish Primary Care Research Network if they had T2DM.  
Essentially any patient with T2DM was screened for entry. 
 
Patients had to have T2DM and an average office BP of less than 150/90 
measured over three readings.  Echo was performed to assess for echo LVH.  
LVH on echo was defined by the American Society of Echocardiography 
criteria of LVM index of greater than 115g/m2 for men and greater than 95g/m2 
for women (using the average of three measurements of LVM by one trained 
operator (BRS)) (243). 
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b. Exclusion Criteria 
 
Exclusion criteria included: gout, patients currently prescribed allopurinol, 
previous adverse reaction to allopurinol, eGFR less than 60ml/min/1.73m2, 
conditions that exclude CMR, LV ejection fraction less than 45%, cancer or 
other life threatening illness, pregnancy or breast feeding and being unable to 
provide consent. 
 
c. Allopurinol: Dosing and Side Effects 
 
The dose of allopurinol used was 600mg per day in two divided doses of 
300mg. 
 
Allopurinol is a drug that has been used for over 40 years.  According to the 
BNF it can be given in doses up to 1000mg/day.  Caution should be used in 
hepatic and renal impairment.  Pregnancy and breast feeding is a contra-
indication for use.  Rashes and gastrointestinal disorders are the commonest 
side effects.  Hypersensitivity reactions occur rarely and include exfoliation, 
fever, lymphadenopathy, arthralgia, and eosinophilia resembling Stevens-
Johnson or Lyell’s syndrome.  The BNF lists malaise, headache, vertigo, 
drowsiness, visual and taste disturbances, hypertension, alopecia, 
hepatotoxicity, paraesthesia and neuropathy, gynaecomastia, blood disorders 
(including leucopenia, thrombocytopenia, haemolytic anaemia and aplastic 
anaemia) as being very rare.  
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d. Study visits and Drug Titration 
 
After recruitment, patients attended for six visits over a nine-month period.  An 
initial dose of allopurinol 100mg per day or placebo was dispensed and this 
was increased to 300mg per day or placebo after two weeks.  The dose was 
further increased to 600mg per day or placebo at four weeks and continued 
for the duration of the trial. The study visits are outlined in Figure 2.2.1.  Office 
BP was measured for all the patents at each visit and nine randomly selected 
patients had a 24-hour ambulatory BP monitor at baseline and final visit.  
Availability of ambulatory monitors was limited which is why 24-hour BP was 
only done in a random subset. 
 
The final dose of allopurinol was decided upon when there were no reported 
side effects or change in full blood count, renal and liver function.  Patients 
were told to inform their General Practitioner of any side effects and the Chief 
Investigator.  Contact details of the chief investigator were given to both 
patient and GP. 
 
The criteria for stopping allopurinol was if they had any of the following side 
effects: rashes, gastrointestinal disorders, hypersensitivity reactions, malaise, 
headache, vertigo, drowsiness, visual and taste disturbances, hypertension, 
alopecia, hepatotoxicity, paraesthesia and neuropathy, gynaecomastia, blood 
disorders (including leucopenia, thrombocytopenia, haemolytic anaemia and 
aplastic anaemia).  If there was an increase in creatinine by 26 µmol/L from 
 107 
 
baseline.  Also if there was an increase in ALT/AST (liver function tests) by 
three times the upper limit of normal. 
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Figure 2.2.1. Outline of Study Visits. 
Visit 1 (week 0) 
Blood tests: Uric acid, fasting glucose/insulin, 
BNP, Oxidised LDL, high sensitivity Trop T, 
urine protein/creatinine ratio 
Sphygmocor to measure augmentation index 
Flow mediated dilatation (FMD) 
Cardiac MRI 
24 hour blood pressure monitoring (nine 
randomly selected patients) 
Start trial drug (Allopurinol 100mg/placebo) 
 
Visit 3 (week 4) 
Blood tests (Urea and electrolytes, LFT, FBC) 
Urine protein/creatinine ratio 
Increase trial drug (Allopurinol 600mg/placebo) 
 
 
Visit 4 (week 8) 
Blood test (Urea and electrolytes, LFT, FBC) 
 
 
Visit 2 (week 2) 
Blood test (Urea and electrolytes, LFT, FBC) 
Increase trial drug (Allopurinol 300mg/placebo) 
 
 
Visit 6 (month 9) 
Blood tests: Uric acid, fasting glucose/insulin, 
BNP, Oxidised LDL, high sensitivity Trop T, 
urine protein/creatinine ratio, 
Sphygmocor to measure augmentation index 
Flow mediated dilatation (FMD) 
Cardiac MRI 
24 hour blood pressure monitoring (nine 
randomly selected patients 
 
Visit 5 (month 6) 
Blood tests (Urea and electrolytes, LFT, FBC, 
uric acid) 
Urine protein/creatinine ratio 
Sphygmocor 
FMD 
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e.  Cardiac Magnetic Resonance Imaging 
 
CMR was performed at baseline and at nine months only using a 3T 
Magnetom Trio scanner (Siemens, Erlangen, Germany).  The scanner uses a 
body coil for RF transmission, and a combination of body array and spine 
matrix coils for RF detection.  Short axis images from the atrio-ventricular ring 
to the LV apex were acquired using a 2D ECG-gated breath-hold segmented 
CINE TrueFISP sequence with retrospective gating. The imaging parameters 
included repetition time TR 3·4ms, Echo time of 1·5ms and flip angle 50°. 
Each slice was 6mm thick (with 4mm gap between adjacent slices). Two 
slices were acquired per breath hold of less than 15 seconds and scan time 
was minimized using parallel imaging “GRAPPA’ (factor two). 
 
Quantitative measurement of LVM, ejection fraction (EF), end-diastolic 
volume (EDV), end-systolic volume (ESV) and stroke volume (SV) were 
derived by ‘region of interest’ contours placed around endocardial and 
epicardial LV borders.  This was done on all CMR image slices at end-diastole 
and end-systole that were identified to contain 50% or more full-thickness 
myocardium.  All CMR images were analysed using commercial software 
(‘Argus’, Siemens Multi-modality Work Platform, version VB 15).  An 
independent MRI Physicist (Steve Gandy) analysed all images in fully 
‘blinded’ fashion.  Papillary muscles were included in the LVM if the muscle 
structure was indistinguishable from the myocardial wall, but otherwise 
assigned to the LV blood pool.  Contouring was performed twice for every 
dataset to ensure that repeatability was consistently <5%.  Figure 2.2.2 shows 
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an example of CMR images, highlighting typical endocardial and epicardial 
border region-of-interest contouring of a set of images from the study.  In this 
example, a total of nine slices were acquired from the base of the LV 
myocardium (image 1-top left) to the apex (image 9-bottom right). 
 
 
 
 
 
 
Figure 2.2.2 Typical endocardial and epicardial border region-of-interest 
contouring of a set of images from the study. 
 
f. Flow-mediated Dilatation 
 
Endothelial function was assessed by measuring FMD of the brachial artery.  
FMD was measured using a Sequoia 512 (Siemens, Camberley, UK) 
ultrasound machine with a 8 MHz linear array probe.  FMD was performed at 
baseline, six months and nine months, shown in Figure 2.2.1.  The response 
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to hyperaemia and endothelial independent dilatation was performed as per 
the International Brachial Artery Reactivity Task Force guidelines and has 
been performed regularly at our institute (211, 244, 245).  The brachial artery 
image was located and a baseline measurement captured over one minute. 
Firstly the artery was assessed for the response to hyperaemia by inflating the 
cuff distal to the elbow to 200mmHg for five minutes. The cuff was then 
rapidly deflated and the reactive hyperaemia was recorded for two minutes. A 
10-minute rest period was included before assessment of endothelial 
independent dilatation.  This was done by assessing the response of brachial 
artery size to two puffs of sublingual glyceryl trinitrate spray. FMD was the 
percentage change in average diameter achieved after cuff deflation relative 
to the baseline average brachial artery diameter. The FMD was analysed 
using Vascular Research Tools software (Medical Imaging Applications LLC, 
Coralville, IA, USA). The acquisition and analyses of the FMD images was 
performed by a single trained investigator (BRS), who was blinded to the 
allocated treatment. 
 
g. Applanation Tonometry 
 
Pulse wave analysis (PWA) and pulse wave velocity (PWV) were measured at 
baseline, six months and nine months by a single trained investigator (BRS) 
who was blinded to the allocated treatment.  Analysis was performed using an 
Sphygmocor (AtCor, Sydney, Australia) machine using a high fidelity 
micromanometer.  Prior to taking measurements patients were lay supine for 
10 minutes.  Firstly, for PWA, the radial artery was used to acquire peripheral 
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pressure waveforms (radial artery waveform) by applanation tonometry. The 
radial artery waveform was used to generate the central aortic pressure using 
the Sphygmocor manufactures validated calculation factors. AIx was 
calculated as the difference between the first and second systolic peaks from 
the calculated aortic pressure wave.  AIx is expressed as a percentage of the 
pulse pressure normalised for a heart rate of 75 beats per minute.  Secondly 
for PWV, radial and carotid arterial waveforms were obtained with ECG gating 
so the velocity could be calculated measuring the time interval between R-
wave and the pulse waveforms.  This was performed at the radial and carotid 
arteries separately and the distance between the two sites measured.   
 
h. Laboratory Methods 
 
i. Biochemistry and Haematology Tests 
 
Blood samples for haemoglobin, urea and electrolytes, liver function tests, 
glucose, HBA1c, urine PCR and uric acid were all analysed locally at the 
laboratories in Ninewells Hospital, Dundee.  The samples were collected 
using standard vacutainer tubes and the samples stored at room temperature 
before immediate transfer to our laboratory. 
 
ii. Brain Natriuretic Peptide 
 
BNP was collected in a 5ml. EDTA blood tube.  Blood was centrifuged then 
the plasma was decanted into an aliquot that was stored at -700C.  The assay 
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was a radio-immunoassay using Bachem UK equipment.  The inter-observer 
variability was 26% and the intra-observer variability was 14%. 
 
iii. Uric Acid 
 
Uric acid was not analysed until the end of the trial as changes in uric acid 
may have given clues to the drug prescribed during the trial.  Blood was 
centrifuged then the plasma was decanted into an aliquot that was stored at -
200C.  The assay was a colorimetric assay using Alpha (sentinel kit) 
equipment.  The inter-observer variability was 5% and the intra-observer 
variability was 5.4%. 
 
iv. Insulin 
 
Blood was centrifuged then the plasma was decanted into an aliquot that was 
stored at -200C.  The assay was a radio-immunoassay using Diasorin UK 
equipment.  The inter-observer variability was 4.40%.  The normal range 
quoted by the manufacturer is <5.25uU/L. 
 
v. Oxidised LDL 
 
Oxidised LDL was collected in a 5ml. EDTA blood tube.  Blood was 
centrifuged then the plasma was decanted into an aliquot that was stored at -
700C.  The assay was an ELISA assay using Mercodia Diagenics, Sweden 
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equipment.  The inter-observer variability was 15% and the intra-observer 
variability was 8.6%. 
 
i. Drug Manufacture and Randomisation 
 
The study trial drugs were manufactured by Pharmacy Production Unit, St. 
Thomas’ Hospital, London, UK.  The blinding and randomisation was 
conducted by the Clinical Trials Pharmacy Department, Ninewells Hospital, 
Dundee.  The un-blinding code was held by the pharmacy department.  The 
trial was un-blinded when the database was locked and all data had been 
analysed in a group only fashion. 
 
J. Statistical Analysis 
 
66 patients were required to achieve 90% power to detect a clinically 
significant change in LV mass based on previous studies (246) and 80% 
power to detect a clinically significant change in FMD at a significance level of 
p < 0·05, allowing for a 20% dropout rate.  Using published data from 
Grothues et al (2002), 60 completed patients were anticipated to have 90% 
power to detect a five gram difference in LVM between active and placebo 
which is a figure similar to the difference between the two treatments in the 
echo sub-study of the LIFE study (see below) (247). 
 
Data for continuous variables are presented as mean (SD) for normally 
distributed data and median and inter-quartile range for non-normally 
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distributed data.  Categorical data are expressed as numbers (%).  
Comparison between continuous variables were analysed using the Student t-
test or Mann-Whitney U test whilst categorical variables were analysed using 
χ2 test.  Correlation analysis was performed for changes in LVM and LVMI.  A 
multivariate ANOVA using important covariates was also performed for 
baseline BP, change in BP and prescription of ACE inhibitor or ARBs.  These 
variables were chosen, as they may have been confounding factors in 
allopurinol’s effects.  Change in LVM was not incorporated into the 
multivariate analysis as this was accounted for in the analysis of LVM indexed 
to BSA. 
 
All statistical analyses were undertaken using SPSS version 18·0 (SPSS, 
Chicago, IL).  A two-sided p value < 0.05 was considered statistically 
significant. 
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CHAPTER THREE 
RESULTS 
 
1. Study Recruitment 
 
In total, 66 patients were recruited, and this was the target number.  33 
patients were recruited to the allopurinol arm and 33 patients to the placebo 
arm of the trial.  Recruitment is described graphically in the Consort diagram, 
Figure 3.1.1. 
 
Seven participants withdrew from the study (three from the placebo group and 
four from the active group), Figure 3.1.1.  A further four participants were 
unable to undergo CMR (one from the placebo group and three from the 
active group).  Therefore 56 participants completed the CMR parts of the trial 
and 59 completed all other aspects.  The reasons for withdrawing from the 
trial included:  side effects n = 3, cancer n = 1, pacemaker insertion n=1 and 
patient preference n = 2.  One patient developed a rash thought to be due to 
allopurinol.  One patient felt nauseated but turned out to have been on 
placebo.  Another patient felt more short of breath and although it was felt not 
a classical side effect of allopurinol the patient was withdrawn.  During the 
study period, one patient required insertion of a pacemaker that was felt to 
invalidate the trial due inability to have the final MRI scan and the possible 
haemodynamic effect on endothelial function that may have invalidated further 
FMD.  The requirement for a pacemaker was not thought to be related to 
allopurinol.  Of the patients unable to undergo CMR the reasons where: 
obesity n = 1 and claustrophobia n = 3.  Therefore the percentage of adverse 
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events in this study was 4.5%.  Of the 162 patients screened at entry, 96 
patients failed screening due to: raised BP n= 24, renal function n= 9, no LVH 
on echocardiogram n = 77, patient preference n = 7 and valvular disease n = 
2 (there could, of course, be more than one reason for failing screening).  
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Figure 3.1.1. Study recruitment CONSORT diagram. 
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2.  Baseline Characteristics 
 
Baseline characteristics are shown in Table 3.2.1.  There were no significant 
differences between the groups for baseline characteristics other than for 
body mass index (BMI).  Importantly this included LVM, BP, uric acid and 
medications including ACE inhibitors.  The average duration of diabetes was 
nine years before entry into the trial.  Patients were well treated with modern 
risk factor modification namely ACE inhibitors (49%), ARB (21%), beta-
blockers (23%) and statins (85%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
 
Variable All patients Placebo Allopurinol P value 
Total patients N = 59 N = 30 N= 29  
     
Did not have MRI 4 1 3  
Completed MRI 56 29 26  
Completed FMD 59 30 29  
     
Mean Age (years) 64.63 ± 8.79 66.03 ±8.86 63.17 ± 8.64 0.214 
Male 36 (61.02%) 21 (70.00%) 16 (55.17%) 0.101 
     
BMI baseline 32.59 ± 4.78 31.12 ± 3.93 34.13 ± 5.14 0.014 
24 hour SBP 
baseline 
121.67 ± 11.55 122.25 ± 11.59 121.20 ± 12.87 0.903 
24 hour DBP 
baseline 
66.22 ± 3.31 68.25 ± 2.75 64.60 ± 2.97 0.101 
Office SBP baseline 139.51 ± 11.33 141.63 ± 11.03 137.31 ± 11.41 0.144 
Office DBP baseline 77.66 ± 8.69 76.70 ± 10.18 78.66 ± 6.87 0.392 
Echo LV mass index 
(g/m2) 
126.18 ± 19.04 126.39 ± 17.46 125.97 ± 20.88 0.933 
Absolute MRI LV 
mass (g) (n=56) 
122.60 ± 28.32 119.92 ± 27.89 125.59 ± 29.36 0.464 
MRI LV mass index 
(g/m2) (n=56) 
60.67 ± 9.78 60.16 ± 10.11 61.23 ± 9.56 0.691 
     
Hypertension 53 (89.83%) 27 (90.00%) 26 (89.66%) 0.534 
IHD 6 (10.17%) 3 (10%) 3 (10.34%) 0.534 
Stroke 6 (10.67%) 5 (16.67%) 1 (3.45%) 0.026 
Raised cholesterol 54 (91.52%) 27 (90.00%) 27 (93.10%) 0.056 
     
Smoker 8 (13.56%) 6 (20.00%) 2 (6.90%) 0.454 
Ex-smoker 26 (44.07%) 11 (36.66%) 15 (51.72%) 0.518 
Never smoked 25 (42.37%) 13 (43.33%) 12 (41.38%) 0.638 
     
Duration of diabetes 
(years) 
9.46 ± 6.02 8.97 ± 5.36 9.97 ±6.68 0.528 
     
ACE inhibitor 29 (49.15%) 13 (43.33%) 16 (55.17%) 0.363 
ARB 16 (21.73%) 8 (26.67%) 8 (27.59%) 0.937 
CCB 16 (27.12%) 11 (36.67%) 5 (17.24%) 0.093 
Thiazide diuretic 13 (22.03%) 8 (26.67%) 5 (17.24%) 0.383 
Frusemide 4 (6.78%) 3 (10.00%) 1 (3.45%) 0.317 
Beta-blocker 14 (23.73%) 7 (23.33%) 7 (24.14% 0.942 
Metformin 45 (76.27%) 20 (66.67%) 25 (86.21%) 0.078 
Gliclazide 15 (24.42%) 7 (23.33%) 8 (27.58%) 0.708 
TZD 7 (11.86%) 3 (10.00%) 4 (13.79%) 0.652 
Exenatide 2 (3.39%) 0 (0.00%) 2 (6.90%) 0.143 
Insulin 9 (15.25%) 4 (13.33%) 5 (17.24%) 0.676 
Aspirin 28 (47.46%) 15 (50.00%) 13 (44.53%) 0.691 
Clopidogrel 2 (3.39%) 0 (0.00%) 2 (6.90%) 0.143 
Statin 50 (84.75%) 25 (83.33%) 28 (86.21%) 0.759 
     
Haemoglobin (g/L) 13.73 ± 1.43 14.06 ±1.27 13.40 ± 1.53 0.076 
eGFR (ml/min//1.732) 86.31 ± 13.75 83.21 ± 10.38 89.52 ± 16.09 0.078 
Creatinine (µm/L) 76.88 ± 12.08 80.00 ± 11.16 73.66 ± 12.33 0.043 
Fasting glucose 
(mmol/L) 
6.62 ± 1.96 6.14 ± 1.66 7.11 ± 2.15 0.056 
Fasting insulin (uU/L) 32.16 ± 25.34 34.37 ± 27.74 29.88 ± 22.87 0.501 
HBA1c (%) 7.25 ± 0.94 7.12 ± 0.83 7.39 ± 1.04 0.274 
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Urine PCR 
(mg/mmol) 
13.05 ± 8.26 14.13 ± 10.51 11.93 ± 4.93 0.310 
BNP (pg/ml) 29.01 ± 25.81 30.01 ±22.74 27.97 ± 29.03 0.764 
Uric acid (mmol/L) 0.54 ± 0.13 0.54 ± 0.10 0.55 ± 0.15 0.613 
PIINP (n=23) (ug/l) 4.37 ± 1.05 4.56 ± 0.94 4.16 ± 1.16 0.379 
HS TropT (ng/L) 7.46 ± 4.85 7.90 ± 5.59 7.01 ± 3.99 0.486 
Oxidised LDL (U/L) 28.51 ± 9.90 27.58 ± 10.07 29.48 ± 9.81 0.467 
     
EF (%) 75.15 ± 5.317 75.21 ± 4.66 75.08 ± 5.78 0.927 
EDV (mls) 123.52 ± 35.94 118.36 ± 36.41 129.28 ± 35.23 0.264 
ESV (mls) 31.17 ± 13.01 29.80 ± 12.00 32.71 ± 14.12 0.412 
SV (mls) 92.36 ± 25.42 88.57 ± 26.06 96.58 ± 24.50 0.247 
CO (mls) 6.41 ± 1.60 6.18 ± 1.70 6.66 ± 1.47 0.265 
     
FMD (%) 4.11 ± 0.08 4.16 ± 0.59 4.07 ± 0.64 0.578 
AIx (%) 11.09 ± 10.07 10.47 ± 10.78 11.76 ± 9.40 0.629 
PWV (m/s) 7.07 ± 1.14 6.94 ± 1.03 7.19 ± 1.24 0.468 
Table 3.2.1. Baseline characteristics. 
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3. Changes in Measured Parameters 
 
The main finding from this study is that allopurinol significantly reduced LVM 
over the nine-month study period both for absolute LVM and LVMI. Change in 
LVM was -2.65 ± 5.91g and +1.21 ± 5.10g (p=0.012) for the allopurinol group 
and placebo group respectively.  Change in LVMI was -1.32 ± 2.84g/m2 and 
+0.65 ± 3.07g/m2 (p=0.017) for the allopurinol group and placebo group 
respectively.  The results are detailed further in Table 3.3.1 and in Figure 
3.3.1.  Multivariate analysis was performed using co-variates of baseline BP, 
change in BP and prescription of ACE inhibitor or ARBs that showed p=0.013 
for LVM and p=0.021 for LVMI, Table 3.3.2.  It is quite common for LVM to 
increase with ageing in the placebo group of MRI studies, as we saw here and 
have seen before (248). 
 
 Placebo Allopurinol P value 
Change LVM (g) +1.21 ± 5.10 -2.65 ± 5.91 0.012 
Change LVMI (g/m2) +0.65 ± 3.07 -1.32 ± 2.84 0.017 
    
Change in EF (mls) 0.08 ± 7.41 1.46 ± 6.10 0.458 
Change in EDV (mls) 4.45 ± 39.60 6.12 ±40.57 0.878 
Change in ESV (mls) 2.44 ± 21.84 0.20 ± 14.60 0.660 
Change in SV (mls) 2.01 ± 24.83 5.89 ± 28.88 0.595 
Change in CO 
(L/min) 
-0.75 ± 1.61 0.67 ± 1.45 0.081 
Table 3.3.1: Changes in MRI parameters (Over 9 month study period) 
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Tests of Between-Subjects Effects 
Source Dependent Variable Type III Sum of 
Squares df Mean Square F Sig. 
LVM 399.779a 4 99.945 3.554 .013 Corrected Model 
dimension1 
LVMI 105.239b 4 26.310 3.191 .021 
LVM 1.870 1 1.870 .067 .798 Intercept 
dimension1 
LVMI 2.384 1 2.384 .289 .593 
LVM 58.782 1 58.782 2.091 .154 SBP9 
dimension1 
LVMI 10.911 1 10.911 1.323 .255 
LVM 1.018 1 1.018 .036 .850 ACEI 
dimension1 
LVMI 5.832 1 5.832 .707 .404 
LVM 118.950 1 118.950 4.230 .045 ARB 
dimension1 
LVMI 14.585 1 14.585 1.769 .190 
LVM 159.878 1 159.878 5.686 .021 Drugchange 
dimension1 
LVMI 48.516 1 48.516 5.884 .019 
LVM 1405.900 50 28.118   Error 
dimension1 
LVMI 412.264 50 8.245   
LVM 1826.316 55    Total 
dimension1 
LVMI 521.826 55    
LVM 1805.680 54    Corrected Total 
dimension1 
LVMI 517.503 54    
a. R Squared = .221 (Adjusted R Squared = .159) 
b. R Squared = .203 (Adjusted R Squared = .140) 
Table 3.3.2: Output from multivariate analysis using co-variates of baseline 
BP, change in BP and prescription of ACE inhibitor or ARBs 
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(1)* 
 
(2)* 
 
*Standard Deviation  
Figure 3.3.1 Diagrams of changes in (1) LVM and (2) LVMI  
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For the other parameters measured on cardiac MRI there was no significant 
changes in EF, EDV, ESV, SV and cardiac output (CO), shown in Table 3.3.1. 
 
There was no change in BNP, oxidised low-density lipoprotein (LDL) or high 
sensitivity troponin T (HS Troponin T) over the study period, Table 3.3.3.  
There was as expected a significant reduction in uric acid levels in the 
allopurinol group.  Allopurinol was safe and had no affect on urine protein 
creatinine ratio (PCR) or eGFR.  There was no difference in office or 24 hour 
BP over time, Table 3.3.4.  No significant change was seen in both FMD and 
AIx as shown in Table 3.3.4. 
 
 Placebo Allopurinol P value 
Haemoglobin (g/L)  -1.50 ± 3.19 -1.51 ± 2.99 0.993 
Creatinine (µm/L) -7.00 ± 13.88 -7.67 ± 7.39 0.910 
eGFR  (ml/min//1.732) 6.57 ± 11.75 8.78 ± 10.00 0.441 
Fasting glucose (mmol/L) 0.84 ± 4.05 0.41 ± 3.64 0.668 
Fasting insulin (uU/L) -6.41 ± 19.26 -1.64 ± 15.96 0.306 
HBA1c (%) -0.063 ± 0.47 -0.43 ± 1.80 0.279 
Urine PCR (mg/mmol) 2.67 ± 12.76 5.03 ± 20.13 0.590 
BNP (pg/ml) -1.49 ± 20.22 -3.16 ± 20.36 0.754 
Uric acid (6 months) 
(mmol/L) 
-0.019 ± 0.12 -0.27 ± 0.17 <0.001 
Uric acid (9 months) 
(mmol/L) 
-0.01 ± 0.06 -0.25 ± 0.18 <0.001 
HS TropT (ng/L) 0.34 ± 2.98 0.35 ± 2.25 0.656 
Oxidised LDL (U/L) -0.11 ± 7.69 0.74 ± 8.80 0.692 
Table 3.3.3. Change in blood parameters (Over 9 month study period) 
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 Placebo Allopurinol P value 
Office SBP (6 
months) 
-3.17 ± 17.08 -1.69 ± 11.31 0.698 
Office SBP (9 
months) 
-6.50 ± 28.67 0.52 ± 14.82 0.245 
Office DBP (6 
months) 
-4.10 ± 14.13 -8.55 ± 6.88 0.132 
Office DBP (9 
months) 
-4.53 ± 13.25 -7.17 ± 8.44 0.367 
24hr SBP (9 months) -1.00 ± 0.61 0.41 ± 1.72 0.129 
    
FMD hyperaemia (6 
months) (%) 
-0.53 ± 2.93 -0.079 ± 4.21 0.602 
FMD hyperaemia (9 
months) (%) 
0.48 ± 4.38 1.00 ± 6.95 0.733 
FMD GTN (6 months) 
(%) 
1.42 ± 5.43 0.11 ± 1.21 0.405 
FMD GTN (9 months) 
(%) 
1.10 ± 4.84 0.84 ± 5.95 0.856 
    
AIx (6 months) (%) -1.88 ± 9.46 -1.51 ± 11.54 0.890 
AIx (9 months) (%) -1.17 ± 12.67 -1.36 ± 9.58 0.948 
    
PWV (6 months) 
(m/s) 
-0.32 ± 1.75 -0.87 ± 2.19 0.288 
PWV (9 months) 
(m/s) 
-0.71 ± 2.65 -0.70 ± 2.22 0.987 
Table 3.3.4. Change in parameters of endothelial function and blood pressure 
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4. Changes in Measured Parameters for Above and Below Median 
LVM and LVMI  
 
In order to assess the differing affects of having high or low LVM and LVMI at 
baseline as assessed by CMR, an analysis was made of measured 
parameters for each sub-group.  The effect of LVM regression was more 
marked if the baseline LVM and LVMI was higher at baseline, as shown in 
Tables 3.4.1 and 3.4.2.  For the above median baseline LVM sub-group 
change in LVM was -4.03 ± 6.77g and +2.67 ± 4.87g (p=0.006) for the 
allopurinol group and placebo group respectively.  Change in LVMI in the 
above median LVM group was -1.93 ± 3.09g/m2 and +1.32 ± 2.13g/m2 
(p=0.004) for the allopurinol group and placebo group respectively. For the 
above median baseline LVMI sub-group change in LVM was -4.03 ± 6.77g 
and +1.42 ± 6.77g (p=0.025) for the allopurinol group and placebo group 
respectively.  Change in LVMI in the above median LVMI group was -1.93 ± 
3.09g/m2 and +1.58 ± 2.59g/m2 (p=0.003) for the allopurinol group and 
placebo group respectively.  These changes are represented graphically in 
Figures 3.4.1 and 3.4.2.  Conversely, when below median LVM and LVMI 
were analysed the change in LVM and LVMI becomes non-significant.  For 
the below median baseline LVM sub-group, change in LVM was -1.27 ± 4.76g 
and -0.16 ± 5.10g (p=0.559) for the allopurinol group and placebo group 
respectively.  Change in LVMI in the below median LVM group was -0.71 ± 
2.52g/m2 and +0.02 ± 2.70g/m2 (p=0.552) for the allopurinol group and 
placebo group respectively. For the below median baseline LVMI sub-group, 
change in LVM was -1.27 ± 4.76g and 0.95 ± 4.59g (p=0.240) for the 
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allopurinol group and placebo group respectively.  Change in LVMI in the 
below median LVMI group was -0.71 ± 2.52g/m2 and -0.50 ± 3.31g/m2 
(p=0.299) for the allopurinol group and placebo group respectively.  This 
suggests the patients with the highest LVM at baseline have the most to gain 
from regression in LVM, which makes sense, as LVM can never be reduced 
to zero.  As for the other parameters measured on CMR, sub-group analysis 
of above and below median LVM showed no new trends, as shown in Table 
3.4.1 and 3.4.2. 
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 Placebo 
(LVM 
above 
median) 
Allopurinol 
(LVM 
above 
median) 
P value Placebo 
(LVM 
below 
median) 
Allopurinol 
(LVM 
below 
median) 
P value 
Change LVM 
(g) 
2.67±4.87 -4.03±6.77 0.006 -0.16±5.10 -1.27±4.76 0.559 
Change 
LVMI (g/m2) 
1.32±2.13 -1.93±3.09 0.004 0.02± 2.70 -0.71±2.52 0.552 
       
Change in 
EF (mls) 
-0.64±9.17 0.26±5.48 0.913 0.22±5.63 2.66±6.67 0.303 
Change in 
EDV (mls) 
-
0.75±44.45 
5.81±40.28 0.692 9.30±35.34 6.43±42.50 0.847 
Change in 
ESV (mls) 
3.09±30.63 1.78±15.00 0.889 1.83±10.64 -
1.38±14.61 
0.507 
Change in 
SV (mls) 
-
3.83±21.28 
3.99±27.90 0.418 7.47±27.32 7.80±30.85 0.977 
Change in 
CO (L/min) 
-0.23±1.65 0.68±1.07 0.107 0.07±1.62 0.65±1.81 0.373 
Table 3.4.1. Changes in measured parameters analysed as sub-groups of 
above and below median LVM 
 
 Placebo 
(LVMI 
above 
median) 
Allopurinol 
(LVMI 
above 
median) 
P value Placebo 
(LVMI 
below 
median) 
Allopurinol 
(LVMI 
below 
median) 
P value 
Change LVM 
(g) 
1.42±5.63 -4.03±6.77 0.025 0.95±4.59 -1.27±4.76 0.240 
Change 
LVMI (g/m2) 
1.58±2.59 -1.93±3.09 0.003 -0.50±3.31 -0.71±2.52 0.299 
       
Change in 
EF (mls) 
-0.13±9.67 0.26±5.48 0.899 0.35±3.36 2.66±6.67 0.274 
Change in 
EDV (mls) 
1.44±41.48 5.81±40.28 0.778 8.16±38.48 6.43±42.50 0.062 
Change in 
ESV (mls) 
3.30±28.47 1.78±15.00 0.864 1.38±9.86 -
1.38±14.61 
0.110 
Change in 
SV (mls) 
-
1.85±20.38 
3.99±27.90 0.520 6.77±29.57 7.80±30.85 0.932 
Change in 
CO (L/min) 
-0.18±1.65 0.68±1.07 0.117 0.06±1.63 0.65±1.81 0.383 
Table 3.4.2. Changes in measured parameters analysed as sub-groups of 
above and below median LVMI 
 
All measured parameters were also divided into sub-groups of above and 
below median LVM and LVMI, see Tables 3.4.3, 3.4.4., 3.4.5. and 3.4.6.  This 
sub-group analysis revealed no new changes or trends in measured 
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parameters.  Of note there was no significant changes renal function, BNP, 
markers of OS and BP.  Furthermore, no significant differences or trends are 
seen in FMD and AIx in the sub-group analysis.  
 
 Placebo 
(LVM 
above 
median) 
Allopurinol 
(LVM 
above 
median) 
P value Placebo 
(LVM 
below 
median) 
Allopurinol 
(LVM below 
median) 
P value 
Haemoglobin 
(g/L)  
-0.53±0.57 -0.45±0.56 0.735 -2.39±4.36 -2.76±4.18 0.822 
Creatinine 
(µm/L) 
4.21±10.15 -5.92±7.44 0.625 -5.07±8.89 -6.46±5.41 0.627 
eGFR  
(ml/min//1.732) 
-0.19±0.42 -0.95±2.57 0.284 0.053±0.51 -0.12±0.48 0.380 
Fasting 
glucose 
(mmol/L) 
2.38±5.37 0.03±3.79 0.205 -0.67±1.50 0.53±4.00 0.288 
HBA1c (%) 3.66±16.88 1.18±13.48 0.421 7.83±21.76 5.14±18.86 0.731 
Urine PCR 
(mg/mmol) 
6.93±14.90 0.77±6.37 0.181 -1.27±9.80 10.23±29.13 0.161 
BNP (pg/ml) 4.46±24.09 3.27±25.44 0.902 0.93±14.86 -5.67±14.66 0.405 
Uric acid (6 
months) 
(mmol/L) 
0.00±0.08 -0.23±0.13 <0.001 -0.01±0.06 -0.28±0.19 <0.001 
Uric acid (9 
months) 
(mmol/L) 
0.00±0.063 -0.21±0.17 <0.001 0.03±.05 -0.27±0.17 <0.001 
HS TropT 
(ng/L) 
-0.11±3.84 0.56±1.50 0.561 0.29±0.80 -0.89±2.73 0.122 
Oxidised LDL 
(U/L) 
-0.41±5.78 2.41±8.73 0.328 -0.43±9.24 -0.88±45 0.900 
Table 3.4.3. Sub-group analysis of above and below median baseline LVM for 
change in blood parameters (Over 9 month study period) 
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 Placebo 
(LVMI 
above 
median) 
Allopurinol 
(LVMI 
above 
median) 
P value Placebo 
(LVMI 
below 
median) 
Allopurinol 
(LVMI 
below 
median) 
P value 
Haemoglobin 
(g/L)  
-0.44±0.50 -0.45±0.56 0.935 -2.79±4.58 -2.76±4.18 0.986 
Creatinine 
(µm/L) 
-3.00±9.71 -5.92±7.44 0.380 -6.69±8.85 -6.46±5.41 0.937 
eGFR  
(ml/min//1.732) 
-0.14±0.43 -0.95±2.57 0.220 0.02±0.53 -0.12±0.48 0.495 
Fasting 
glucose 
(mmol/L) 
1.71±5.18 0.03±3.79 0.338 -0.32±1.87 0.53±4.00 0.492 
HBA1c (%) 4.28±15.78 1.18±13.48 0.332 7.71±23.52 5.14±18.86 0.761 
Urine PCR 
(mg/mmol) 
5.00±15.09 0.77±6.37 0.355 -0.15±9.62 10.23±29.13 0.234 
BNP (pg/ml) 0.47±20.75 3.27±25.44 0.746 5.29±18.48 -5.67±14.66 0.956 
Uric acid (6 
months) 
(mmol/L) 
-0.00±0.08 -0.23±0.13 <0.001 0.00±0.05 -0.28±0.19 <0.001 
Uric acid (9 
months) 
(mmol/L) 
-0.01±0.06 -0.21±0.17 <0.001 -0.01±0.06 -0.27±0.17 <0.001 
HS TropT 
(ng/L) 
-0.10±3.59 0.56±1.50 0.539 0.33±0.82 -0.89±2.73 0.134 
Oxidised LDL 
(U/L) 
-0.28±7.05 2.41±8.73 0.366 -0.59±8.58 -0.88±45 0.936 
Table 3.4.4. Sub-group analysis of above and below median baseline LVMI 
for change in blood parameters (Over 9 month study period) 
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 Placebo 
(LVM 
above 
median) 
Allopurinol 
(LVM 
above 
median) 
P value Placebo 
(LVM 
below 
median) 
Allopurinol 
(LVM 
below 
median) 
P value 
Office SBP 
(6 months) 
6.71±10.52 10.24±11.07 0.403 7.37±12.99 9.18±9.21 0.679 
Office SBP 
(9 months) 
5.50±18.07 -8.31±6.26 0.600 3.00±10.30 9.18±9.21 0.253 
Office DBP 
(6 months) 
6.64±15.96 -4.15±13.47 0.666 0.73±18.40 -0.77±8.15 0.995 
Office DBP 
(9 months) 
8.21±18.73 -4.38±14.04 0.556 5.27±37.01 4.54±13.67 0.376 
24hr SBP (9 
months) 
-0.14±0.86 -0.08±0.28 0.795 0.667±0.26 0.62±1.56 0.106 
       
FMD 
hyperaemia 
(6 months) 
(%) 
-0.47±3.84 1.40±3.16 0.182 -0.72±1.96 -1.65±4.95 0.508 
FMD 
hyperaemia 
(9 months) 
(%) 
-0.26±4.65 1.24±3.84 0.373 1.14±4.31 0.76±9.68 0.894 
FMD GTN (6 
months) (%) 
0.69±.55 0.62±3.96 0.964 2.09±6.95 -0.85±8.19 0.312 
FMD GTN (9 
months) (%) 
1.72±4.60 0.59±4.27 0.511 0.49±5.30 1.49±7.72 0.690 
       
AIx (6 
months) (%) 
1.02±11.11 -2.33±10.13 0.297 -3.40±.73 0.02±13.99 0.429 
AIx (9 
months) (%) 
0.57±3.04 -4.26±10.23 0.906 1.08±12.46 1.18±9.14 0.483 
Table 3.4.5. Sub-group analysis of above and below median baseline LVM for 
change in parameters of endothelial function and blood pressure 
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 Placebo 
(LVMI 
above 
median) 
Allopurinol 
(LVMI 
above 
median) 
P value Placebo 
(LVMI 
below 
median) 
Allopurinol 
(LVMI 
below 
median) 
P value 
Office SBP 
(6 months) 
4.41±10.24 10.24±11.07 0.153 10.30±12.85 9.18±9.21 0.800 
Office SBP 
(9 months) 
4.31±16.87 -8.31±6.26 0.427 -4.08±11.20 9.18±9.21 0.448 
Office DBP 
(6 months) 
3.19±16.51 -4.15±13.47 0.866 -4.08±18.73 -0.77±8.15 0.565 
Office DBP 
(9 months) 
14.06±35.74 -4.38±14.04 0.367 2.38±15.00 4.54±13.67 0.705 
24hr SBP (9 
months) 
-0.13±0.81 -0.08±0.28 0.839 -0.77±0.28 0.62±1.56 0.127 
       
FMD 
hyperaemia 
(6 months) 
(%) 
-0.56±3.56 1.40±3.16 0.132 -0.64±2.15 -1.65±4.95 0.505 
FMD 
hyperaemia 
(9 months) 
(%) 
-0.03±4.57 1.24±3.84 0.431 1.07±4.42 0.76±9.68 0.917 
FMD GTN 
(6 months) 
(%) 
1.40±4.11 0.62±3.96 0.610 1.43±7.07 -0.85±8.19 0.454 
FMD GTN 
(9 months) 
(%) 
1.93±4.54 0.59±4.27 0.421 0.05±5.37 1.49±7.72 0.585 
       
AIx (6 
months) (%) 
-0.96±10.39 -2.33±10.13 0.723 -3.84±8.19 0.02±13.99 0.404 
AIx (9 
months) (%) 
0.10±11.98 -4.26±10.23 0.308 -1.59±13.70 1.18±9.14 0.550 
Table 3.4.6. Sub-group analysis of above and below median baseline LVM for 
change in parameters of endothelial function and blood pressure 
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(1)* 
 
(2)* 
 
*Standard Deviation 
 
Figure 3.4.1 Graphs of above and below median LVM changes in (1) LVM 
and (2) LVMI  
 
 135 
 
(1)* 
 
(2)* 
 
 
*Standard Deviation 
 
Figure 3.4.2. Graphs of above and below median LVMI changes in (1) LVM 
and (2) LVMI  
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5. Correlations  
 
There was no correlation shown between change in blood parameters and 
change in LVM and LVMI.  There was a trend seen with change in uric acid 
and change in LVM with a p value of 0.09.  Although not reaching significance 
it does hint toward a trend that is probably explained by the fact that the group 
where the LVM fell was the allopurinol patients and hence there was a 
significant fall in uric acid.  Baseline FMD correlated significantly with change 
in LVM and LVMI.  Finally, a positive correlation was seen between change in 
LVM and LVMI and change in office systolic BP. This could be meaningful 
and leaves open the possibility that subtle changes in BP might be a factor in 
our results.  Correlation results are shown in Table 3.5.1. 
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 Change LVM Change LVMI 
Change in Uric 
Acid 
r = 0.228 
p = 0.09 
r = 0.223 
p = 0.102 
Baseline Uric Acid r = 0.201 
p = 0.141 
r = 0.245 
p = 0.072 
Change oxidised 
LDL 
r = 0.068 
p = 0.622 
r = 0.053 
p = 0.698 
Baseline Oxidised 
LDL 
r = -0.107 
p = 0.437 
r = -0.035 
p =0.800 
Change BNP r = 0.174 
p = 0.203 
r = 0.198 
p = 0.148 
Baseline BNP r = -0.099 
p = 0.470 
r = -0.144 
p =0.263 
Change HS Trop 
T 
r = 0.248 
p = 0.068 
r = 0.220 
p = 0.107 
Baseline HS Trop 
T 
r = 0.193 
p = 0.158 
r = 0.094  
p = 0.497 
Change PCR r = -0.042 
p = 0.759 
r = 0.013 
p = 0.926 
Baseline PCR r = 0.175 
p = 0.201 
r = 0.125 
p = 0.362 
Change Glucose r = 0.026 
p = 0.852 
r = 0.010 
p = 0.945 
Baseline Glucose r = 0.176 
p = 0.198 
r = 0.066 
p = 0.632 
Change Insulin r = -0.172 
p = 0.211 
r = -0.36 
p = 0.794 
Baseline Insulin r = 0.105 
p = 0.444 
r = 0.077 
p = 0.576 
Change eGFR r = -0.067 
p = 0.627 
r = -0.083 
p = 0.545 
Baseline eGFR r = -0.54 
p = 0.694 
r = -0.062 
p = 0.653 
Change FMD r = 0.022 
p = 0.870 
r = -0.039 
p = 0.777 
Baseline FMD r = 0.363 
p = 0.007* 
r = 0.300 
p = 0.027* 
Change AIx r = -0.181 
p = 0.187 
r = -0.143 
p = 0.298 
Baseline AIx r = -0.149 
p = 0.284 
r = -0.164 
p = 0.235 
Change Office 
SBP 
r = -0.370 
p = 0.005* 
r = -0.342 
p = 0.011* 
Baseline Office 
SBP 
r = 0.163 
p = 0.234 
r = 0.169 
p = 0.219 
Change 24 hour 
SBP 
r = 0.039 
p = 0.778 
r = 0.039 
p = 0.780 
Baseline 24 hour 
SBP 
r = 0.257 
p = 0.539 
r = 0.285 
p = 0.493 
* = Significant correlation 
Table 3.5.1. Correlation of LVM and LVMI with measured parameters. 
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6. Important Drug Changes over Nine-Month Study Period 
 
Table 3.6.1 shows important changes made to study participants over the 
nine-month study period.  As can be seen few patients had changes made to 
their medications.  The most common change to medication was a titration of 
anti-diabetic drugs during the study. 
 
 Allopurinol Group Placebo Group 
New anti-hypertensive 1 1 
Increase in anti-
hypertensive 
1 0 
Titration of diabetic 
medication 
6 4 
Table 3.6.1. Important drug changes over nine-month study period 
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CHAPTER 4 
DISCUSSION 
 
The key finding from this study is that allopurinol reduces LVM in patients with 
T2DM and baseline LVH.  All patients had an office BP at baseline below 
150/90.  There was no significant change in either office BP or 24 ambulatory 
BP over the nine-month study period.  This is important because until recently 
the only way that has been shown to regress LVH was to decrease BP (79, 
159, 161, 163).  These findings are in keeping with two, recently published 
studies, showing similar findings.  Kao et al (2011) was the first to show the 
effects of allopurinol on regression of LVM in patients with chronic kidney 
disease (236).  These findings agree with Kao et al (2011), although it should 
be noted a higher dose of allopurinol was used in this study (600mg as 
compared with 300mg) over the same nine-month study period.  Rekhraj et al 
(2013) also showed that allopurinol regresses LVM in patients with chronic 
stable angina (242).  Their study was of similar design to this one, giving 
allopurinol 600mg over nine months.  Again, this study showed no effects on 
BP.  This is the third such study showing regression of LVM, which is 
compelling evidence the effects of allopurinol are very unlikely to be due to 
chance. 
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1. Blood Pressure 
 
As BP has been previously strongly associated with development of LVH and 
the strategies for regression of LVH, the first issue to address is to whether 
allopurinol has any effects on BP, however subtle. We found no change in BP 
in the allopurinol group and other studies have also shown no significant 
effect of allopurinol on BP (211, 236).  There has been one study that has 
shown allopurinol decreases BP in adolescents with newly diagnosed 
essential hypertension (237).  This was a small cross-over study of 30 
patients over a very short period of time (four weeks) and the fall in systolic 
BP was modest (-6mmHg).  A similar finding was seen when allopurinol was 
given to 48 hyper-uricaemic patients and compared to normouricaemic 
patients.  Allopurinol had small improvements in BP over three months in the 
hyper-uricaemic patients but there was no effect on BP in the normo-
uricaemic patients (238).  Conversely, all other studies using allopurinol in 
adults over long periods of time did not show any significant changes in BP, 
as was found in this study (211, 236).  The difference here is that uric acid 
was not significantly raised in this or other studies quoted.  There is an 
association between high uric acid and raised BP (240). It can be postulated 
that allopurinol may have small effects on BP in specific sub-sets of patients 
with high uric acid.  Therefore it seems that allopurinol has minimal (if any) 
effect on BP over time in an unselected group of patients without high uric 
acid and high degrees of hypertension.  It would seem therefore allopurinol is 
the first ‘non anti-hypertensive drug’ ever shown to regress LVH in man. 
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2. Prognostic Benefits of Regressing LVH 
 
Regressing LVH improves CV morbidity and mortality irrespective of BP 
changes.  Indeed, Schillaci et al (2004) claims in an editorial ‘LVH stands out 
as the only available marker whose treatment induced regression has been 
unequivocally associated with a better prognosis, even after accounting for 
treatment induced BP reduction’ (249).  The largest trial to show this is the 
LIFE trial that studied hypertensive patients with signs of ECG LVH (77, 163).  
In LIFE, Devereux et al (2002) found that LVH regression per se (independent 
of BP) was overall associated with reduced all cause mortality (by 28%), CV 
mortality (by 38%), sudden cardiac death (by 19%), myocardial infarction (by 
15%), new HF (by 36%), new AF (by 12%) and stroke (by 24%) (169, 171, 
250). 
 
A slightly unclear picture has arisen from the diabetic sub-study of the LIFE 
trial.  Losartan was associated, over atenolol, with even fewer CV events and 
deaths in patients with diabetes than in those without diabetes (167).  
Losartan was also more effective than atenolol in reversing LVH in those with 
diabetes (167).  Yet in an analysis of ECG-LVH changes per se, the presence 
of diabetes lessened the link between ECG-LVH changes and CV events.  
Indeed it appears from the LIFE study that reduction of BP does not regress 
ECG-LVH as much in patients with diabetes as it does in those without 
diabetes (168).  This highlights the potential importance of finding novel ways 
to regress LVH in T2DM, like allopurinol.  It is also worth noting that the 
change in LVM on CMR in this study is of similar magnitude to the changes 
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seen with allopurinol in a previous renal study which raises the possibility that, 
unlike BP reduction, allopurinol may regress LVH as well in patients with 
diabetes as in those without diabetes (236). 
 
As the sub-group who conferred the highest change in LVM had the highest 
baseline LVM, this would suggest in the future studies are targeted toward 
patients with the highest baseline LVM as they may confer the most benefit.  It 
is not surprising that LVM regression is greater in those the highest baseline 
LVM. 
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3. Magnitude of Changes in Left Ventricular Mass 
 
The magnitude of the LVM changes we produced here appears modest.  The 
difference between allopurinol and placebo was 3.2% for LVM and 3.3% for 
LVMI.  When compared to other studies looking at regression of LVM the 
changes seen in this study are comparable.  Simpson et al (2010), Kao et al 
(2011) and Rekhraj et al (2013) showed similar falls in LVM to this study with 
changes in LVM over time (one year and nine months respectively).  In the 
echo sub-study of the LIFE study, the difference between the two active 
treatments was only 3% and yet when this was maintained over many years 
(4.8 years), the differential effect on CV events between the two treatments 
was a 14% reduction in CV events and a 25% reduction in strokes (165).  
These were the results in the main LIFE trial although the effects were even 
greater in the diabetic sub-study of LIFE where CV events were reduced by 
24% and total mortality by 39% (167).  The LIFE trial is in fact the best 
comparator for our trial because only the LIFE trial and our study eliminated 
the effect of BP on LVH regression.  In any case, we only gave allopurinol for 
nine months and it would be expected that the small difference we saw in 
LVM would increase over the first two years of treatment as also occurred in 
the echo sub-study of the LIFE trial (165).  The full LVH regressing effect of 
allopurinol may take two years to manifest itself. 
 
The effect of regression of LVM is concentrated to the sub group of patients 
with highest baseline LVM.  This is logical as the higher the LVM at baseline 
then the greater potential for it to regress. 
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4. Other Studies Regressing Left Ventricular Hypertrophy Using 
Allopurinol 
 
There are now two direct comparisons to this trial, Kao et al (2011) and 
Rekhraj et al (2013) both of similar design.  In both these studies allopurinol 
was given over the same time frame of nine months (236, 242).  Kao et al 
(2011) gave allopurinol at a dose of 300mg over nine months to patients with 
chronic kidney disease stage 3 and LVH.  The primary end-point was change 
in LVM in active and placebo arms.  Their findings were similar to this trial 
with significant fall in LVMI (change in LVMI at nine months for the allopurinol 
group -1.42 ± 4.67g/m2 and for the placebo group 1.28 ± 4.45g/m2).  Rekhraj 
et al (2013) found very similar results in 66 patients with chronic stable 
angina.  Allopurinol was given at a higher dose in this study, 600mg per day 
over nine months.  LVM fell by 2.2 ± 2.78g/m2 in the active group and rose by 
0.53 ± 2.5g/m2 in the placebo group.  Although these trials were done on 
different cohorts of patients, allopurinol has now consistently regressed LVM 
in two other randomised control trials.  The findings in this trial are consistent 
with three experimental studies in animal models that have also shown that 
allopurinol regresses LVH (225, 251, 252). 
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5. Reducing Cardiovascular Risk Further in Diabetes 
 
Improving mortality and morbidity in diabetes is important.  The incidence of 
diabetes is increasing and CV disease is a key reason for increased morbidity 
and mortality.  Although it may be overstating it, death from CV disease has in 
general fallen over the last 35 years but there has not been a decline in CV 
deaths in T2DM (7).  Therefore, it is vitally important to find new therapies that 
may reduce CV burden in diabetes, despite aggressive treatments for IHD.  
LVH is common in diabetes (in fact, diabetes is a risk factor for LVH in its own 
right) and we know that LVH confers significant CV risk (32).  Hence novel 
ways of regressing LVH in diabetic patients is one potential way of addressing 
this issue such as allopurinol. 
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6. Possible Mechanisms Why Allopurinol Reduces Left Ventricular 
Mass 
 
In this study our secondary end-points do not give any clues as to why 
allopurinol may regress LVH.  There were no significant changes seen in 
FMD, AIx or tissue markers of OS (oxidised LDL) or BNP.  There was also no 
change in other parameters measured on CMR.  The most obvious reason for 
these findings could be relatively small numbers of patients recruited and 
short follow period of the trial which prevented our seeing small changes in 
oxidised LDL and BNP.  
 
George et al (2006) is one of the best examples of the effects of allopurinol on 
FMD, especially the higher dose of 600mg (211).  They showed that 
allopurinol 600mg improved endothelial function by 143% compared to 
placebo in patients with chronic heart failure.  Allopurinol has improved 
endothelial function in various other patient groups including smokers, 
hypertension and diabetes (212, 215, 229). Allopurinol has been shown to 
reduce tissue OS and we know OS is a mediator of LVH (95).  Therefore it 
could be the reduction in OS that mediated LVH regression as discussed 
above.  However we found no change in oxidised LDL.  ROS are only 
detectable in plasma for very short periods of time and this study is not unique 
in not changing plasma biomarkers of OS.  This does not preclude an effect 
on OS as plasma biomarkers tend to change very little (if at all) after 
allopurinol whereas vascular tissue OS has been shown to change profoundly 
following allopurinol (211, 245).  This disconnect between plasma OS 
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biomarkers and tissue OS was particularly obvious in George et al (2006) and 
Rajendra et al (2010).  Overall current plasma OS biomarkers may be fairly 
insensitive in this situation with allopurinol.  The reason for a lack of effect of 
allopurinol on endothelial function in this study might be that our T2DM 
patients were very well treated with statins, ACE inhibitors and ARB’s which 
are each known to improve endothelial function.  Indeed, this was evident in 
the baseline measures of vascular health in our patients. The baseline AIx 
was only 11% and therefore, it may have made it difficult to improve it further 
with allopurinol.  This notion is in general supported by a previous study in a 
cohort of T2DM patients whose co-treatment was not as optimal as in our 
cohort.  In that study, allopurinol was able to improve endothelial function in 
patients with T2DM but had no effect on endothelial function in healthy 
individuals who had much better endothelial function at baseline than the 
T2DM patients (212).  Another reason why we were able to demonstrate an 
effect of allopurinol on LVH but not on endothelial function in this study may 
have been because we pre-selected those with baseline LVH whereas 
abnormal endothelial function at baseline was not a prerequisite in this study: 
this was obviously because our primary end-point was LVM but it may have 
made it easier to change LVM because it was elevated.  This theory is further 
confirmed as when high and low LVM was analysed separately a bigger fall in 
LVM was observed. 
 
Benzbromarone has shown improvements in fasting insulin in 82 patients with 
heart failure (253).  Benzbromarone is a potent uricosuric drug that has been 
used previously in the treatment of gout but it has been withdrawn from the 
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market due to fears surrounding hepatotoxicity (254).  Questions have been 
raised about how allopurinol affects fasting insulin and in this study had it no 
effects on fasting insulin.  This may be due to small numbers of patients and 
short follow-up, but if allopurinol were to improve fasting insulin, like 
benzobromarone, this may be another mechanism whereby it might decrease 
OS. 
 
The second possibility is that LVH might regress due to a reduction in LV 
after-load and some studies have found allopurinol reduces AIx although this 
was not seen here (231, 236).  Allopurinol has also been shown to reduce 
BNP in chronic heart failure (232).  With regards to BNP not falling in this 
study, baseline BNP was not particularly high therefore there was probably 
little scope to see a significant fall in BNP. 
 
A third possible reason is that energy depletion may produce hypertrophy and 
in small studies allopurinol has improved energetics (255, 256). In 
hypertrophic cardiomyopathy, a genetic condition causing LVH, one 
hypothesis based on observations of mutant contractile protein function, 
together with mouse models and clinical studies, suggests that sarcomeric 
hypertrophic cardiomyopathy mutations lead to inefficient ATP utilisation 
(256). The suggestion that energy depletion underlies hypertrophic 
cardiomyopathy may have implications for therapy in hypertrophic 
cardiomyopathy.  This could be extended to LVH due to other causes (e.g. 
hypertension and OS) and recently it has been shown intravenous allopurinol 
acutely improves the relative and absolute concentrations of myocardial high-
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energy phosphates and ATP flux through creatinine kinase in heart failure 
(255).  
 
Overall this study does not clarify the exact mechanism of allopurinol’s effect 
on LVM in T2DM, although a number of mechanisms remain possible from 
previous studies. Irrespective of the mechanism, it is encouraging that 
allopurinol was able to regress LVH despite optimal medical treatment. 
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7. Allopurinol and its Effects on BNP 
 
BNP can be raised in LVH and heart failure; we have not shown a change in 
BNP with allopurinol.  This is in contrast to previous studies in heart failure 
and stroke patients (231).  The change observed in this study on LVM was 
small and over a short period of time.  It can be postulated that quite dramatic 
changes in LVM would need to be seen before a statistically significant 
change in BNP could be observed.  The trial was powered to see a change in 
LVM, not BNP.  Hence too few patients were probably recruited and followed 
up over a short period of change to see anything more than a trend in BNP 
improvement (placebo -1.49 ± 20.22 vs. allopurinol -3.16 ± 20.36, p =0.754).  
If allopurinol truly does change BNP, this suggests that allopurinol is 
decreasing after load probably via an effects on OS. 
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8. Effects of Allopurinol on other Cardiac MRI Parameters 
 
Over the nine-month study period there were no other significant changes 
observed in other parameter measured on CMR, namely EF, EDV, ESV, SV 
and CO.  We would not necessarily expect to see an improvement in EF, SV 
or CO as we have postulated allopurinol improves LVH by mechanisms that 
would not affect these parameters.  However, allopurinol has improved 
ventricular volumes in other studies.  Kao et al (2011) showed a trend towards 
an improvement in EDV (just not reaching significance p = 0.084) in their 
study of patients with chronic kidney disease.  In mouse models allopurinol 
limited the increase in EDV after coronary artery ligation, and similar findings 
have been shown in rat and rabbit models with heart failure (257-259).  In 
Rekhraj et al (2013) allopurinol significantly reduced ESV.  These 
observations may be due to allopurinol improving mechanoenergetic 
uncoupling or it reducing LV afterload (216).  In this study we did not see any 
change in EDV or ESV and this may have been due to the small numbers 
recruited or the short follow up period or due to the fact that LV afterload (as 
measured by AIx) did not fall in this study. 
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9. Association of Uric Acid with Cardiovascular Disease 
 
High uric acid levels have been shown to be associated with increased risk of 
CV morbidity and mortality and hypertension.  Verdeccia et al (2000) showed 
that in untreated subjects with essential hypertension, raised uric acid is a 
powerful risk marker for subsequent CV and all-cause mortality (260).  It has 
been postulated that uric acid level itself is associated with an increased risk 
of having LVH and other target organ damage from hypertension (261, 262).  
In fact Viazzi et al (2005) showed each standard deviation increase in serum 
uric acid entailed a 75% higher risk of having LVH and a two-times greater 
risk of having carotid abnormalities (261).  Also, uric acid is an anti-oxidant in 
it’s own right (263), so therefore may play a role in the regression of LVH in 
this study.  George et al (2006) specifically addressed this question (211).  
They showed that allopurinol improved FMD, whereas probenecid did not.  
Therefore it would seem that allopurinol improves endothelial function by 
reducing OS and not by reducing uric acid.  In this study there was no 
correlation between baseline and change in uric acid levels and change in 
LVM or FMD, which supports this theory.  Kao et al (2011) also found no 
correlation between baseline or change in urate with FMD or LVM (236). 
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10. Dose Response of Allopurinol 
 
There appears to be an important dose response relationship with allopurinol.  
A lot of previous research using allopurinol had been with 300mg once daily 
(214).  However, George et al (2006) showed that increasing the dose of 
allopurinol from 300mg to 600mg improved endothelial function by a further 
52% such that allopurinol 600mg improved endothelial function by 143% 
compared to placebo (211).  Previous studies using 300mg allopurinol may 
actually have used a suboptimal dose of allopurinol, hence our choice of 
dosing.  Allopurinol was well tolerated in our study at this high dose.  
Allopurinol can be given up to 800mg or 900mg per day, according to the FDA 
and British National Formulary respectively. 
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11. Effects of Allopurinol on Hyperglycaemia 
 
It is worth noting that there had been previous reports of the effect of 
allopurinol on glycaemia.  At least one case report suggests that allopurinol 
can induce new T2DM whereas one large database suggests exactly the 
opposite (264).  Our study is the largest there is to study the effect of 
allopurinol on glycaemic control in T2DM and we have shown fairly 
conclusively that allopurinol has no positive or negative effect on glycaemic 
control in T2DM.  We also found that high dose allopurinol has no adverse 
effect on renal function in T2DM. 
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12. Side Effects and Tolerance of Allopurinol 
 
Allopurinol was very well tolerated in this study at a high dose of 600mg.  
There were no effects on renal function and liver function tests over the nine-
month study period.  There was one true side effect, which was a rash.  This 
is in keeping with other studies done within our department.  It should be 
noted that all recruited patients did not have impaired renal function or heart 
failure and this might help explain the high tolerance rate. 
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13. Clinical Relevance 
 
In this study we have shown that allopurinol regresses LVH in patients with 
T2DM and controlled BP.  However, this study was too small to examine CV 
outcomes over time.  There are a number of reasons why it can be hoped that 
allopurinol might improve prognosis if given to patients T2DM and LVH.  As 
previously discussed, the best comparator is the LIFE study where regressing 
LVH was associated with improved CV outcomes.  We know from the echo 
sub-study of LIFE that the difference between the two active treatments was 
only 3% compared with this study where the difference between allopurinol 
and placebo was 3.2% for LVM and 3.3% for LVMI.  In LIFE there was a 14% 
reduction in CV events and a 25% reduction in strokes (165).  Hence this 
study could be very clinically relevant if we extrapolate the LIFE improvement 
in CV outcomes with small reductions in LVM to our study.  Furthermore, this 
study was conducted over a relatively short time period of nine months; one 
could hope for further reductions in LVM over years.  We know allopurinol 
usually has beneficial effects on endothelial function, although we did not 
show that here.  Struthers et al (2002) has shown in a retrospective cohort 
study of heart failure patients that long-term low dose allopurinol was 
associated with a significant worsening in mortality over those who never 
received allopurinol (228).  Long-term high dose allopurinol was associated 
with a significantly better mortality than longstanding low dose allopurinol.  
MacDonald et al (2009) showed very similar findings in heart failure patients 
using record linkage (265).  This may be due to the generally improved CV 
health through reduced OS, urate-lowering effects or even some unlooked for 
 157 
 
regression of LVM.  It raises the possibility that allopurinol may have future 
beneficial effects in patients with diabetes not only due to regression of LVH 
but also due to it improving endothelial function. 
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14. Limitations 
 
The main limitation is the relatively small numbers of patients recruited.  It is 
almost inevitable with so many demographic parameters that a few will by 
chance be different at baseline, although few differences were statistically 
significant.  However, because of the relatively small sample size, we cannot 
exclude the possibility that some subtle demographic differences between the 
two groups may have contributed to our results.  
 
The baseline LVMI in this study was not particularly high.  This was due in 
part to the segmentation process, where the physicist actively excluded 
‘partial volume’ (defined as <50% full thickness myocardium) areas at the 
extreme basal end of the ventricle.  The inclusion or exclusion of a single slice 
in this region is known to alter the outcome value for the LVMI by typically 
10%.  However the emphasis at all stages of this work was to ensure 
optimised repeatability in order to maximise the potential sensitivity of the 
primary endpoint (change in LVMI). 
 
The effect of allopurinol on LVM is modest but is similar in percentage terms 
to the differential effect in the echo sub-study of the LIFE trial which clearly 
delivered major benefits, especially in T2DM patients (165).  Furthermore, we 
only gave treatment for nine months and the echo sub-study of LIFE suggests 
that full LVH regression takes longer, usually two years (165). 
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15. Future Research 
 
a. Cardiovascular Outcomes 
 
A large, multi-centre trial including follow up of CV outcomes over a longer 
time period would be the logical next step.  Allopurinol has been shown to 
regress LVH in chronic kidney disease patients and chronic stable angina 
patients, therefore a larger trial could encompass a range of pathologies.  We 
have shown in this study that allopurinol confers most benefit in those with 
highest baseline LVM, therefore selecting patients with highest LVM may help 
to target those who will gain most benefit. 
 
b. Myocardial Fibrosis 
 
One effect of allopurinol as yet untested is effects on fibrosis of the 
myocardium associated with LVH.  This is because OS might stimulate 
myocardial fibrosis.  A future study in similar design incorporating gadolium 
enhancement on CMR wold be one way of assessing this further.   
 
c. Left Atrial Size 
 
The effects of LVH include diastolic dysfunction, or heart failure with normal 
ejection fraction.  Here LVH often leads to LA dilatation and future studies 
could involve measurements of LA volume.  An interesting hypothesis is that if 
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LVH is regressed and LA size reduced then this may have benefits in 
preventing AF developing. 
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16. Prizes, Publications and Presentations 
 
a. Prizes 
 
Winner of ‘Best Poster’ for all poster submissions, American College of 
Cardiology Annual Scientific Sessions. San Francisco, 2013. Abstract 
‘Allopurinol Reduces Left Ventricular Mass in Patients with Type II Diabetes 
and Left Ventricular Hypertrophy’. 
 
Tayside Institute of Clinical Research (TICR) college symposium prize-
winner 2012.  Awarded £500 for significant achievement in the field of 
Cardiovascular Research for study ‘Allopurinol Reduces Left Ventricular Mass 
in Patients with Type II Diabetes and Left Ventricular Hypertrophy’. 
 
b. Publications 
 
Szwejkowski BR, Gandy SJ, Rekhraj S, Houston G, Lang CC, Morris AD, 
George J, Struthers AD. Allopurinol Reduces Left Ventricular Mass in Patients 
with Type 2 Diabetes and Left Ventricular Hypertrophy. Journal of American 
College of Cardiology.  2013 Dec 17;62(24):2284-93. 
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c. Poster Presentations 
 
European Cardiac Society Annual Congress 
 
2013 Szwejkowski BR, Gandy SJ, Rekhraj S, Houston G, Lang CC, George 
J, Struthers AD. Allopurinol Regresses Left Ventricular Hypertrophy 
Especially those with Highest Left Ventricular Mass. 
 
British Cardiovascular Society 
 
2013 Szwejkowski BR, Gandy SJ, Rekhraj S, Houston G, Lang CC, George 
J, Struthers AD. Allopurinol Reduces Left Ventricular Mass in Patients 
with Type 2 Diabetes and Left Ventricular Hypertrophy. 
 
American College of Cardiology 
 
2013 Szwejkowski BR, Gandy SJ, Rekhraj S, Houston G, Lang CC, George 
J, Struthers AD. Allopurinol Reduces Left Ventricular Mass in Patients 
with Type 2 Diabetes and Left Ventricular Hypertrophy. 
 
Scottish Society of Physicians 
 
2012 Szwejkowski BR, Gandy SJ, Rekhraj S, Houston G, Lang CC, George 
J, Struthers AD. Allopurinol Regresses Left Ventricular Hypertrophy in 
Patients with Diabetes and Angina. 
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25/09/2009 
Version 3.0 
Study Number: eb/lm/let390/ln950/20038 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and 
Endothelial Dysfunction in Cardiovascular Patients with Diabetes? 
Name of Researcher: Dr Ben Szwejkowski 
Please initial box 
1.  I confirm that I have read and understood the information sheet dated 
24/9/09 (version 5) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
 
2.  I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without any medical care or legal 
rights being affected 
 
 
 
3.  I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from regulatory authorities 
or from NHS Tayside, where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my records. 
 
 
 
4.  I agree to my GP being informed of my participation in the study. 
 
 
5.  I agree to any tissue (blood samples) taken during the study being retained 
for use in future studies.   
6.  I agree to have an x-ray of my eyes if required prior to undergoing an MRI 
scan for safety reasons. 
 
7.  I agree to take part in the above study.  
 
______________________      _______________________            ________________ 
Name of participant       Date     Signature 
 
_____________________     ______________________            _________________ 
Name of person taking consent     Date     Signature 
When complete, 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical 
notes 
Division of Medicine and Therapeutics 
Head of Division and Professor of Cardiovascular Medicine and Therapeutics 
Professor Allan D Struthers BSc MD FRCP FESC 
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12/01/2009 
Version 6.0 
 
Do Xanthine Oxidase Inhibitors Reduce Left Ventricular Hypertrophy in 
Diabetic Patients? 
 
 
PATIENT INFORMATION SHEET 
 
You are being asked to participate in a research project.  This research will also be 
used in part towards an educational qualification with the University of Dundee. 
Before you decide, it is important for you to understand why the research is being 
carried out and what it involves.  Please take time to read the following information 
carefully and discuss it with others, if you wish.  Ask us if there is anything that is not 
clear or if you would like more information.  Take time decide whether or not you 
would like to take part. 
 
Background 
 
In patients with diabetes, “left ventricular hypertrophy” or thickened heart muscle is a 
very common occurrence.   Thickened heart muscle is diagnosed using an ultrasound 
scan of the heart (also known as echocardiography) and this has been shown to 
adversely affect one’s long term prognosis (symptoms and survival).  Patients with 
thickened heart muscle are also known to have thick blood vessels and more prone to 
life threatening abnormal heart beats.  Studies have shown that if we can reverse 
thickened heart muscle and stiffened blood vessels we can substantially reduce the 
long term complications associated with these conditions.  Recently it has been found 
that a tablet called allopurinol, a drug commonly used in the treatment of gout for 
many years, has beneficial effects that may reduce thickened heart muscle, stiffened 
blood vessels and the chance of life threatening irregular heart beats. Thickened heart 
muscle will be evaluated with Magnetic Resonance Imaging (MRI). 
 
What are we asking you to do? 
 
The study takes 9 months to complete.  The study is of a randomised, double blind 
design.  This means that you will take a tablet, which will be either allopurinol (the 
test drug) or a placebo (an inactive tablet).  The tablet that you will be allocated is 
decided in a random way (a bit like tossing a coin), such that neither you nor the 
research team will know which tablet you are taking, until after the study is completed 
when a special randomisation code is opened.  This means the results of the study 
cannot be influenced.  
 
Division of Medicine and Therapeutics 
Head of Division and Professor of Cardiovascular Medicine and Therapeutics 
Professor Allan D Struthers BSc MD FRCP FESC 
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Firstly, we will ask you to visit us so that we can answer any questions that you may 
have.  If you have not undergone an ultrasound scan of your heart before, we will 
perform this simple test during this visit to see if you have thickened heart muscles.   
After making sure that you are suitable to participate in the trial and obtaining your 
consent, we will also arrange a suitable date and time to perform an MRI scan to 
assess the structure of your heart. You will also be assigned to take either the test 
medication i.e. allopurinol or the placebo. During your subsequent visits to the 
department, we will also assess the stiffness of your blood vessels using ultrasound.  
Throughout the study duration, we will monitor your kidney function closely by 
means of a simple blood test (about 5 ml blood, or about a teaspoonful will be taken). 
Urine samples will also be collected during each visit to check for the amount of 
protein in the urine. Your blood pressure will also be measured during these visits. 
The rest of the study visits are outlined in the visit schedule (see attached sheet).  
 
Blood samples will be stored and analysed at the end of the study. We will also store 
the blood samples for a period of 10 years after the end of the study, in case there are 
any new tests of blood vessel function or thickened heart muscle that become 
available after this time that we can analyse on your blood samples. Blood samples 
are not taken for genetic testing. These blood samples will be registered with the 
Tayside Tissue Bank  
 
The tablets  
 
Allopurinol is a tablet that has been in use for around 50 years for the treatment of 
gout. It has a good safety record and is generally well tolerated. However, like most 
medicines, allopurinol occasionally causes side effects, particularly in the period soon 
after it is first taken. The most common side effect is nausea and some abdominal 
discomfort which affects less than 5-10% of patients treated with allopurinol and the 
effects of which can be minimised by taking the tablets with food.   The dose of 
Allopurinol used in this study has been tested before in previous studies undertaken at 
the University of Dundee where the dose you are being asked to take was found to be 
safe. 
 
Allopurinol causes a skin rash in a small proportion of patients (about 1% or less) as a 
result of a type of allergy to the medication. This may be associated with fever, 
swollen glands, joint pain and unusual blistering or bleeding. Were any of these 
symptoms to develop, you should stop taking allopurinol immediately and contact the 
study doctor as soon as possible. You may also seek advice from your GP.  
 
Reports of other side effects to allopurinol are very rare (e.g. affect less than 1 in 
10,000 people) and it is not always clear if they are truly related to the treatment.  The 
complete range of reported side effects is set out in a Patient Information Leaflet, a 
copy of which is attached for your information. This will be further discussed with 
you before you make a final decision about taking part in this study.  
 
Placebo tablets are inactive and we do not expect you to experience any side effects at 
all whilst taking these. All your other medications should be taken as normal.  
 
 
The MRI scan  
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The MRI scanner allows us to look in a detailed way at the heart without the use of 
radiation. Having an MRI involves lying flat for about 45 minutes. You have to go 
into a narrow tube during the scan, thus the scans are not suitable for people who are 
claustrophobic. The scanner takes pictures of your heart by the use of a large magnet. 
Hence, people who have any fragments of metal in their bodies may not be able to 
have these scans. If you have ever been exposed to metal fragments in your eyes it is 
sometimes necessary to x-ray the eyes.  This is purely for your safety and involves 
minimal radiation exposure. The nurse will ask you more questions regarding this 
before the scan. If you would like to see the MRI scanner before you make up your 
mind, this can be arranged.  
 
Assessing blood vessel stiffness using ultrasound  
 
At each of these four visits, we will measure how one of the blood vessels in your arm 
functions, to check the stiffness of it. This technique is called Flow Mediated 
Dilatation, FMD. This is done using an ultrasound machine. To see how stiff the 
blood vessel is, we need to see how it responds to short period of having the 
circulation to the forearm blocked and then see how it responds to a substance called 
GTN that is used to treat angina. What does this involve?  
 
You will be asked to lie on a couch for approximately 30 minutes. A blood pressure 
cuff will be placed below your elbow. We will then take an ultrasound measurement 
of the artery above the elbow. This involves placing a probe gently on the skin above 
the elbow. We will then inflate the blood pressure cuff to occlude the circulation to 
the forearm for a period of 5 minutes. After 5 minutes, we will release the cuff and 
take another measurement at the artery above the elbow. Similarly, a further 
measurement will be taken before and after giving GTN spray under your tongue.  
 
In addition to using the ultrasound machine, you will also have the pressure of your 
pulse at your wrist, neck and groin measured in a technique called Sphygmocor. This 
is a very simple procedure, which involves placing a small probe gently on your skin 
above the arteries on your wrist, neck and groin. It only takes about 15 minutes and is 
completely painless.  
 
What are the discomforts, risks and side effects?  
 
The side effects of the tablets are listed above. Having blood taken can cause some 
mild bruising. GTN (that is used under the tongue when we ultrasound the artery) can 
cause very transient headache, which usually goes away quickly. When the blood 
pressure cuff is inflated, there can be a mild discomfort, which goes away quickly 
once it is deflated. Finally, some people may feel claustrophobic in the MRI scanner.   
 
What are the benefits of taking part in the study?  
 
As mentioned earlier, you have been diagnosed with diabetes. You are attending you 
own doctor and possibly, the specialist clinic in the hospital. You will be monitored 
closely and will be seen by a heart specialist for each of your visit as part of the study. 
Besides having those tests as mentioned earlier being carried out, your medications 
will be reviewed on a regular basis. These tests will give us more information about 
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the function of your heart, blood circulation and kidney function. If any of these 
investigations reveal any new abnormalities, we will refer you to a specialist clinic in 
Ninewells Hospital. The study itself may not directly benefit you, but the results of 
the study may change how physicians treat diabetic patients and thickened heart 
muscle, and this potentially will have an impact on the way future patients are treated 
with this condition.   
 
What are my rights?  
 
All data collected in the study will be coded and stored on a computer protected by a 
password available only to the researchers. The storage and processing of data is fully 
compliant with the guidelines of the Tayside Committee on Medical Research Ethics. 
If you wish, results of the study can be made available to you or your GP when the 
study is complete.   
 
Participation in this study is entirely voluntary, and you are free to refuse to take part 
or to withdraw from the study at any time, without having to give a reason and 
without this affecting your future medical care or your relationship with medical staff 
looking after you. Some insurance companies consider that participation in medical 
research such as this is a “material fact”, which should be mentioned in any proposal 
for health-related insurance, or which could influence their judgement in 
consideration of claims made under existing policies. You should check that 
participation in this research does not affect any policy you might be thinking about 
taking out or any existing policy. We will provide a taxi or reasonable travel expenses 
for all of the visits.   
 
Will the research influence the treatment I receive?  
 
The research does not alter the treatment you receive. Your specialist will start and 
stop treatments as determined by your clinical condition.  
 
What will happen to the information collected in the study and will my taking 
part in the study be kept confidential? 
 
Identifiable information about you and the data collected during the study will be held 
by the Institute of Cardiovascular Research, Ninewells Hospital and Medical School. 
No one outside the research team will have access to any identifying information and 
all identifiable information and the data will be kept securely.  Parts of the samples 
taken will be stored in a locked freezer for up to 10 years.  The samples will only be 
handled by approved members of the laboratory.  The samples will only be used for 
future research if it is deemed appropriate by the Ethics and Research Committee. 
 
Will I continue to receive the medicine used on this study after it finishes?  
 
There is no guarantee of this. The study is designed to give an indication of possible 
benefit from the medicine being tested and it may be some time, before we can be 
sure about how useful it actually is. Decisions about your continued treatment will be 
taken by your family doctor, who is responsible for writing your prescriptions, 
although he/she may seek the advice of a hospital specialist, if necessary. It is 
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therefore likely that you will revert to your pre-study medication, unless there are 
good reasons to change.   
 
Who has reviewed the study?  
 
This study has been reviewed by an NHS Research Ethics, which has the 
responsibility for scrutinising proposals for medical research on humans, in 
accordance with the requirements of the Clinical Trials Regulations.  In this case, the 
reviewing Committee was the Fife & Forth Valley Research Ethics Committee who 
have raised no objections from the point of view of medical ethics. 
 
We will contact your GP to inform him/her of your participation in the study, unless 
you ask us not to. If you are worried at any time about the research, or the results, or 
wish to discuss things generally in further detail, then please do not hesitate to 
contact: 
 
Dr Ben Szwejkowski MBChB, MRCP (UK)  
Specialty Registrar in Cardiology and Clinical Research Fellow in Cardiovascular 
Medicine 
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, 
Dundee DD1 9SY  
Tel: (01382) 632180  
e mail: b.szwejkowski@dundee.ac.uk  
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Visit Schedule 
 
Identify diabetic patients with thickened heart muscle  
↓ 
Apply exclusion criteria 
↓ 
Visit 1 (screening visit) 
Echocardiogram ?left ventricular hypertrophy 
↓ 
If LVH, proceed for study 
↓ 
Visit 2 (week 0) – baseline 
Consent 
Brief history 
Blood test 
Urine test 
24 hour blood pressure monitoring 
Ultrasound of the arm 
MRI of heart 
↓ 
Randomised to either Allopurinol or Placebo 
↓ 
Visit 3 (week 2) 
Blood test 
↓ 
Visit 4 (week 4) 
Blood test  
Urine test 
↓ 
Visit 5 (week 8) 
Blood test 
↓ 
Visit 6 (month 6) 
Blood test  
Urine test 
Ultrasound of arm 
↓ 
Visit 7 (9 months) 
Blood test 
Urine test 
24 hour blood pressure monitoring 
Ultrasound of the arm 
MRI of heart 
↓ 
Unblinding of trial 
 
Thank You for taking time to read this Information Sheet and for considering taking part. 
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12/01/2010  
Version 4.0  
 
Dear Doctor, 
 
RE:   
 
 
 
 
 
Your patient has been asked to take part in a clinical trial entitled “Do Xanthine 
Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Vascular 
Dysfunction in Diabetic Patients”.   This project is funded by Diabetes UK and will be 
carried out at the University of Dundee. The primary endpoint is to assess if 
Allopurinol reduces left ventricular hypertrophy in patients with diabetes. The 
secondary endpoint is to assess if Allopurinol improves endothelial function in 
diabetic patients.  
 
This is a randomised, double blind placebo controlled trial using Allopurinol at a 
maximal dose of 600mg.  They will undergo cardiac MRI at the beginning of the trial 
and at 9 months.  They will also periodically have Flow Mediated Dilatation studies.  
 
A detailed information sheet has been given to the patient.  I would also ask you to 
contact myself directly if you feel the patient develops side effects from Allopurinol 
or has any problems finishing the study.  I have outlined the study protocol for your 
information and attached it to this letter. 
 
Yours sincerely, 
 
 
 
 
 
Dr Ben Szwejkowski MBChB MRCP (UK) 
Cardiology Specialty Registrar, West of Scotland 
Cardiovascular Clinical Research Fellow, University of Dundee 
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, 
Dundee DD1 9SY 
Tel: (01382) 632180 or (01382) 660111 extension 40097 
e mail: b.szwejkowski@dundee.ac.uk 
 
 
Division of Medicine and Therapeutics 
Head of Division and Professor of Cardiovascular Medicine and Therapeutics 
Professor Allan D Struthers BSc MD FRCP FESC 
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Protocol “Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and 
Vascular Dysfunction in Diabetic patients” 
 
Visit 1 screening visit 
 
Interested patients will be screened by echocardiography to look for LVH, thickened heart muscle. If 
LVH is present they will be recruited to the study.  The criteria for LVH will be American Society of 
Echocardiography (ASE) criteria of 115 gm for men and 95 gm women. 
 
Visit 2 (week 0) 
 
Informed consent 
Baseline blood tests urea and electrolytes (U and E) 
   Liver function tests 
   Full blood count 
   Uric acid 
   Fasting glucose/insulin (HOMA index) 
   HbA1c 
   BNP 
   PIIINP (collagen marker) 
   Renin and aldosterone 
Urine test for protein concentration  
Sphygmocor to measure augmentation index (involves a small probe on the wrist, neck and groin to 
assess the character of the pulse) 
Flow mediated dilatation (FMD) (ultrasound of the brachial artery to assess blood flow response 
Cardiac MRI 
24 hour blood pressure monitoring 
 
Visit 3 (week 2) 
 
Blood test U and E only 
 
Visit 4 (week 4) 
 
Blood tests 
Urine test 
 
Visit 5 (week 8) 
 
Blood tests 
Urine test 
 
Visit 6 (month 6) 
 
Blood tests 
Urine test 
Sphygmocor 
FMD 
 
Visit 7 (month 6) 
 
Blood tests 
Urine test for protein concentration 
Sphygmocor 
FMD 
Cardiac MRI 
24 hour blood pressure monitoring 
 190 
 
 
 
CASE REPORT FORM 
 
Do Xanthine Oxidase Inhibitors Regress Left 
Ventricular Hypertrophy in Diabetes? 
Protocol number: eb/lm/let390/ln950/20038   
 
DATE: 
 
Patient code:          
 
Randomisation number: 
 
TAXI : YES/NO 
 Date/time Comments 
Visit 1 
(screening) 
 
 
             
Visit 2 
(week 0) 
 
 
  
Visit 3 
(week 2) 
 
 
  
Visit 4 
(week 4) 
 
 
  
Visit 5 
(week 8) 
 
 
  
Visit 6 
(6 months) 
 
 
  
Visit 7   
 191 
 
SCREENING VISIT  (VISIT 1)    DATE: 
 
MALE/FEMALE 
 
Past Medical History: 
 
 
 
 
 
 
 
 
 
 
 
Drug History:       ALLERGIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
Social History:  Smoker/ Non-Smoker   If yes amount and years:  
   Alcohol: 
 
 
 
 
 
 
 
 
 
 
Family History:  
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EXAMINATION 
 
Pulse rate:     BP:     
    
Ankle Oedema:     JVP: 
 
Height:     Weight: 
 
BSA: 
 
 
General remarks: 
 
 
 
CVS: 
 
 
 
 
 
 
RS: 
 
 
 
 
 
 
 
 
 
CRITERIA: 
Diabetic         ⁪ 
Possible LVH (ECG)        ⁭ 
Office target BP <150/90       ⁭ 
  
EXCLUSION CRITERIA: 
Gout          ⁭ 
Already on Allopurinol       ⁭ 
Previous adverse reaction to Allopurinol     ⁭ 
Poor kidney function (eGFR <60ml/mm)     ⁭ 
Conditions that exclude Magnetic Resonance Imaging (MRI)  ⁭ 
Heart failure (LVEF <45%)       ⁭ 
Cancer or other life threatening illness     ⁭ 
Pregnancy or breast feeding (?pregnancy test)    ⁭ 
Unable to provide consent       ⁭ 
Atrial fibrillation (not definite exclusion criteria)    ⁭ 
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INITIAL INVESTIGATIONS: 
 
Consent          ⁭ 
Letter to GP          ⁭ 
File letter/consent in notes        ⁭ 
Blood pressure         ⁭ 
Information about study given       ⁪  
Echo report          ⁪ 
 
Urea and electrolytes (U and E)       ⁭ 
Liver function tests         ⁭ 
Full blood count         ⁭ 
HbA1c           ⁭ 
 
         
Date for next visit:        
 
 
Any other comments: 
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ECHO 
 
IVSd:     IVSs: 
 
LVIDd:    IVIDs: 
 
LVPWd:    LVPWs: 
 
LV mass: 
 
BSA: 
 
MV: 
 
 
 
AV: 
 
 
 
TV: 
 
 
 
PV: 
 
 
 
General comments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed:     Date:
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VISIT 2 (week 0)       DATE: 
  
SCREENING BLOOD RESULTS CHECKED     ⁪ 
 
SYMPTOMS/ PROBLEMS SINCE LAST VISIT (inc. new drugs)    
 
 
 
 
 
Uric acid          ⁭ 
Fasting glucose/insulin (HOMA index)      ⁭ 
HbA1c           ⁭ 
BNP           ⁭ 
PIIINP (collagen marker)        ⁭ 
Renin and aldosterone        ⁭ 
 
ECG           ⁭ 
Urine test          ⁭ 
Sphygmocor           ⁭ 
Flow mediated dilatation (FMD)        ⁭ 
Cardiac MRI organised        ⁭ 
24 hour blood pressure monitoring       ⁭ 
 
 
FIRST SET OF STUDY TABLETS  (Allopurinol 100mg/placebo)   ⁪ 
  
Date for next visit:        
 
 
 
 
 
Any other comments: 
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Flow Mediated Dilatation 
 
BP 
 
 
 
 
GTN 
 
 
 
 
Sphygmocor 
 
PWA 
 
 
 
PWV 
 
 
 
 
Cardiac MRI 
 
LVM 
 
 
LVM Corrected 
 
 
LA volumes 
 
 
EF 
 
 
 
 
ECG 
 
 
 
 
 
 
 
 
 
Signed:     Date: 
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VISIT 3 (Week 2)       DATE: 
 
VISIT 2 BLOOD RESULTS CHECKED      ⁪
    
SYMPTOMS/ PROBLEMS SINCE LAST VISIT (inc. new drugs)   
 
 
 
 
 
 
 
 
 
Urea and electrolytes (U and E), FBC, LFT      ⁭ 
 
SECOND SET OF STUDY TABLETS (Allopurinol 300mg/placebo)  ⁭
         
Date for next visit:        
 
 
 
 
 
Any other comments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed:     Date: 
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VISIT 4 (Week 4)      DATE: 
 
VISIT 3 BLOOD RESULTS CHECKED      ⁪
    
SYMPTOMS/ PROBLEMS SINCE LAST VISIT (inc. new drugs)    
 
 
 
 
 
 
 
 
 
U and E, LFT, FBC          ⁭ 
Urine test          ⁭
      
 
THIRD SET OF STUDY TABLETS (Allopurinol 600mg/placebo)  ⁭
         
Date for next visit:        
 
 
 
 
 
Any other comments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed:     Date: 
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VISIT 5 (Week 8)      DATE: 
 
VISIT 4 BLOOD RESULTS CHECKED      ⁪
    
SYMPTOMS/ PROBLEMS SINCE LAST VISIT (inc. new drugs)    
 
 
 
 
 
 
 
 
 
U and E, LFT, FBC          ⁭ 
         
Date for next visit:        
 
 
 
 
 
Any other comments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed:     Date: 
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VISIT 6 (month 6)      DATE: 
 
VISIT 4 BLOOD RESULTS CHECKED      ⁪
    
SYMPTOMS/ PROBLEMS SINCE LAST VISIT (inc. new drugs)   
 
 
 
 
 
 
 
 
 
U and E, LFT, FBC, uric acid        ⁭ 
Urine test          ⁭ 
Sphygmocor           ⁭ 
Flow mediated dilatation (FMD)       ⁭ 
Cardiac MRI booked for next visit       ⁭ 
      
BP: 
 
 
Date for next visit:        
 
 
 
 
 
Any other comments: 
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Flow Mediated Dilatation: 
 
BP 
 
 
 
 
GTN 
 
 
 
 
Sphygmocor 
 
PWA 
 
 
 
PWV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed:     Date: 
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VISIT 7 (9 months) FINAL VISIT     DATE: 
 
VISIT 5 BLOOD RESULTS CHECKED      ⁪
    
SYMPTOMS/ PROBLEMS SINCE LAST VISIT (inc. new drugs)   
 
 
 
 
 
 
 
 
 
 
Urea and electrolytes (U and E)       ⁭ 
Liver function tests         ⁭ 
Full blood count         ⁭ 
Uric acid          ⁭ 
Fasting glucose/insulin (HOMA index)      ⁭ 
HbA1c           ⁭ 
BNP           ⁭ 
PIIINP (collagen marker)        ⁭ 
Renin and aldosterone        ⁭ 
Urine test    ⁭ 
Sphygmocor           ⁭ 
Flow mediated dilatation (FMD)        ⁭ 
Cardiac MRI organised        ⁭ 
24 hour blood pressure monitoring       ⁭ 
 
BP: 
 
STUDY TABLETS STOPPED          ⁪ 
  
Any other comments: 
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Flow Mediated Dilatation 
 
BP 
 
 
 
 
GTN 
 
 
 
 
Sphygmocor 
 
PWA 
 
 
 
PWV 
 
 
 
 
Cardiac MRI 
 
LVM 
 
 
LVM Corrected 
 
 
LA volumes 
 
 
EF 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed:     Date: 
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Blood results: 
 Week 0    Week 2 Week 4 Week 8 Month 6 1 year 
Na 
 
      
K 
 
      
Urea 
 
      
Creatinine 
 
      
Hb 
 
      
WCC 
 
      
Plt 
 
      
Bilirubin 
 
      
AST 
 
      
ALT 
 
      
Alk Phos 
 
      
Albumin 
 
      
Uric acid 
 
      
Fasting 
glucose/insulin 
 
      
HbA1c 
 
      
BNP 
 
      
PIIINP 
 
      
Renin 
 
      
Aldosterone  
 
      
Creatinine 
clearance 
 
      
24hour urine 
protein 
 
      
Microalbinuria 
 
      
 
 
